<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
	<META HTTP-EQUIV="CONTENT-TYPE" CONTENT="text/html; charset=utf-8">
	<TITLE></TITLE>
	<META NAME="GENERATOR" CONTENT="LibreOffice 3.5  (Linux)">
	<META NAME="AUTHOR" CONTENT="Jacinto Dávila">
	<META NAME="CREATED" CONTENT="20150817;19141500">
	<META NAME="CHANGEDBY" CONTENT="Jacinto Dávila">
	<META NAME="CHANGED" CONTENT="20150817;19355300">
	<STYLE TYPE="text/css">
	<!--
		@page { margin: 2cm }
		P { margin-bottom: 0.21cm }
	-->
	</STYLE>
</HEAD>
<BODY LANG="es-VE" DIR="LTR">
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Inhibition of
mitogen-activated protein kinase (MEK, also known as</P>
<P STYLE="margin-bottom: 0cm">MAPK2, MAPKK), a key molecule of the
Ras/MAPK (mitogen-activated protein kinase) 
</P>
<P STYLE="margin-bottom: 0cm">pathway, has shown promising effects on
B-raf-mutated and some RAS (rat</P>
<P STYLE="margin-bottom: 0cm">sarcoma)-activated tumors in clinical
trials. The objective of this study is to</P>
<P STYLE="margin-bottom: 0cm">examine the efficacy of a novel
allosteric MEK inhibitor RO4987655 in</P>
<P STYLE="margin-bottom: 0cm">K-ras-mutated human tumor xenograft
models using [(18)F] FDG-PET imaging and</P>
<P STYLE="margin-bottom: 0cm">proteomics technology.</P>
<P STYLE="margin-bottom: 0cm">METHODS: [(18)F] FDG uptake was studied
in human lung carcinoma xenografts from</P>
<P STYLE="margin-bottom: 0cm">day 0 to day 9 of RO4987655 therapy
using microPET Focus 120 (CTI Concorde</P>
<P STYLE="margin-bottom: 0cm">Microsystems, Knoxville, TN, USA). The
expression levels of GLUT1 and hexokinase 
</P>
<P STYLE="margin-bottom: 0cm">1 were examined using semi-quantitative
fluorescent immunohistochemistry (fIHC). 
</P>
<P STYLE="margin-bottom: 0cm">The in vivo effects of RO4987655 on
MAPK/PI3K pathway components were assessed by</P>
<P STYLE="margin-bottom: 0cm">reverse phase protein arrays (RPPA).</P>
<P STYLE="margin-bottom: 0cm">RESULTS: We have observed modest
metabolic decreases in tumor [(18)F] FDG uptake 
</P>
<P STYLE="margin-bottom: 0cm">after MEK inhibition by RO4987655 as
early as 2 h post-treatment. The greatest</P>
<P STYLE="margin-bottom: 0cm">[(18)F] FDG decreases were found on day
1, followed by a rebound in [(18)F] FDG</P>
<P STYLE="margin-bottom: 0cm">uptake on day 3 in parallel with
decreasing tumor volumes. Molecular analysis of 
</P>
<P STYLE="margin-bottom: 0cm">the tumors by fIHC did not reveal
statistically significant correlations of GLUT1</P>
<P STYLE="margin-bottom: 0cm">and hexokinase 1 expressions with the
[(18)F] FDG changes. RPPA signaling</P>
<P STYLE="margin-bottom: 0cm">response profiling revealed not only
down-regulation of pERK1/2, pMKK4, and pmTOR</P>
<P STYLE="margin-bottom: 0cm">on day 1 after RO4987655 treatment but
also significant up-regulation of pMEK1/2,</P>
<P STYLE="margin-bottom: 0cm">pMEK2, pC-RAF, and pAKT on day 3. The
up-regulation of these markers is</P>
<P STYLE="margin-bottom: 0cm">interpreted to be indicative of a
reactivation of the MAPK and activation of the 
</P>
<P STYLE="margin-bottom: 0cm">compensatory PI3K pathway, which can
also explain the rebound in [(18)F] FDG</P>
<P STYLE="margin-bottom: 0cm">uptake following MEK inhibition with
RO4987655 in the K-ras-mutated human tumor</P>
<P STYLE="margin-bottom: 0cm">xenografts.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: We have performed the
first preclinical evaluation of a new MEK</P>
<P STYLE="margin-bottom: 0cm">inhibitor, RO4987655, using a
combination of [(18)F] FDG-PET imaging and</P>
<P STYLE="margin-bottom: 0cm">molecular proteomics. These results
provide support for using preclinical [(18)F]</P>
<P STYLE="margin-bottom: 0cm">FDG-PET imaging in early, non-invasive
monitoring of the effects of MEK and</P>
<P STYLE="margin-bottom: 0cm">perhaps other Ras/MAPK signaling
pathway inhibitors, which should facilitate a</P>
<P STYLE="margin-bottom: 0cm">wider implementation of clinical
[(18)F] FDG-PET to optimize their clinical use.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4452660</P>
<P STYLE="margin-bottom: 0cm">PMID: 26116108 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">17. Tumour Biol. 2015 Jun 25. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The comparison between dual inhibition
of mTOR with MAPK and PI3K signaling</P>
<P STYLE="margin-bottom: 0cm">pathways in KRAS mutant NSCLC cell
lines.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Dogan Turacli I(1), Ozkan AC(2),
Ekmekci A(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Faculty of Medicine, Department of
Medical Biology and Genetics, Ufuk</P>
<P STYLE="margin-bottom: 0cm">University, Ankara, Turkey.
iremdgn@yahoo.com. (2)Faculty of Medicine, Department</P>
<P STYLE="margin-bottom: 0cm">of Medical Biology and Genetics, Gazi
University, Ankara, Turkey.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">KRAS mutations are found in 15-25 % of
patients with lung adenocarcinoma, and</P>
<P STYLE="margin-bottom: 0cm">they lead to constitutive activation of
KRAS signaling pathway that results in</P>
<P STYLE="margin-bottom: 0cm">sustained cell proliferation.
Currently, there are no direct anti-KRAS therapies 
</P>
<P STYLE="margin-bottom: 0cm">available. Therefore, it is rational to
target the downstream molecules of KRAS</P>
<P STYLE="margin-bottom: 0cm">signaling pathway, which are
mitogen-activated protein kinase (MAPK) signaling</P>
<P STYLE="margin-bottom: 0cm">pathway (RAF-MEK-ERK) and PI3K pathway
(PI3K-AKT-mTOR). Here, we examined the</P>
<P STYLE="margin-bottom: 0cm">inhibition of both these pathways alone
and in combination and analyzed the</P>
<P STYLE="margin-bottom: 0cm">anti-proliferative and apoptotic events
in KRAS mutant NSCLC cell lines, A549 and</P>
<P STYLE="margin-bottom: 0cm">Calu-1. Cytotoxicity was determined by
MTT assay after the cells were treated</P>
<P STYLE="margin-bottom: 0cm">with LY294002 (PI3K inhibitor), U0126
(MEK inhibitor), and RAD001 (mTOR</P>
<P STYLE="margin-bottom: 0cm">inhibitor) for 24 and 48 h. The
expression levels of p-ERK, ERK, AKT, p-AKT, p53,</P>
<P STYLE="margin-bottom: 0cm">cyclinD1, c-myc, p27(kip1), BAX, BIM,
and GAPDH were detected by western blot</P>
<P STYLE="margin-bottom: 0cm">after 6 and 24 h treatment. Although
PI3K/mTOR inhibition is more effective in</P>
<P STYLE="margin-bottom: 0cm">cytotoxicity in A549 and Calu-1 cells,
MEK/mTOR inhibition markedly decreases</P>
<P STYLE="margin-bottom: 0cm">cell proliferation protein marker
expressions. Our data show that combined</P>
<P STYLE="margin-bottom: 0cm">targeting of MEK and PI3K-AKT with mTOR
is a better option than single agents</P>
<P STYLE="margin-bottom: 0cm">alone for KRAS mutant NSCLC, thus
opening the possibility of a beneficial</P>
<P STYLE="margin-bottom: 0cm">treatment strategy in the future.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26108998 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">18. Breast Cancer Res Treat. 2015
Jul;152(2):337-46. doi: 10.1007/s10549-015-3458-4. 
</P>
<P STYLE="margin-bottom: 0cm">Epub 2015 Jun 24.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">CIB1 depletion impairs cell survival
and tumor growth in triple-negative breast</P>
<P STYLE="margin-bottom: 0cm">cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Black JL(1), Harrell JC, Leisner TM,
Fellmeth MJ, George SD, Reinhold D, Baker</P>
<P STYLE="margin-bottom: 0cm">NM, Jones CD, Der CJ, Perou CM, Parise
LV.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biochemistry and
Biophysics, University of North Carolina, 120</P>
<P STYLE="margin-bottom: 0cm">Mason Farm Rd Ste 3010, Chapel Hill,
NC, 27599, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Triple-negative breast cancer (TNBC) is
an aggressive breast cancer subtype with 
</P>
<P STYLE="margin-bottom: 0cm">generally poor prognosis and no
available targeted therapies, highlighting a</P>
<P STYLE="margin-bottom: 0cm">critical unmet need to identify and
characterize novel therapeutic targets. We</P>
<P STYLE="margin-bottom: 0cm">previously demonstrated that CIB1 is
necessary for cancer cell survival and</P>
<P STYLE="margin-bottom: 0cm">proliferation via regulation of two
oncogenic signaling pathways, RAF-MEK-ERK and</P>
<P STYLE="margin-bottom: 0cm">PI3K-AKT. Because these pathways are
often upregulated in TNBC, we hypothesized</P>
<P STYLE="margin-bottom: 0cm">that CIB1 may play a broader role in
TNBC cell survival and tumor growth. Methods</P>
<P STYLE="margin-bottom: 0cm">utilized include inducible RNAi
depletion of CIB1 in vitro and in vivo,</P>
<P STYLE="margin-bottom: 0cm">immunoblotting, clonogenic assay, flow
cytometry, RNA-sequencing, bioinformatics 
</P>
<P STYLE="margin-bottom: 0cm">analysis, and Kaplan-Meier survival
analysis. CIB1 depletion resulted in</P>
<P STYLE="margin-bottom: 0cm">significant cell death in 8 of 11 TNBC
cell lines tested. Analysis of components 
</P>
<P STYLE="margin-bottom: 0cm">related to PI3K-AKT and RAF-MEK-ERK
signaling revealed that elevated AKT</P>
<P STYLE="margin-bottom: 0cm">activation status and low PTEN
expression were key predictors of sensitivity to</P>
<P STYLE="margin-bottom: 0cm">CIB1 depletion. Furthermore, CIB1
knockdown caused dramatic shrinkage of</P>
<P STYLE="margin-bottom: 0cm">MDA-MB-468 xenograft tumors in vivo.
RNA sequence analysis also showed that CIB1 
</P>
<P STYLE="margin-bottom: 0cm">depletion in TNBC cells activates gene
programs associated with decreased</P>
<P STYLE="margin-bottom: 0cm">proliferation and increased cell death.
CIB1 expression levels per se did not</P>
<P STYLE="margin-bottom: 0cm">predict TNBC susceptibility to CIB1
depletion, and CIB1 mRNA expression levels</P>
<P STYLE="margin-bottom: 0cm">did not associate with TNBC patient
survival. Our data are consistent with the</P>
<P STYLE="margin-bottom: 0cm">emerging concept of non-oncogene
addiction, where a large subset of TNBCs depend 
</P>
<P STYLE="margin-bottom: 0cm">on CIB1 for cell survival and tumor
growth, independent of CIB1 expression</P>
<P STYLE="margin-bottom: 0cm">levels. Our data establish CIB1 as a
novel therapeutic target for TNBC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4516161 [Available on
2016-07-01]</P>
<P STYLE="margin-bottom: 0cm">PMID: 26105795 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">19. Am J Cancer Res. 2015 Mar
15;5(4):1308-18. eCollection 2015.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Mogrol represents a novel leukemia
therapeutic, via ERK and STAT3 inhibition.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Liu C(1), Zeng Y(2), Dai LH(2), Cai
TY(3), Zhu YM(2), Dou DQ(3), Ma LQ(4), Sun</P>
<P STYLE="margin-bottom: 0cm">YX(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Beijing University of Agriculture
Beijing 102206, China ; National Engineering</P>
<P STYLE="margin-bottom: 0cm">Laboratory for Industrial Enzymes,
Tianjin Institute of Industrial Biotechnology,</P>
<P STYLE="margin-bottom: 0cm">Chinese Academy of Sciences Tianjin
300308, China ; Key Laboratory of Urban</P>
<P STYLE="margin-bottom: 0cm">Agriculture (North) of Ministry of
Agriculture P. R. China, Beijing University of</P>
<P STYLE="margin-bottom: 0cm">Agriculture Beijing 102206, China.
(2)National Engineering Laboratory for</P>
<P STYLE="margin-bottom: 0cm">Industrial Enzymes, Tianjin Institute
of Industrial Biotechnology, Chinese</P>
<P STYLE="margin-bottom: 0cm">Academy of Sciences Tianjin 300308,
China. (3)Beijing University of Agriculture</P>
<P STYLE="margin-bottom: 0cm">Beijing 102206, China. (4)Beijing
University of Agriculture Beijing 102206, China</P>
<P STYLE="margin-bottom: 0cm">; Key Laboratory of Urban Agriculture
(North) of Ministry of Agriculture P. R.</P>
<P STYLE="margin-bottom: 0cm">China, Beijing University of
Agriculture Beijing 102206, China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Unlike solid tumors, the primary
strategy for leukemia treatment is chemotherapy.</P>
<P STYLE="margin-bottom: 0cm">However, leukemia chemotherapy is
associated with adverse drug effects and drug</P>
<P STYLE="margin-bottom: 0cm">resistance. Therefore, it is imperative
to identify novel agents that effectively</P>
<P STYLE="margin-bottom: 0cm">treat leukemia while minimizing adverse
effects. The Raf/MEK/extracellular</P>
<P STYLE="margin-bottom: 0cm">regulated kinase (ERK) and signal
transducer and activator of transcription 3</P>
<P STYLE="margin-bottom: 0cm">(STAT3) pathways have been implicated
in leukemia carcinogenesis, and provide</P>
<P STYLE="margin-bottom: 0cm">novel molecular targets for therapeutic
intervention in cancer. Mogrol, a</P>
<P STYLE="margin-bottom: 0cm">biometabolite of mogrosides found in
Siraitia grosvenorii, has exhibited</P>
<P STYLE="margin-bottom: 0cm">anti-cancer activities; however, the
underlying mechanism of this effect remains 
</P>
<P STYLE="margin-bottom: 0cm">unclear. To clarify its anti-cancer
activity and mechanism of action, we treated 
</P>
<P STYLE="margin-bottom: 0cm">K562 leukemia cells with mogrol. Mogrol
suppressed leukemia cell growth via</P>
<P STYLE="margin-bottom: 0cm">inhibition of the ERK1/2 and STAT3
pathways, in particular, through the</P>
<P STYLE="margin-bottom: 0cm">suppression of p-ERK1/2 and p-STAT3.
Inhibition of these pathways suppressed</P>
<P STYLE="margin-bottom: 0cm">Bcl-2 expression, thereby inducing K562
cell apoptosis. Furthermore, mogrol</P>
<P STYLE="margin-bottom: 0cm">enhanced p21 expression, resulting in
G0/G1 cell cycle arrest. The findings</P>
<P STYLE="margin-bottom: 0cm">provide new perspectives regarding the
role of mogrol in leukemia treatment.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4473312</P>
<P STYLE="margin-bottom: 0cm">PMID: 26101699 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">20. J Surg Res. 2015 May 29. pii:
S0022-4804(15)00654-X. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.jss.2015.05.043. [Epub ahead
of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Melatonin attenuates hepatic ischemia
through mitogen-activated protein kinase</P>
<P STYLE="margin-bottom: 0cm">signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gim SA(1), Koh PO(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Anatomy, College of
Veterinary Medicine, Research Institute of</P>
<P STYLE="margin-bottom: 0cm">Life Science, Gyeongsang National
University, Jinju, South Korea. (2)Department</P>
<P STYLE="margin-bottom: 0cm">of Anatomy, College of Veterinary
Medicine, Research Institute of Life Science,</P>
<P STYLE="margin-bottom: 0cm">Gyeongsang National University, Jinju,
South Korea. Electronic address:</P>
<P STYLE="margin-bottom: 0cm">pokoh@gnu.ac.kr.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Melatonin exerts a
protective effect during hepatic</P>
<P STYLE="margin-bottom: 0cm">ischemia-reperfusion (I/R) injury
through modulation of the apoptotic cell death 
</P>
<P STYLE="margin-bottom: 0cm">program. Mitogen-activated protein
kinases mediate various intracellular</P>
<P STYLE="margin-bottom: 0cm">processes such as cell differentiation,
survival, and death. This study</P>
<P STYLE="margin-bottom: 0cm">investigated whether melatonin exerts a
protective effect through the activation 
</P>
<P STYLE="margin-bottom: 0cm">of Raf-MEK-ERK and its downstream
targets, including 90 ribosomal S6 kinase</P>
<P STYLE="margin-bottom: 0cm">(p90RSK) and Bad, during hepatic I/R
damage.</P>
<P STYLE="margin-bottom: 0cm">METHODS: Hepatic ischemia was induced
in mice by occlusion of the hepatic artery,</P>
<P STYLE="margin-bottom: 0cm">portal vein, and bile duct. Adult mice
were subjected to 1 h of hepatic ischemia 
</P>
<P STYLE="margin-bottom: 0cm">and 3 h of reperfusion. Vehicle or
melatonin (10 mg/kg, intraperitoneal) was</P>
<P STYLE="margin-bottom: 0cm">injected 15 min before ischemia and
just before reperfusion. Serum aspartate</P>
<P STYLE="margin-bottom: 0cm">aminotransferase and alanine
aminotransferase levels were measured, and terminal 
</P>
<P STYLE="margin-bottom: 0cm">deoxynucleotidyl transferase dUTP
nick-end labeling histochemistry was performed.</P>
<P STYLE="margin-bottom: 0cm">Moreover, Western blot and
immunoprecipitation analyses were performed.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: Melatonin treatment attenuated
hepatic I/R-induced increases in alanine 
</P>
<P STYLE="margin-bottom: 0cm">aminotransferase and aspartate
aminotransferase levels and also ameliorated</P>
<P STYLE="margin-bottom: 0cm">hepatic injury-induced pathologic
lesions and increases of positive terminal</P>
<P STYLE="margin-bottom: 0cm">deoxynucleotidyl transferase dUTP
nick-end labeling staining in hepatic tissues. 
</P>
<P STYLE="margin-bottom: 0cm">Hepatic I/R injury induced decreases in
the phosphorylation of Raf-1, MEK1/2, and</P>
<P STYLE="margin-bottom: 0cm">extracellular-regulated kinase
(ERK)1/2, whereas melatonin attenuated decreases</P>
<P STYLE="margin-bottom: 0cm">in these phosphorylation levels.
Moreover, melatonin prevented the injury-induced</P>
<P STYLE="margin-bottom: 0cm">decreases in phosphorylation of
downstream targets, p90RSK and Bad.</P>
<P STYLE="margin-bottom: 0cm">Immunoprecipitation analysis showed
that the interaction between phospho-Bad and 
</P>
<P STYLE="margin-bottom: 0cm">14-3-3 was decreased in vehicle-treated
animals, while melatonin prevented this</P>
<P STYLE="margin-bottom: 0cm">decrease. Melatonin also attenuated the
injury-induced increase in cleaved</P>
<P STYLE="margin-bottom: 0cm">caspase-3. In cultured hepatocytes,
melatonin treatment prevented the hydrogen</P>
<P STYLE="margin-bottom: 0cm">peroxide-induced cell death and
decrease in phosphorylation of ERK1/2. Moreover, 
</P>
<P STYLE="margin-bottom: 0cm">blocking MEK by PD98059 attenuated the
effect of melatonin.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: These data suggest that
melatonin protects hepatic cells against</P>
<P STYLE="margin-bottom: 0cm">hepatic I/R damage through the
activation of the Raf-MEK-ERK cascade and</P>
<P STYLE="margin-bottom: 0cm">phosphorylation of its downstream
targets.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015 Elsevier Inc. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26101163 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Front Immunol. 2015 Jul 8;6:340.
doi: 10.3389/fimmu.2015.00340. eCollection 2015.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cellular and Molecular Mechanisms of
Chronic Kidney Disease with Diabetes</P>
<P STYLE="margin-bottom: 0cm">Mellitus and Cardiovascular Diseases as
Its Comorbidities.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gajjala PR(1), Sanati M(1), Jankowski
J(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Institute for Molecular
Cardiovascular Research, Universitätsklinikum RWTH</P>
<P STYLE="margin-bottom: 0cm">Aachen , Aachen , Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Chronic kidney disease (CKD), diabetes
mellitus (DM), and cardiovascular diseases</P>
<P STYLE="margin-bottom: 0cm">(CVD) are complex disorders of partly
unknown genesis and mostly known</P>
<P STYLE="margin-bottom: 0cm">progression factors. CVD and DM are the
risk factors of CKD and are strongly</P>
<P STYLE="margin-bottom: 0cm">intertwined since DM can lead to both
CKD and/or CVD, and CVD can lead to kidney 
</P>
<P STYLE="margin-bottom: 0cm">disease. In recent years, our knowledge
of CKD, DM, and CVD has been expanded and</P>
<P STYLE="margin-bottom: 0cm">several important experimental,
clinical, and epidemiological associations have</P>
<P STYLE="margin-bottom: 0cm">been reported. The tight cellular and
molecular interactions between the renal,</P>
<P STYLE="margin-bottom: 0cm">diabetic, and cardiovascular systems in
acute or chronic disease settings are</P>
<P STYLE="margin-bottom: 0cm">becoming increasingly evident. However,
the (patho-) physiological basis of the</P>
<P STYLE="margin-bottom: 0cm">interactions of CKD, DM, and CVD with
involvement of multiple endogenous and</P>
<P STYLE="margin-bottom: 0cm">environmental factors is highly complex
and our knowledge is still at its</P>
<P STYLE="margin-bottom: 0cm">infancy. Not only single pathways and
mediators of progression of these diseases 
</P>
<P STYLE="margin-bottom: 0cm">have to be considered in these
processes but also the mutual interactions of</P>
<P STYLE="margin-bottom: 0cm">these factors are essential. The recent
advances in proteomics and integrative</P>
<P STYLE="margin-bottom: 0cm">analysis technologies have allowed
rapid progress in analyzing complex disorders 
</P>
<P STYLE="margin-bottom: 0cm">and clearly show the opportunity for
new efficient and specific therapies. More</P>
<P STYLE="margin-bottom: 0cm">than a dozen pathways have been
identified so far, including hyperactivity of the</P>
<P STYLE="margin-bottom: 0cm">renin-angiotensin (RAS)-aldosterone
system, osmotic sodium retention, endothelial</P>
<P STYLE="margin-bottom: 0cm">dysfunction, dyslipidemia,
RAS/RAF/extracellular-signal-regulated kinase pathway,</P>
<P STYLE="margin-bottom: 0cm">modification of the purinergic system,
phosphatidylinositol 3-kinase (PI</P>
<P STYLE="margin-bottom: 0cm">3-kinase)-dependent signaling pathways,
and inflammation, all leading to</P>
<P STYLE="margin-bottom: 0cm">histomorphological alterations of the
kidney and vessels of diabetic and</P>
<P STYLE="margin-bottom: 0cm">non-diabetic patients. Since a better
understanding of the common cellular and</P>
<P STYLE="margin-bottom: 0cm">molecular mechanisms of these diseases
may be a key to successful identification 
</P>
<P STYLE="margin-bottom: 0cm">of new therapeutic targets, we review
in this paper the current literature about 
</P>
<P STYLE="margin-bottom: 0cm">cellular and molecular mechanisms of
CKD.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4495338</P>
<P STYLE="margin-bottom: 0cm">PMID: 26217336 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. Nat Prod Res. 2015 Jul 27:1-4. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Anticancer activity of Ophiobolin A,
isolated from the endophytic fungus</P>
<P STYLE="margin-bottom: 0cm">Bipolaris setariae.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Bhatia DR(1), Dhar P, Mutalik V,
Deshmukh SK, Verekar SA, Desai DC, Kshirsagar R,</P>
<P STYLE="margin-bottom: 0cm">Thiagarajan P, Agarwal V.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)a Department of Pharmacology ,
Piramal Enterprises Limited , Mumbai ,</P>
<P STYLE="margin-bottom: 0cm">Maharashtra , India.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The present work describes the
anticancer activity of Ophiobolin A isolated from 
</P>
<P STYLE="margin-bottom: 0cm">the endophytic fungus Bipolaris
setariae. Ophiobolin A was isolated using</P>
<P STYLE="margin-bottom: 0cm">preparative HPLC and its structure was
confirmed by HRMS, (1)H NMR, (13)C NMR,</P>
<P STYLE="margin-bottom: 0cm">COSY, DEPT, HSQC and HMBC. It inhibited
solid and haematological cancer cell</P>
<P STYLE="margin-bottom: 0cm">proliferation with IC50 of 0.4-4.3 μM.
In comparison, IC50 against normal cells</P>
<P STYLE="margin-bottom: 0cm">was 20.9 μM. It was found to inhibit
the phosphorylation of S6</P>
<P STYLE="margin-bottom: 0cm">(IC50 = 1.9 ± 0.2 μM), ERK (IC50 =
0.28 ± 0.02 μM) and RB (IC50 = 1.42 ± 0.1 μM),</P>
<P STYLE="margin-bottom: 0cm">the effector proteins of PI3K/mTOR,
Ras/Raf/ERK and CDK/RB pathways,</P>
<P STYLE="margin-bottom: 0cm">respectively. It induced apoptosis and
inhibited cell cycle progression in</P>
<P STYLE="margin-bottom: 0cm">MDA-MB-231 cancer cells with
concomitant inhibition of signalling proteins. Thus,</P>
<P STYLE="margin-bottom: 0cm">this study reveals that anticancer
activity of Ophiobolin A is associated with</P>
<P STYLE="margin-bottom: 0cm">simultaneous inhibition of multiple
oncogenic signalling pathways namely</P>
<P STYLE="margin-bottom: 0cm">PI3K/mTOR, Ras/Raf/ERK and CDK/RB.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26212208 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. Cell Signal. 2015 Jul 21. pii:
S0898-6568(15)00211-9. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.cellsig.2015.07.014. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Apoptotic induction by lovastatin and
γ-tocotrienol in HL-60 cells via</P>
<P STYLE="margin-bottom: 0cm">Ras/ERK/NF-κB and Ras/Akt/NF-κB
signaling dependent down-regulation of glyoxalase</P>
<P STYLE="margin-bottom: 0cm">1 and HMG-CoA reductase.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Chen CC(1), Liu TY(2), Huang SP(3), Ho
CT(4), Huang TC(5).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Food Science, National
Pingtung University of Science and</P>
<P STYLE="margin-bottom: 0cm">Technology, Pingtung 91201, Taiwan.
Electronic address: tkc720901@gmail.com.</P>
<P STYLE="margin-bottom: 0cm">(2)Department of Biological Science and
Technology, National Pingtung University 
</P>
<P STYLE="margin-bottom: 0cm">of Science and Technology, Pingtung
91201, Taiwan. Electronic address:</P>
<P STYLE="margin-bottom: 0cm">yubaby118@hotmail.com. (3)Department of
Biological Science and Technology,</P>
<P STYLE="margin-bottom: 0cm">National Pingtung University of Science
and Technology, Pingtung 91201, Taiwan.</P>
<P STYLE="margin-bottom: 0cm">Electronic address:
wenily0617@gmail.com. (4)Department of Food Science, Rutgers 
</P>
<P STYLE="margin-bottom: 0cm">University, New Brunswick, NJ 08901,
USA. Electronic address:</P>
<P STYLE="margin-bottom: 0cm">ho@aesop.rutgers.edu. (5)Department of
Food Science, National Pingtung University</P>
<P STYLE="margin-bottom: 0cm">of Science and Technology, Pingtung
91201, Taiwan; Department of Biological</P>
<P STYLE="margin-bottom: 0cm">Science and Technology, National
Pingtung University of Science and Technology,</P>
<P STYLE="margin-bottom: 0cm">Pingtung 91201, Taiwan. Electronic
address: tchuang@mail.npust.edu.tw.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Glyoxalase 1 (GLO1) and HMG-CoA
reductase (HMGCR) are highly expressed in most</P>
<P STYLE="margin-bottom: 0cm">tumor cells and little in normal cells.
In this study, treatment of HL-60 cells</P>
<P STYLE="margin-bottom: 0cm">with lovastatin induced characteristic
apoptosis in a dose-dependent manner. We</P>
<P STYLE="margin-bottom: 0cm">demonstrated that lovastatin treatment
inhibited Ras and Raf protein</P>
<P STYLE="margin-bottom: 0cm">translocation to cell membrane and
eliminated the phosphorylation of the</P>
<P STYLE="margin-bottom: 0cm">downstream effectors Akt and ERK, and
the subsequent NF-κB translocation into</P>
<P STYLE="margin-bottom: 0cm">nucleus. Specific inhibitors and
γ-tocotrienol confirmed the</P>
<P STYLE="margin-bottom: 0cm">Ras/Raf/ERK/NF-κB/GLO1 and
Ras/Akt/NF-κB/GLO1 pathways. Data revealed that</P>
<P STYLE="margin-bottom: 0cm">lovastatin induced HL-60 cell death was
attenuated by mevalonate treatment. We</P>
<P STYLE="margin-bottom: 0cm">demonstrated also that γ-tocotrienol
showed its apoptotic effect on the HL-60</P>
<P STYLE="margin-bottom: 0cm">cell through the same pathway.
γ-Tocotrienol enhanced the apoptotic effect of</P>
<P STYLE="margin-bottom: 0cm">lovastatin through the down-regulation
of GLO1 and HMGCR resulting in an increase</P>
<P STYLE="margin-bottom: 0cm">of methylglyoxal and a decrease of
cholesterol and led to the apoptosis of HL-60 
</P>
<P STYLE="margin-bottom: 0cm">cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015. Published by
Elsevier Inc.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26208883 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">4. Pharmacol Res. 2015 Jul 21. pii:
S1043-6618(15)00143-7. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.phrs.2015.07.010. [Epub ahead
of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A historical overview of protein
kinases and their targeted small molecule</P>
<P STYLE="margin-bottom: 0cm">inhibitors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Roskoski R Jr(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Blue Ridge Institute for Medical
Research, 3754 Brevard Road, Suite 116, Box</P>
<P STYLE="margin-bottom: 0cm">19, Horse Shoe, NC 28742-8814, United
States. Electronic address: rrj@brimr.org.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Protein kinases play a predominant
regulatory role in nearly every aspect of cell</P>
<P STYLE="margin-bottom: 0cm">biology and they can modify the
function of a protein in almost every conceivable</P>
<P STYLE="margin-bottom: 0cm">way. Protein phosphorylation can
increase or decrease enzyme activity and it can 
</P>
<P STYLE="margin-bottom: 0cm">alter other biological activities such
as transcription and translation.</P>
<P STYLE="margin-bottom: 0cm">Moreover, some phosphorylation sites on
a given protein are stimulatory while</P>
<P STYLE="margin-bottom: 0cm">others are inhibitory. The human
protein kinase gene family consists of 518</P>
<P STYLE="margin-bottom: 0cm">members along with 106 pseudogenes.
Furthermore, about 50 of the 518 gene</P>
<P STYLE="margin-bottom: 0cm">products lack important catalytic
residues and are called protein pseudokinases. 
</P>
<P STYLE="margin-bottom: 0cm">The non-catalytic allosteric
interaction of protein kinases and pseudokinases</P>
<P STYLE="margin-bottom: 0cm">with other proteins has added an
important regulatory feature to the biochemistry</P>
<P STYLE="margin-bottom: 0cm">and cell biology of the protein kinase
superfamily. With rare exceptions, a</P>
<P STYLE="margin-bottom: 0cm">divalent cation such as Mg(2+) is
required for the reaction. All protein kinases 
</P>
<P STYLE="margin-bottom: 0cm">exist in a basal state and are
activated only as necessary by divergent</P>
<P STYLE="margin-bottom: 0cm">regulatory stimuli. The mechanisms for
switching between dormant and active</P>
<P STYLE="margin-bottom: 0cm">protein kinases can be intricate.
Phosphorylase kinase was the first protein</P>
<P STYLE="margin-bottom: 0cm">kinase to be characterized
biochemically and the mechanism of its regulation led 
</P>
<P STYLE="margin-bottom: 0cm">to the discovery of cAMP-dependent
protein kinase (protein kinase A, or PKA),</P>
<P STYLE="margin-bottom: 0cm">which catalyzes the phosphorylation and
activation of phosphorylase kinase. This 
</P>
<P STYLE="margin-bottom: 0cm">was the first protein kinase cascade or
signaling module to be elucidated. The</P>
<P STYLE="margin-bottom: 0cm">epidermal growth factor
receptor-Ras-Raf-MEK-ERK signaling module contains</P>
<P STYLE="margin-bottom: 0cm">protein-tyrosine,
protein-serine/threonine, and dual specificity protein kinases.</P>
<P STYLE="margin-bottom: 0cm">PKA has served as a prototype of this
enzyme family and more is known about this 
</P>
<P STYLE="margin-bottom: 0cm">enzyme than any other protein kinase.
The inactive PKA holoenzyme consists of two</P>
<P STYLE="margin-bottom: 0cm">regulatory and two catalytic subunits.
After binding four molecules of cAMP, the 
</P>
<P STYLE="margin-bottom: 0cm">holoenzyme dissociates into a
regulatory subunit dimer (each monomer binds two</P>
<P STYLE="margin-bottom: 0cm">cAMP) and two free and active catalytic
subunits. PKA and all other protein</P>
<P STYLE="margin-bottom: 0cm">kinase domains have a small
amino-terminal lobe and large carboxyterminal lobe as</P>
<P STYLE="margin-bottom: 0cm">determined by X-ray crystallography.
The N-lobe and C-lobe form a cleft that</P>
<P STYLE="margin-bottom: 0cm">serves as a docking site for MgATP.
Nearly all active protein kinases contain a</P>
<P STYLE="margin-bottom: 0cm">K/E/D/D signature sequence that plays
important structural and catalytic roles.</P>
<P STYLE="margin-bottom: 0cm">Protein kinases contain hydrophobic
catalytic and regulatory spines and</P>
<P STYLE="margin-bottom: 0cm">collateral shell residues that are
required to assemble the active enzyme. There 
</P>
<P STYLE="margin-bottom: 0cm">are two general kinds of conformational
changes associated with most protein</P>
<P STYLE="margin-bottom: 0cm">kinases. The first conformational
change involves the formation of an intact</P>
<P STYLE="margin-bottom: 0cm">regulatory spine to form an active
enzyme. The second conformational change</P>
<P STYLE="margin-bottom: 0cm">occurs in active kinases as they toggle
between open and closed conformations</P>
<P STYLE="margin-bottom: 0cm">during their catalytic cycles. Because
mutations and dysregulation of protein</P>
<P STYLE="margin-bottom: 0cm">kinases play causal roles in human
disease, this family of enzymes has become one</P>
<P STYLE="margin-bottom: 0cm">of the most important drug targets over
the past two decades. Imatinib was</P>
<P STYLE="margin-bottom: 0cm">approved by the United States FDA for
the treatment of chronic myelogenous</P>
<P STYLE="margin-bottom: 0cm">leukemia in 2001; this small molecule
inhibits the BCR-Abl protein kinase</P>
<P STYLE="margin-bottom: 0cm">oncoprotein that results from the
formation of the Philadelphia chromosome. More 
</P>
<P STYLE="margin-bottom: 0cm">than two dozen other orally effective
mechanism-based small molecule protein</P>
<P STYLE="margin-bottom: 0cm">kinase inhibitors have been
subsequently approved by the FDA. These drugs bind to</P>
<P STYLE="margin-bottom: 0cm">the ATP-binding site of their target
enzymes and extend into nearby hydrophobic</P>
<P STYLE="margin-bottom: 0cm">pockets. Most of these protein kinase
inhibitors prolong survival in cancer</P>
<P STYLE="margin-bottom: 0cm">patients only weeks or months longer
than standard cytotoxic therapies. In</P>
<P STYLE="margin-bottom: 0cm">contrast, the clinical effectiveness of
imatinib against chronic myelogenous</P>
<P STYLE="margin-bottom: 0cm">leukemia is vastly superior to that of
any other targeted protein kinase</P>
<P STYLE="margin-bottom: 0cm">inhibitor with overall survival lasting
a decade or more. However, the near</P>
<P STYLE="margin-bottom: 0cm">universal and expected development of
drug resistance in the treatment of</P>
<P STYLE="margin-bottom: 0cm">neoplastic disorders requires new
approaches to solve this therapeutic challenge.</P>
<P STYLE="margin-bottom: 0cm">Cancer is the predominant indication
for these drugs, but disease targets are</P>
<P STYLE="margin-bottom: 0cm">increasing. For example, we can expect
the approval of new drugs inhibiting other</P>
<P STYLE="margin-bottom: 0cm">protein kinases in the treatment of
illnesses such as hypertension, Parkinson's</P>
<P STYLE="margin-bottom: 0cm">disease, and autoimmune diseases.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015. Published by
Elsevier Ltd.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26207888 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">5. Postepy Hig Med Dosw (Online). 2015
Jul 6;69(0):729-43. doi:</P>
<P STYLE="margin-bottom: 0cm">10.5604/17322693.1160360.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">CNC proteins in physiology and
pathology.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gęgotek A(1), Skrzydlewska E(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Zakład Chemii Nieorganicznej i
Analitycznej, Uniwersytet Medyczny w</P>
<P STYLE="margin-bottom: 0cm">Białymstoku.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">CNC proteins consist of Bach1, Bach2
and 4 homologous transcription factors:</P>
<P STYLE="margin-bottom: 0cm">Nrf1, Nrf2, Nrf3 and p45NF-E2.
Transcription factors belonging to this group of</P>
<P STYLE="margin-bottom: 0cm">proteins play a crucial role in
protection of cells against oxidative stress.</P>
<P STYLE="margin-bottom: 0cm">Under physiological conditions, they
remain in the cytoplasm in the inactive form</P>
<P STYLE="margin-bottom: 0cm">or are degraded. However, in oxidative
stress conditions, they are translocated</P>
<P STYLE="margin-bottom: 0cm">to the nucleus, and bind to DNA in the
ARE sequence. Consequently, there is</P>
<P STYLE="margin-bottom: 0cm">transcription of genes encoding
cytoprotective proteins, such as phase II</P>
<P STYLE="margin-bottom: 0cm">enzymes, or low molecular weight
antioxidant proteins (i.e., thioredoxin,</P>
<P STYLE="margin-bottom: 0cm">ferritin, metallothionein) responsible
for protecting cells from reactive oxygen 
</P>
<P STYLE="margin-bottom: 0cm">species (ROS) action. The activity of
transcriptional proteins depends directly</P>
<P STYLE="margin-bottom: 0cm">on the redox state of the cell. ROS as
second messenger signals, control</P>
<P STYLE="margin-bottom: 0cm">inhibitors of cytoplasmic CNC proteins
or potentiate the activity of kinases</P>
<P STYLE="margin-bottom: 0cm">(MAPK, PKC, PI3K, PERK), leading to
phosphorylation of transcription factors.</P>
<P STYLE="margin-bottom: 0cm">This is conducive to translocation of
these molecules into the nucleus and to</P>
<P STYLE="margin-bottom: 0cm">formation of complexes that initiate
the gene expression. Disorders of regulation</P>
<P STYLE="margin-bottom: 0cm">of the activity of transcription
factors belonging to the CNC proteins caused by 
</P>
<P STYLE="margin-bottom: 0cm">gene mutations, epigenetic
modifications or increased activity of p62, p21, or</P>
<P STYLE="margin-bottom: 0cm">k-Ras, B-Raf and c-Myc oncogenes,
induce changes in the level of ARE-dependent</P>
<P STYLE="margin-bottom: 0cm">gene expression, which can lead even to
the development of carcinogenesis. On the</P>
<P STYLE="margin-bottom: 0cm">other hand, Nrf transcription factors,
inducing the expression of antioxidants</P>
<P STYLE="margin-bottom: 0cm">and enzymes responsible for the
detoxification of xenobiotics, can be considered 
</P>
<P STYLE="margin-bottom: 0cm">as a potential target of the action of
chemopreventive factors in anticancer</P>
<P STYLE="margin-bottom: 0cm">therapy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26206989 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">6. Mol Cancer. 2015 Jul 22;14:135. doi:
10.1186/s12943-015-0399-9.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3-BrPA eliminates human bladder cancer
cells with highly oncogenic signatures via</P>
<P STYLE="margin-bottom: 0cm">engagement of specific death programs
and perturbation of multiple signaling and 
</P>
<P STYLE="margin-bottom: 0cm">metabolic determinants.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Konstantakou EG(1), Voutsinas GE(2),
Velentzas AD(3), Basogianni AS(4), Paronis</P>
<P STYLE="margin-bottom: 0cm">E(5), Balafas E(6), Kostomitsopoulos
N(7), Syrigos KN(8,)(9), Anastasiadou E(10),</P>
<P STYLE="margin-bottom: 0cm">Stravopodis DJ(11).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Cell Biology and
Biophysics, Faculty of Biology, University of</P>
<P STYLE="margin-bottom: 0cm">Athens, Panepistimiopolis, Zografou
15784, Athens, Greece. eumokon@biol.uoa.gr.</P>
<P STYLE="margin-bottom: 0cm">(2)Laboratory of Environmental
Mutagenesis and Carcinogenesis, Institute of</P>
<P STYLE="margin-bottom: 0cm">Biosciences and Applications, NCSR
Demokritos, Athens, Greece.</P>
<P STYLE="margin-bottom: 0cm">mvoutsin@bio.demokritos.gr.
(3)Department of Cell Biology and Biophysics, Faculty</P>
<P STYLE="margin-bottom: 0cm">of Biology, University of Athens,
Panepistimiopolis, Zografou 15784, Athens,</P>
<P STYLE="margin-bottom: 0cm">Greece. tveletz@biol.uoa.gr.
(4)Department of Cell Biology and Biophysics,</P>
<P STYLE="margin-bottom: 0cm">Faculty of Biology, University of
Athens, Panepistimiopolis, Zografou 15784,</P>
<P STYLE="margin-bottom: 0cm">Athens, Greece.
stefania.basogianni@stud.ki.se. (5)Center of Clinical,</P>
<P STYLE="margin-bottom: 0cm">Experimental Surgery and Translational
Research, Biomedical Research Foundation</P>
<P STYLE="margin-bottom: 0cm">of the Academy of Athens, Athens,
Greece. eparonis@bioacademy.gr. (6)Center of</P>
<P STYLE="margin-bottom: 0cm">Clinical, Experimental Surgery and
Translational Research, Biomedical Research</P>
<P STYLE="margin-bottom: 0cm">Foundation of the Academy of Athens,
Athens, Greece. vbalafas@bioacademy.gr.</P>
<P STYLE="margin-bottom: 0cm">(7)Center of Clinical, Experimental
Surgery and Translational Research,</P>
<P STYLE="margin-bottom: 0cm">Biomedical Research Foundation of the
Academy of Athens, Athens, Greece.</P>
<P STYLE="margin-bottom: 0cm">nkostom@bioacademy.gr. (8)Oncology Unit
GPP, Sotiria General Hospital, Athens</P>
<P STYLE="margin-bottom: 0cm">School of Medicine, Athens, Greece.
ksyrigos@med.uoa.gr. (9)Yale School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, New Haven, Connecticut, USA.
ksyrigos@med.uoa.gr. (10)Center of Basic</P>
<P STYLE="margin-bottom: 0cm">Research, Biomedical Research
Foundation of the Academy of Athens, Athens,</P>
<P STYLE="margin-bottom: 0cm">Greece. anastasiadou@bioacademy.gr.
(11)Department of Cell Biology and</P>
<P STYLE="margin-bottom: 0cm">Biophysics, Faculty of Biology,
University of Athens, Panepistimiopolis, Zografou</P>
<P STYLE="margin-bottom: 0cm">15784, Athens, Greece.
dstravop@biol.uoa.gr.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Urinary bladder cancer is
one of the most fatal and expensive</P>
<P STYLE="margin-bottom: 0cm">diseases of industrialized world.
Despite the strenuous efforts, no seminal</P>
<P STYLE="margin-bottom: 0cm">advances have been achieved for its
clinical management. Given the importance of 
</P>
<P STYLE="margin-bottom: 0cm">metabolic reprogramming in cancer cell
survival and growth, we have herein</P>
<P STYLE="margin-bottom: 0cm">employed 3-BrPA, a halogenated
derivative of pyruvate and historically considered</P>
<P STYLE="margin-bottom: 0cm">inhibitor of glycolysis, to eliminate
bladder cancer cells with highly oncogenic 
</P>
<P STYLE="margin-bottom: 0cm">molecular signatures.</P>
<P STYLE="margin-bottom: 0cm">METHODS: Bladder cancer cells were
exposed to 3-BrPA in the absence or presence</P>
<P STYLE="margin-bottom: 0cm">of several specific inhibitors. Cell
viability was determined by MTT and</P>
<P STYLE="margin-bottom: 0cm">flow-cytometry assays; cell death,
signaling activity and metabolic integrity by 
</P>
<P STYLE="margin-bottom: 0cm">Western blotting and
immunofluorescence; mutant-gene profiling by DNA sequencing;</P>
<P STYLE="margin-bottom: 0cm">and gene expression by RT-sqPCR.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: 3-BrPA could activate
dose-dependent apoptosis (type 1 PCD) and</P>
<P STYLE="margin-bottom: 0cm">regulated necrosis (type 3 PCD) of T24
(grade III; H-Ras(G12V); p53(ΔY126)), but 
</P>
<P STYLE="margin-bottom: 0cm">not RT4 (grade I), cells, with PARP,
MLKL, Drp1 and Nec-7-targeted components</P>
<P STYLE="margin-bottom: 0cm">critically orchestrating necrotic
death. However, similarly to RIPK1 and CypD,</P>
<P STYLE="margin-bottom: 0cm">p53 presented with non-essential
contribution to 3-BrPA-induced cellular</P>
<P STYLE="margin-bottom: 0cm">collapse, while reactivation of mutant
p53 with PRIMA-1 resulted in strong</P>
<P STYLE="margin-bottom: 0cm">synergism of the two agents. Given the
reduced expression of MPC components</P>
<P STYLE="margin-bottom: 0cm">(likely imposing mitochondrial
dysfunction) in T24 cells, the suppression of</P>
<P STYLE="margin-bottom: 0cm">constitutive autophagy (required by
cells carrying oncogenic Ras; also, type 2</P>
<P STYLE="margin-bottom: 0cm">PCD) and derangement of
glucose-homeostasis determinants by 3-BrPA critically</P>
<P STYLE="margin-bottom: 0cm">contribute to drug-directed depletion
of ATP cellular stores. This bioenergetic</P>
<P STYLE="margin-bottom: 0cm">crisis is translated to severe
dysregulation of Akt/FoxO/GSK-3, mTOR/S6, AMPK and</P>
<P STYLE="margin-bottom: 0cm">MAPK (p44/42, p38 and SAPK/JNK)
signaling pathways in 3-BrPA-treated T24 cells.</P>
<P STYLE="margin-bottom: 0cm">Sensitivity to 3-BrPA (and tolerance to
glucose deprivation) does not rely on</P>
<P STYLE="margin-bottom: 0cm">B-Raf(V600E) or K-Ras(G13D) mutant
oncogenic proteins, but partly depends on</P>
<P STYLE="margin-bottom: 0cm">aberrant signaling activities of Akt,
MAPK and AMPK kinases. Interestingly, MCT1-</P>
<P STYLE="margin-bottom: 0cm">and macropinocytosis-mediated influx of
3-BrPA in T24 represents the principal</P>
<P STYLE="margin-bottom: 0cm">mechanism that regulates cellular
responsiveness to the drug. Besides its</P>
<P STYLE="margin-bottom: 0cm">capacity to affect transcription in
gene-dependent manner, 3-BrPA can also induce</P>
<P STYLE="margin-bottom: 0cm">GLUT4-specific splicing silencing in
both sensitive and resistant cells, thus</P>
<P STYLE="margin-bottom: 0cm">dictating alternative routes of drug
trafficking.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Altogether, it seems that
3-BrPA represents a promising agent for</P>
<P STYLE="margin-bottom: 0cm">bladder cancer targeted therapy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4511243</P>
<P STYLE="margin-bottom: 0cm">PMID: 26198749 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">7. J Am Acad Dermatol. 2015 Jul 16.
pii: S0190-9622(15)01745-4. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.jaad.2015.06.006. [Epub ahead
of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Melanocytic nevi excised during B-Raf
proto-oncogene (BRAF) inhibitor therapy: A 
</P>
<P STYLE="margin-bottom: 0cm">study of 19 lesions from 10 patients.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Mochel MC(1), Hammond MR(2), Frederick
DT(2), Alora-Palli MB(3), Piris A(4),</P>
<P STYLE="margin-bottom: 0cm">Flaherty KT(5), Hoang MP(6).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Pathology,
Massachusetts General Hospital, Boston,</P>
<P STYLE="margin-bottom: 0cm">Massachusetts. (2)Department of
Oncology, Massachusetts General Hospital, Boston,</P>
<P STYLE="margin-bottom: 0cm">Massachusetts. (3)Department of
Dermatology, Massachusetts General Hospital,</P>
<P STYLE="margin-bottom: 0cm">Boston, Massachusetts; Harvard Medical
School, Boston, Massachusetts.</P>
<P STYLE="margin-bottom: 0cm">(4)Department of Dermatology, Brigham
and Women's Hospital, Boston,</P>
<P STYLE="margin-bottom: 0cm">Massachusetts; Harvard Medical School,
Boston, Massachusetts. (5)Department of</P>
<P STYLE="margin-bottom: 0cm">Oncology, Massachusetts General
Hospital, Boston, Massachusetts; Harvard Medical 
</P>
<P STYLE="margin-bottom: 0cm">School, Boston, Massachusetts.
(6)Department of Pathology, Massachusetts General 
</P>
<P STYLE="margin-bottom: 0cm">Hospital, Boston, Massachusetts;
Harvard Medical School, Boston, Massachusetts.</P>
<P STYLE="margin-bottom: 0cm">Electronic address:
mhoang@mgh.harvard.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: There are limited
descriptions of histopathology and immune profiles 
</P>
<P STYLE="margin-bottom: 0cm">of new or changing melanocytic nevi in
the setting of B-Raf proto-oncogene (BRAF)</P>
<P STYLE="margin-bottom: 0cm">inhibitor therapy.</P>
<P STYLE="margin-bottom: 0cm">OBJECTIVE: We sought to identify their
distinctive features.</P>
<P STYLE="margin-bottom: 0cm">METHODS: Clinical charts and histologic
review, neuroblastoma RAS viral (v-ras)</P>
<P STYLE="margin-bottom: 0cm">oncogene homolog genotyping, and
immunohistochemistry for HMB-45, BRAFV600E,</P>
<P STYLE="margin-bottom: 0cm">phosphorylated extracellular
signal-regulated kinase (pERK), phosphorylated</P>
<P STYLE="margin-bottom: 0cm">protein kinase B, CD4, and CD8 were
performed on 19 melanocytic nevi from 10</P>
<P STYLE="margin-bottom: 0cm">patients and 23 control nevi.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: BRAF inhibitors were
administered for metastatic melanoma (7), colonic</P>
<P STYLE="margin-bottom: 0cm">adenocarcinoma (2), and papillary
thyroid carcinoma (1). The average duration of 
</P>
<P STYLE="margin-bottom: 0cm">BRAF inhibition before lesion excision
was 8 months. Frequently associated</P>
<P STYLE="margin-bottom: 0cm">histologic features included
pigmentation of the stratum corneum, hyperpigmented 
</P>
<P STYLE="margin-bottom: 0cm">keratinocytes, dermal melanophages, and
deep HMB-45 expression. The lesions were 
</P>
<P STYLE="margin-bottom: 0cm">BRAFV600E and neuroblastoma RAS viral
(v-ras) oncogene homolog wild-type,</P>
<P STYLE="margin-bottom: 0cm">expressed diffuse weak-moderate pERK,
and possessed a predominance of CD8(+) in</P>
<P STYLE="margin-bottom: 0cm">comparison with CD4(+) T lymphocytes
within the dermal infiltrates.</P>
<P STYLE="margin-bottom: 0cm">LIMITATION: This is a retrospective
study of a small and heterogeneous group.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: The nevi associated with
BRAF inhibitor therapy invariably lack</P>
<P STYLE="margin-bottom: 0cm">BRAFV600E mutation. BRAF inhibition
appears to cause an increased cytotoxic</P>
<P STYLE="margin-bottom: 0cm">T-cell response and increased
mitogen-activated protein kinase activity in BRAF</P>
<P STYLE="margin-bottom: 0cm">wild-type lesions, supported by pERK
expression, possibly resulting in an</P>
<P STYLE="margin-bottom: 0cm">activated phenotype characterized by
increased melanin pigmentation and deep</P>
<P STYLE="margin-bottom: 0cm">HMB-45 expression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015 American Academy of
Dermatology, Inc. Published by Elsevier Inc.</P>
<P STYLE="margin-bottom: 0cm">All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26190239 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">8. Exp Cell Res. 2015 Jul 14. pii:
S0014-4827(15)30043-4. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.yexcr.2015.07.013. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Differential effects of polyoma virus
middle tumor antigen mutants upon gap</P>
<P STYLE="margin-bottom: 0cm">junctional, intercellular
communication.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Geletu M(1), Guy S(1), Greer S(1),
Raptis L(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biomedical and
Molecular Sciences and Department of Pathology</P>
<P STYLE="margin-bottom: 0cm">and Molecular Medicine, Queen's
University, Kingston, Ontario, Canada K7L 3N6.</P>
<P STYLE="margin-bottom: 0cm">(2)Department of Biomedical and
Molecular Sciences and Department of Pathology</P>
<P STYLE="margin-bottom: 0cm">and Molecular Medicine, Queen's
University, Kingston, Ontario, Canada K7L 3N6.</P>
<P STYLE="margin-bottom: 0cm">Electronic address: raptisl@queensu.ca.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gap junctions are channels that connect
the cytoplasm of adjacent cells.</P>
<P STYLE="margin-bottom: 0cm">Oncogenes such as the middle Tumor
antigen of polyoma virus (mT) are known to</P>
<P STYLE="margin-bottom: 0cm">suppress gap junctional, intercellular
communication (GJIC). mT associates with</P>
<P STYLE="margin-bottom: 0cm">and is tyrosine-phosphorylated by cSrc
family members. Specific mT</P>
<P STYLE="margin-bottom: 0cm">phosphotyrosines provide docking sites
for the phosphotyrosine binding domain of 
</P>
<P STYLE="margin-bottom: 0cm">Shc (mT-tyr250) or the SH2 domain of
the regulatory subunit of the</P>
<P STYLE="margin-bottom: 0cm">phosphatidylinositol-3 kinase (PI3k,
mT-tyr315). Binding results in the</P>
<P STYLE="margin-bottom: 0cm">activation of their downstream
signaling cascades, Ras/Raf/Erk and PI3</P>
<P STYLE="margin-bottom: 0cm">kinase/Akt, respectively, both of which
are needed for full neoplastic</P>
<P STYLE="margin-bottom: 0cm">transformation. To examine the effect
of mT-initiated pathways upon gap</P>
<P STYLE="margin-bottom: 0cm">junctional communication, GJIC was
quantitated in rat liver epithelial T51B cells</P>
<P STYLE="margin-bottom: 0cm">expressing mT-mutants, using a novel
technique of in situ electroporation. The</P>
<P STYLE="margin-bottom: 0cm">results demonstrate for the first time
that, although even low levels of</P>
<P STYLE="margin-bottom: 0cm">wild-type mT are sufficient to
interrupt gap junctional communication, GJIC</P>
<P STYLE="margin-bottom: 0cm">suppression still requires an intact
tyr-250 site, that is activation of the Ras 
</P>
<P STYLE="margin-bottom: 0cm">pathway. In sharp contrast, activation
of the PI3k pathway is not required for</P>
<P STYLE="margin-bottom: 0cm">GJIC suppression, indicating that GJIC
suppression is independent of full</P>
<P STYLE="margin-bottom: 0cm">neoplastic conversion and the
concomitant morphological changes. Interestingly,</P>
<P STYLE="margin-bottom: 0cm">expression of a constitutively active,
myristylated form of the catalytic subunit</P>
<P STYLE="margin-bottom: 0cm">of PI3k, p110, or the constitutively
active mutants E545K and H1047R increased</P>
<P STYLE="margin-bottom: 0cm">GJIC, while pharmacological inhibition
of PI3k eliminated communication.</P>
<P STYLE="margin-bottom: 0cm">Therefore, although PI3k is growth
promoting and in an activated form it can act 
</P>
<P STYLE="margin-bottom: 0cm">as an oncogene, it actually plays a
positive role upon gap junctional,</P>
<P STYLE="margin-bottom: 0cm">intercellular communication.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015 Elsevier Inc. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26187405 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">9. Blood Cancer J. 2015 Jul 17;5:e324.
doi: 10.1038/bcj.2015.52.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Peripheral blood cells from children
with RASopathies show enhanced spontaneous</P>
<P STYLE="margin-bottom: 0cm">colonies growth in vitro and
hyperactive RAS signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gaipa G(1), Bugarin C(1), Cianci P(2),
Sarno J(1), Bonaccorso P(3), Biondi A(4), 
</P>
<P STYLE="margin-bottom: 0cm">Selicorni A(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)M. Tettamanti Research Centre,
Pediatric Clinic, University of Milano-Bicocca,</P>
<P STYLE="margin-bottom: 0cm">Monza, Italy. (2)Pediatrics Clinical
Genetics, MBBM-AO San Gerardo Foundation,</P>
<P STYLE="margin-bottom: 0cm">University of Milano-Bicocca, Monza,
Italy. (3)1] M. Tettamanti Research Centre, 
</P>
<P STYLE="margin-bottom: 0cm">Pediatric Clinic, University of
Milano-Bicocca, Monza, Italy [2] Center of</P>
<P STYLE="margin-bottom: 0cm">Pediatric Hematology Oncology, Azienda
Policlinico-OVE, University of Catania,</P>
<P STYLE="margin-bottom: 0cm">Catania, Italy. (4)1] M. Tettamanti
Research Centre, Pediatric Clinic, University</P>
<P STYLE="margin-bottom: 0cm">of Milano-Bicocca, Monza, Italy [2]
Pediatrics Clinical Genetics, MBBM-AO San</P>
<P STYLE="margin-bottom: 0cm">Gerardo Foundation, University of
Milano-Bicocca, Monza, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Germline mutations in genes coding for
molecules involved in the RAS/RAF/MEK/ERK 
</P>
<P STYLE="margin-bottom: 0cm">pathway are the hallmarks of a newly
classified family of autosomal dominant</P>
<P STYLE="margin-bottom: 0cm">syndromes termed RASopathies.
Myeloproliferative disorders (MPDs), in particular,</P>
<P STYLE="margin-bottom: 0cm">juvenile myelomonocytic leukemia, can
lead to potentially severe complications in</P>
<P STYLE="margin-bottom: 0cm">children with Noonan syndrome (NS). We
studied 27 children with NS or other</P>
<P STYLE="margin-bottom: 0cm">RASopathies and 35 age-matched children
as control subjects. Peripheral blood</P>
<P STYLE="margin-bottom: 0cm">(PB) cells from these patients were
studied for in vitro colony-forming units</P>
<P STYLE="margin-bottom: 0cm">(CFUs) activity, as well as for
intracellular phosphosignaling. Higher</P>
<P STYLE="margin-bottom: 0cm">spontaneous growth of both
burst-forming units-erythroid (BFU-E) and</P>
<P STYLE="margin-bottom: 0cm">CFU-granulocyte/macrophage (CFU-GM)
colonies from RAS-mutated patients were</P>
<P STYLE="margin-bottom: 0cm">observed as compared with control
subjects. We also observed a significantly</P>
<P STYLE="margin-bottom: 0cm">higher amount of GM-colony-stimulating
factor-induced p-ERK in children with</P>
<P STYLE="margin-bottom: 0cm">RASopathies. Our findings demonstrate
for the first time that PB cells isolated</P>
<P STYLE="margin-bottom: 0cm">from children suffering from NS or
other RASopathies without MPD display enhanced</P>
<P STYLE="margin-bottom: 0cm">BFU-E and CFU-GM colony formation in
vitro. The biological significance of these 
</P>
<P STYLE="margin-bottom: 0cm">findings clearly awaits further
studies. Collectively, our data provide a basis</P>
<P STYLE="margin-bottom: 0cm">for further investigating of only
partially characterized hematological</P>
<P STYLE="margin-bottom: 0cm">alterations present in children
suffering from RASopathies, and may provide new</P>
<P STYLE="margin-bottom: 0cm">markers for progression toward
malignant MPD in these patients.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26186557 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">10. Pigment Cell Melanoma Res. 2015 Jul
14. doi: 10.1111/pcmr.12395. [Epub ahead of</P>
<P STYLE="margin-bottom: 0cm">print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A (heat) shocking development: FBXW7
loss unleashes HSF1 to drive melanoma</P>
<P STYLE="margin-bottom: 0cm">invasion and metastasis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cho E, Grim JE.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Melanoma is the deadliest form of skin
cancer because of its strong tendency for 
</P>
<P STYLE="margin-bottom: 0cm">local invasion, distant metastasis, and
resistance to traditional cytotoxic</P>
<P STYLE="margin-bottom: 0cm">chemotherapy. A more complete
understanding of the genetic landscape of melanoma 
</P>
<P STYLE="margin-bottom: 0cm">will define and clarify the molecular
pathways that drive tumor growth and will</P>
<P STYLE="margin-bottom: 0cm">also reveal new therapeutic targets.
Indeed, this is already being borne out:</P>
<P STYLE="margin-bottom: 0cm">multiple studies have demonstrated that
activating mutations in components of the</P>
<P STYLE="margin-bottom: 0cm">RAS/RAF/MEK/ERK pathway occur in over
half of melanoma tumor samples and targeted</P>
<P STYLE="margin-bottom: 0cm">inhibitors of this pathway are
currently used to treat patients with these</P>
<P STYLE="margin-bottom: 0cm">cancers. This article is protected by
copyright. All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">This article is protected by copyright.
All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26178611 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">11. Discov Med. 2015
Jun;19(107):455-61.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Novel mechanisms and therapeutic
approaches in melanoma: targeting the MAPK</P>
<P STYLE="margin-bottom: 0cm">pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Grimaldi AM(1), Simeone E, Festino L,
Vanella V, Palla M, Ascierto PA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)O.U. Melanoma, Cancer Immunotherapy
and Innovative Therapies, National Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Institute of Naples &quot;G. Pascale&quot;
Foundation, Naples, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The development of novel treatments
that selectively inhibit the RAS-RAF-MAPK</P>
<P STYLE="margin-bottom: 0cm">pathway represents a milestone in the
history of melanoma treatment. BRAF</P>
<P STYLE="margin-bottom: 0cm">mutations occur in approximately 45% of
cutaneous melanomas, while mutations in</P>
<P STYLE="margin-bottom: 0cm">NRAS occur in 15-25%. Vemurafenib was
the first BRAF inhibitor to be approved in 
</P>
<P STYLE="margin-bottom: 0cm">2011, based on the results of a phase
III trial (BRIM-3) that showed higher</P>
<P STYLE="margin-bottom: 0cm">progression-free survival and overall
survival compared with dacarbazine</P>
<P STYLE="margin-bottom: 0cm">chemotherapy in metastatic BRAF-mutated
melanoma. Dabrafenib, another BRAF</P>
<P STYLE="margin-bottom: 0cm">inhibitor, has shown similar results
and was approved in 2013. Preclinical</P>
<P STYLE="margin-bottom: 0cm">studies suggested that another novel
group of agents, the MEK inhibitors, showed 
</P>
<P STYLE="margin-bottom: 0cm">stronger inhibition of both mutated
BRAF and NRAS cell cultures than vemurafenib.</P>
<P STYLE="margin-bottom: 0cm">Trametinib was the first MEK inhibitor
approved in 2014, both as a single agent</P>
<P STYLE="margin-bottom: 0cm">and in combination with dabrafenib for
the treatment of advanced BRAF-mutated</P>
<P STYLE="margin-bottom: 0cm">melanoma. Other MEK inhibitors are also
in development. Concomitant inhibition of</P>
<P STYLE="margin-bottom: 0cm">both MEK and BRAF has shown more
durable and greater tumor response than BRAF</P>
<P STYLE="margin-bottom: 0cm">monotherapy, by overcoming the multiple
genetic mechanisms of escape. Combined</P>
<P STYLE="margin-bottom: 0cm">therapy prevents the development of
acquired resistance as well as decreasing</P>
<P STYLE="margin-bottom: 0cm">cutaneous toxicity secondary to
paradoxical activation of the MAPK pathway</P>
<P STYLE="margin-bottom: 0cm">induced by BRAF inhibitors. Various
combinations of BRAF and MEK inhibitors have 
</P>
<P STYLE="margin-bottom: 0cm">shown promising results. Moreover,
triple combination therapies involved other</P>
<P STYLE="margin-bottom: 0cm">agents with novel mechanisms of action
are also being evaluated. These and other 
</P>
<P STYLE="margin-bottom: 0cm">combination strategies involving
immunotherapies and targeted therapies offer the</P>
<P STYLE="margin-bottom: 0cm">hope of improving outcomes beyond those
already achieved with anti-BRAF</P>
<P STYLE="margin-bottom: 0cm">treatments.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26175403 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">12. Biomed Res Int. 2015;2015:203978.
doi: 10.1155/2015/203978. Epub 2015 Jun 18.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A Novel Matrine Derivative WM130
Inhibits Activation of Hepatic Stellate Cells</P>
<P STYLE="margin-bottom: 0cm">and Attenuates
Dimethylnitrosamine-Induced Liver Fibrosis in Rats.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Xu Y(1), Peng Z(1), Ji W(1), Li X(2),
Lin X(1), Qian L(3), Li X(1), Chai X(2), Wu</P>
<P STYLE="margin-bottom: 0cm">Q(2), Gao Q(4), Su C(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Molecular Oncology,
Eastern Hepatobiliary Surgery Hospital and</P>
<P STYLE="margin-bottom: 0cm">National Center of Liver Cancer, Second
Military Medical University, Shanghai</P>
<P STYLE="margin-bottom: 0cm">200438, China. (2)Deparment of
Pharmacy, Second Military Medical University,</P>
<P STYLE="margin-bottom: 0cm">Shanghai 200433, China. (3)Department
of Molecular Oncology, Eastern</P>
<P STYLE="margin-bottom: 0cm">Hepatobiliary Surgery Hospital and
National Center of Liver Cancer, Second</P>
<P STYLE="margin-bottom: 0cm">Military Medical University, Shanghai
200438, China ; Department of General</P>
<P STYLE="margin-bottom: 0cm">Surgery, Wujiang No. 1 People's
Hospital, Suzhou 215200, China. (4)Department of 
</P>
<P STYLE="margin-bottom: 0cm">General Surgery, Wujiang No. 1 People's
Hospital, Suzhou 215200, China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Activation of hepatic stellate cells
(HSCs) is a critical event in process of</P>
<P STYLE="margin-bottom: 0cm">hepatic fibrogenesis and cirrhosis.
Matrine, the active ingredient of Sophora,</P>
<P STYLE="margin-bottom: 0cm">had been used for clinical treatment of
acute/chronic liver disease. However, its</P>
<P STYLE="margin-bottom: 0cm">potency was low. We prepared a high
potency and low toxicity matrine derivate,</P>
<P STYLE="margin-bottom: 0cm">WM130 (C30N4H40SO5F), which exhibited
better pharmacological activities on</P>
<P STYLE="margin-bottom: 0cm">antihepatic fibrosis. This study
demonstrated that WM130 results in a decreased</P>
<P STYLE="margin-bottom: 0cm">proliferative activity of HSC-T6 cells,
with the half inhibitory concentration</P>
<P STYLE="margin-bottom: 0cm">(IC50) of 68 μM. WM130 can inhibit
the migration and induce apoptosis in HSC-T6</P>
<P STYLE="margin-bottom: 0cm">cells at both concentrations of 68 μM
(IC50) and 34 μM (half IC50). The</P>
<P STYLE="margin-bottom: 0cm">expression of α-SMA, Collagen I,
Collagen III, and TGF-β1 could be downregulated,</P>
<P STYLE="margin-bottom: 0cm">and the protein phosphorylation levels
of EGFR, AKT, ERK, Smad, and Raf (p-EGFR, 
</P>
<P STYLE="margin-bottom: 0cm">p-AKT, p-ERK, p-Smad, and p-Raf) were
also decreased by WM130. On the DMN-induced</P>
<P STYLE="margin-bottom: 0cm">rat liver fibrosis model, WM130 can
effectively reduce the TGF-β1, AKT, α-SMA,</P>
<P STYLE="margin-bottom: 0cm">and p-ERK levels, decrease the
extracellular matrix (ECM) formation, and inhibit 
</P>
<P STYLE="margin-bottom: 0cm">rat liver fibrosis progression. In
conclusion, this study demonstrated that WM130</P>
<P STYLE="margin-bottom: 0cm">can significantly inhibit the
activation of HSC-T6 cells and block the rat liver 
</P>
<P STYLE="margin-bottom: 0cm">fibrosis progression by inducing
apoptosis, suppressing the deposition of ECM,</P>
<P STYLE="margin-bottom: 0cm">and inhibiting TGF-β/Smad and Ras/ERK
pathways.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4488526</P>
<P STYLE="margin-bottom: 0cm">PMID: 26167476 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">13. Radiother Oncol. 2015 Jul 8. pii:
S0167-8140(15)00323-0. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.radonc.2015.06.026. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Trametinib radiosensitises RAS- and
BRAF-mutated melanoma by perturbing cell</P>
<P STYLE="margin-bottom: 0cm">cycle and inducing senescence.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Schick U(1), Kyula J(1), Barker H(1),
Patel R(1), Zaidi S(1), Gregory C(1), Hafsi</P>
<P STYLE="margin-bottom: 0cm">H(1), Roulstone V(1), Deutsch E(2),
McLaughlin M(1), Harrington K(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Targeted Therapy Team, The Institute
of Cancer Research, London, United</P>
<P STYLE="margin-bottom: 0cm">Kingdom. (2)INSERM UMR 1030, Gustave
Roussy, Villejuif, France. (3)Targeted</P>
<P STYLE="margin-bottom: 0cm">Therapy Team, The Institute of Cancer
Research, London, United Kingdom.</P>
<P STYLE="margin-bottom: 0cm">Electronic address:
Kevin.Harrington@icr.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PURPOSE: Radiotherapy (RT) is used
frequently in patients with melanoma, but</P>
<P STYLE="margin-bottom: 0cm">results are suboptimal because the
disease is often radioresistant. This may be</P>
<P STYLE="margin-bottom: 0cm">due to constitutive activation of MAPK
pathway signalling through mutations</P>
<P STYLE="margin-bottom: 0cm">involving RAS/RAF. Thus, we studied
whether trametinib, a potent and selective</P>
<P STYLE="margin-bottom: 0cm">allosteric inhibitor of MEK1/2 could
improve the efficacy of RT.</P>
<P STYLE="margin-bottom: 0cm">METHODS AND MATERIALS: Clonogenic
survival assays were performed in human</P>
<P STYLE="margin-bottom: 0cm">BRAF-mutant (A375), NRAS-mutant (D04,
WM1631), KRAS-mutant (WM1791c) and</P>
<P STYLE="margin-bottom: 0cm">wild-type (PMWK) melanoma cell lines.
The effects of trametinib with and without 
</P>
<P STYLE="margin-bottom: 0cm">radiation on protein levels of MEK
effectors were measured by immunoblot</P>
<P STYLE="margin-bottom: 0cm">analyses. Cell cycle effects, DNA
damage repair, mitotic catastrophe and</P>
<P STYLE="margin-bottom: 0cm">senescence were measured using flow
cytometry, γH2Ax staining, nuclear</P>
<P STYLE="margin-bottom: 0cm">fragmentation and β-galactosidase
staining, respectively. Additionally, athymic</P>
<P STYLE="margin-bottom: 0cm">mice with D04 flank tumours were
treated with fractionated RT after gavage with</P>
<P STYLE="margin-bottom: 0cm">trametinib and monitored for tumour
growth.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: All cell lines, except PMWK,
exhibited enhanced cytotoxicity when RT was</P>
<P STYLE="margin-bottom: 0cm">combined with trametinib compared to
either agent alone. Sensitiser enhancement</P>
<P STYLE="margin-bottom: 0cm">ratios were 1.70, 1.32, 1.10, and 1.70
for A375, D04, WM1361 and WM1791c,</P>
<P STYLE="margin-bottom: 0cm">respectively. Trametinib efficiently
blocked RT-induced phosphorylation of ERK at</P>
<P STYLE="margin-bottom: 0cm">nanomolar concentrations. Increased
radiosensitivity correlated with prolonged G1</P>
<P STYLE="margin-bottom: 0cm">arrest and reduction in the
radioresistant S phase up to 48h following RT. A</P>
<P STYLE="margin-bottom: 0cm">larger population of
senescence-activated β-galactosidase-positive cells was seen</P>
<P STYLE="margin-bottom: 0cm">in the trametinib pretreated group, and
this correlated with activation of two of</P>
<P STYLE="margin-bottom: 0cm">the major mediators of induced
senescence, p53 and pRb. Mice receiving the</P>
<P STYLE="margin-bottom: 0cm">combination treatment (trametinib
1mg/kg and RT over 3days) showed a reduced mean</P>
<P STYLE="margin-bottom: 0cm">tumour volume compared with mice
receiving trametinib alone (p=0.016), or RT</P>
<P STYLE="margin-bottom: 0cm">alone (p=0.047). No overt signs of drug
toxicity were observed.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: Trametinib radiosensitised
RAS-/RAF-mutated melanoma cells by</P>
<P STYLE="margin-bottom: 0cm">inducing prolonged G1 arrest and
premature senescence. In this pre-clinical study</P>
<P STYLE="margin-bottom: 0cm">we demonstrate that combining
trametinib and RT is well tolerated, and reduces</P>
<P STYLE="margin-bottom: 0cm">tumour growth in vivo.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015. Published by
Elsevier Ireland Ltd.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26163092 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">14. Evid Based Complement Alternat Med.
2015;2015:641286. doi: 10.1155/2015/641286.</P>
<P STYLE="margin-bottom: 0cm">Epub 2015 Jun 16.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Effect of Repeated Electroacupuncture
Intervention on Hippocampal ERK and p38MAPK</P>
<P STYLE="margin-bottom: 0cm">Signaling in Neuropathic Pain Rats.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Wang JY(1), Chen SP(1), Gao YH(1), Qiao
LN(1), Zhang JL(1), Liu JL(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Physiology, Institute
of Acupuncture and Moxibustion, China</P>
<P STYLE="margin-bottom: 0cm">Academy of Chinese Medical Sciences,
Beijing 100700, China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Results of our past studies showed that
hippocampal muscarinic acetylcholine</P>
<P STYLE="margin-bottom: 0cm">receptor (mAChR)-1 mRNA and
differentially expressed proteins participating in</P>
<P STYLE="margin-bottom: 0cm">MAPK signaling were involved in
electroacupuncture (EA) induced cumulative</P>
<P STYLE="margin-bottom: 0cm">analgesia in neuropathic pain rats, but
the underlying intracellular mechanism</P>
<P STYLE="margin-bottom: 0cm">remains unknown. The present study was
designed to observe the effect of EA</P>
<P STYLE="margin-bottom: 0cm">stimulation (EAS) on hippocampal
extracellular signal-regulated kinases (ERK) and</P>
<P STYLE="margin-bottom: 0cm">p38 MAPK signaling in rats with chronic
constrictive injury (CCI) of the sciatic 
</P>
<P STYLE="margin-bottom: 0cm">nerve, so as to reveal its related
intracellular targets in pain relief. After</P>
<P STYLE="margin-bottom: 0cm">CCI, the thermal pain thresholds of the
affected hind were significantly</P>
<P STYLE="margin-bottom: 0cm">decreased compared with the control
group (P &lt; 0.05). Following one and two</P>
<P STYLE="margin-bottom: 0cm">weeks' EAS of ST 36-GB34, the pain
thresholds were significantly upregulated (P &lt;</P>
<P STYLE="margin-bottom: 0cm">0.05), and the effect of EA2W was
remarkably superior to that of EA2D and EA1W (P</P>
<P STYLE="margin-bottom: 0cm">&lt; 0.05). Correspondingly,
CCI-induced decreased expression levels of Ras, c-Raf, 
</P>
<P STYLE="margin-bottom: 0cm">ERK1 and p-ERK1/2 proteins, and p38
MAPK mRNA and p-p38MAPK protein in the</P>
<P STYLE="margin-bottom: 0cm">hippocampus tissues were reversed by
EA2W (P &lt; 0.05). The above mentioned results</P>
<P STYLE="margin-bottom: 0cm">indicated that EA2W induced cumulative
analgesic effect may be closely associated</P>
<P STYLE="margin-bottom: 0cm">with its function in removing
neuropathic pain induced suppression of</P>
<P STYLE="margin-bottom: 0cm">intracellular ERK and p38MAPK signaling
in the hippocampus.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4487344</P>
<P STYLE="margin-bottom: 0cm">PMID: 26161123 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">15. J Biomed Sci. 2015 Jul 9;22(1):52.
doi: 10.1186/s12929-015-0158-7.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The effects and mechanisms of SLC34A2
in tumorigenesis and progression of human</P>
<P STYLE="margin-bottom: 0cm">non-small cell lung cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Wang Y(1), Yang W(2), Pu Q(3), Yang
Y(4), Ye S(5), Ma Q(6), Ren J(7), Cao Z(8),</P>
<P STYLE="margin-bottom: 0cm">Zhong G(9), Zhang X(10), Liu L(11), Zhu
W(12).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)State Key Laboratory of Biotherapy
and Cancer Center, West China Hospital,</P>
<P STYLE="margin-bottom: 0cm">Sichuan University, and Collaborative
Innovation Center for Biotherapy, NO. 1,</P>
<P STYLE="margin-bottom: 0cm">Keyuan 4th Road, Gaopeng Street, High
Technological Development Zone, 610041,</P>
<P STYLE="margin-bottom: 0cm">Chengdu, Sichuan, P. R. China.
wangyu_4932@163.com. (2)State Key Laboratory of</P>
<P STYLE="margin-bottom: 0cm">Biotherapy and Cancer Center, West
China Hospital, Sichuan University, and</P>
<P STYLE="margin-bottom: 0cm">Collaborative Innovation Center for
Biotherapy, NO. 1, Keyuan 4th Road, Gaopeng</P>
<P STYLE="margin-bottom: 0cm">Street, High Technological Development
Zone, 610041, Chengdu, Sichuan, P. R.</P>
<P STYLE="margin-bottom: 0cm">China. younger1030@163.com.
(3)Department of Thoracic Surgery, West China</P>
<P STYLE="margin-bottom: 0cm">Hospital, Sichuan University, No. 37
Guo Xue Xiang, 610041, Chengdu, Sichuan, P. 
</P>
<P STYLE="margin-bottom: 0cm">R. China. puqiang11@gmail.com. (4)State
Key Laboratory of Biotherapy and Cancer</P>
<P STYLE="margin-bottom: 0cm">Center, West China Hospital, Sichuan
University, and Collaborative Innovation</P>
<P STYLE="margin-bottom: 0cm">Center for Biotherapy, NO. 1, Keyuan
4th Road, Gaopeng Street, High Technological</P>
<P STYLE="margin-bottom: 0cm">Development Zone, 610041, Chengdu,
Sichuan, P. R. China. scu_yanyang@163.com.</P>
<P STYLE="margin-bottom: 0cm">(5)State Key Laboratory of Biotherapy
and Cancer Center, West China Hospital,</P>
<P STYLE="margin-bottom: 0cm">Sichuan University, and Collaborative
Innovation Center for Biotherapy, NO. 1,</P>
<P STYLE="margin-bottom: 0cm">Keyuan 4th Road, Gaopeng Street, High
Technological Development Zone, 610041,</P>
<P STYLE="margin-bottom: 0cm">Chengdu, Sichuan, P. R. China.
shiny9191@163.com. (6)State Key Laboratory of</P>
<P STYLE="margin-bottom: 0cm">Biotherapy and Cancer Center, West
China Hospital, Sichuan University, and</P>
<P STYLE="margin-bottom: 0cm">Collaborative Innovation Center for
Biotherapy, NO. 1, Keyuan 4th Road, Gaopeng</P>
<P STYLE="margin-bottom: 0cm">Street, High Technological Development
Zone, 610041, Chengdu, Sichuan, P. R.</P>
<P STYLE="margin-bottom: 0cm">China. qingpingle2008@163.com. (7)State
Key Laboratory of Biotherapy and Cancer</P>
<P STYLE="margin-bottom: 0cm">Center, West China Hospital, Sichuan
University, and Collaborative Innovation</P>
<P STYLE="margin-bottom: 0cm">Center for Biotherapy, NO. 1, Keyuan
4th Road, Gaopeng Street, High Technological</P>
<P STYLE="margin-bottom: 0cm">Development Zone, 610041, Chengdu,
Sichuan, P. R. China. rjham@126.com. (8)State 
</P>
<P STYLE="margin-bottom: 0cm">Key Laboratory of Biotherapy and Cancer
Center, West China Hospital, Sichuan</P>
<P STYLE="margin-bottom: 0cm">University, and Collaborative
Innovation Center for Biotherapy, NO. 1, Keyuan 4th</P>
<P STYLE="margin-bottom: 0cm">Road, Gaopeng Street, High
Technological Development Zone, 610041, Chengdu,</P>
<P STYLE="margin-bottom: 0cm">Sichuan, P. R. China.
caozhixing007@163.com. (9)State Key Laboratory of</P>
<P STYLE="margin-bottom: 0cm">Biotherapy and Cancer Center, West
China Hospital, Sichuan University, and</P>
<P STYLE="margin-bottom: 0cm">Collaborative Innovation Center for
Biotherapy, NO. 1, Keyuan 4th Road, Gaopeng</P>
<P STYLE="margin-bottom: 0cm">Street, High Technological Development
Zone, 610041, Chengdu, Sichuan, P. R.</P>
<P STYLE="margin-bottom: 0cm">China. guoxingzhong@gmail.com.
(10)State Key Laboratory of Biotherapy and Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Center, West China Hospital, Sichuan
University, and Collaborative Innovation</P>
<P STYLE="margin-bottom: 0cm">Center for Biotherapy, NO. 1, Keyuan
4th Road, Gaopeng Street, High Technological</P>
<P STYLE="margin-bottom: 0cm">Development Zone, 610041, Chengdu,
Sichuan, P. R. China. 42539791@qq.com.</P>
<P STYLE="margin-bottom: 0cm">(11)Department of Thoracic Surgery,
West China Hospital, Sichuan University, No. 
</P>
<P STYLE="margin-bottom: 0cm">37 Guo Xue Xiang, 610041, Chengdu,
Sichuan, P. R. China. lunxu_liu@aliyun.com.</P>
<P STYLE="margin-bottom: 0cm">(12)State Key Laboratory of Biotherapy
and Cancer Center, West China Hospital,</P>
<P STYLE="margin-bottom: 0cm">Sichuan University, and Collaborative
Innovation Center for Biotherapy, NO. 1,</P>
<P STYLE="margin-bottom: 0cm">Keyuan 4th Road, Gaopeng Street, High
Technological Development Zone, 610041,</P>
<P STYLE="margin-bottom: 0cm">Chengdu, Sichuan, P. R. China.
zhuwen@scu.edu.cn.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: SLC34A2 with highest
expressions in lung, small intestine and kidney 
</P>
<P STYLE="margin-bottom: 0cm">encoded a type 2b sodium-dependent
phosphate transporter (NaPi-IIb). In lung,</P>
<P STYLE="margin-bottom: 0cm">SLC34A2 only expressed in the apical
membrane of type II alveolar epithelium</P>
<P STYLE="margin-bottom: 0cm">cells (ATII cells) and played a pivotal
role during the fetal lung development</P>
<P STYLE="margin-bottom: 0cm">and embryonic development. ATII cells
acting as multifunctional stem cells might 
</P>
<P STYLE="margin-bottom: 0cm">transform into NSCLC after undergoing
exogenous or endogenous factors. Increasing</P>
<P STYLE="margin-bottom: 0cm">evidences showed that the genes
performing critical roles during embryogenesis</P>
<P STYLE="margin-bottom: 0cm">were also expressed during the
development of cancer. In addition, recent</P>
<P STYLE="margin-bottom: 0cm">research found the expression of
SLC34A2 had a significant difference between the</P>
<P STYLE="margin-bottom: 0cm">surgical samples of NSCLC and normal
tissues, and SLC34A2 was down-regulated in</P>
<P STYLE="margin-bottom: 0cm">lung adenocarcinoma cell line A549 and
up-regulation expression of SLC34A2 could 
</P>
<P STYLE="margin-bottom: 0cm">significantly inhibit cell viability
and invasion of A549 in vitro. These results</P>
<P STYLE="margin-bottom: 0cm">suggested SLC34A2 might play an
important role in the development of NSCLC.</P>
<P STYLE="margin-bottom: 0cm">However, the role of SLC34A2 in
tumorigenesis and progression of NSCLC remains</P>
<P STYLE="margin-bottom: 0cm">unknown.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: Our study found that SLC34A2
was also significantly down-regulated in</P>
<P STYLE="margin-bottom: 0cm">14/15 of examined NSCLC tissues.
Moreover, we found that expressions of SLC34A2</P>
<P STYLE="margin-bottom: 0cm">were reduced in six NSCLC cell lines
for the first time. Our result also revealed</P>
<P STYLE="margin-bottom: 0cm">a dramatic inhibitory effects of
SLC34A2 on cell growth, migration and invasion</P>
<P STYLE="margin-bottom: 0cm">of several NSCLC cell lines. SLC34A2
also strongly inhibited tumor growth and</P>
<P STYLE="margin-bottom: 0cm">metastasis ability in A549 subcutaneous
tumor model and lung metastasis model,</P>
<P STYLE="margin-bottom: 0cm">respectively. Further studies found
that the suppressive effects of SLC34A2 on</P>
<P STYLE="margin-bottom: 0cm">tumorigenesis and progression might be
associated with the down-regulation of</P>
<P STYLE="margin-bottom: 0cm">related protein in PI3K/Akt and
Ras/Raf/MEK signal pathway.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: For the first time, our
data indicated that SLC34A2 could exert</P>
<P STYLE="margin-bottom: 0cm">significantly suppressive effects on
tumorigenesis and progression of NSCLC.</P>
<P STYLE="margin-bottom: 0cm">SLC34A2 might provide new insights for
further understanding the early</P>
<P STYLE="margin-bottom: 0cm">pathogenesis of human NSCLC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4497375</P>
<P STYLE="margin-bottom: 0cm">PMID: 26156586 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">16. Saudi J Biol Sci. 2015
Jul;22(4):359-73. doi: 10.1016/j.sjbs.2014.10.002. Epub</P>
<P STYLE="margin-bottom: 0cm">2014 Oct 23.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BRAF gene: From human cancers to
developmental syndromes.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hussain MR(1), Baig M(2), Mohamoud
HS(3), Ulhaq Z(4), Hoessli DC(4), Khogeer</P>
<P STYLE="margin-bottom: 0cm">GS(5), Al-Sayed RR(5), Al-Aama JY(6).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Faculty of Genetic Medicine, King
Abdulaziz University, Jeddah, Saudi Arabia ;</P>
<P STYLE="margin-bottom: 0cm">CAS-Institute of microbiology,
University of Chinese Academy of Sciences,</P>
<P STYLE="margin-bottom: 0cm">Beijing, China. (2)Faculty of Medicine,
King Abdulaziz University, Rabigh Branch,</P>
<P STYLE="margin-bottom: 0cm">Saudi Arabia. (3)Human Genetics
Research Centre, Division of Biomedical Sciences 
</P>
<P STYLE="margin-bottom: 0cm">(BMS), St. George's University of
London (SGUL), London, UK. (4)Dr. Panjwani</P>
<P STYLE="margin-bottom: 0cm">Center for Molecular Medicine and Drug
Research, International Center for</P>
<P STYLE="margin-bottom: 0cm">Chemical and Biological Sciences,
University of Karachi, Karachi 75270, Pakistan.</P>
<P STYLE="margin-bottom: 0cm">(5)Department of Biology, Genomics and
Biotechnology Section, King Abdulaziz</P>
<P STYLE="margin-bottom: 0cm">University, Jeddah, Saudi Arabia.
(6)Faculty of Genetic Medicine, King Abdulaziz 
</P>
<P STYLE="margin-bottom: 0cm">University, Jeddah, Saudi Arabia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The BRAF gene encodes for a
serine/threonine protein kinase that participates in 
</P>
<P STYLE="margin-bottom: 0cm">the MAPK/ERK signalling pathway and
plays a vital role in cancers and</P>
<P STYLE="margin-bottom: 0cm">developmental syndromes (RASopathies).
The current review discusses the clinical 
</P>
<P STYLE="margin-bottom: 0cm">significance of the BRAF gene and other
members of RAS/RAF cascade in human</P>
<P STYLE="margin-bottom: 0cm">cancers and RAS/MAPK syndromes, and
focuses the molecular basis and clinical</P>
<P STYLE="margin-bottom: 0cm">genetics of BRAF to better understand
its parallel involvement in both</P>
<P STYLE="margin-bottom: 0cm">tumourigenesis and RAS/MAPK
syndromes-Noonan syndrome, cardio-facio-cutaneous</P>
<P STYLE="margin-bottom: 0cm">syndrome and LEOPARD syndrome.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4486731</P>
<P STYLE="margin-bottom: 0cm">PMID: 26150740 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">17. Proc Natl Acad Sci U S A. 2015 Jul
21;112(29):E3855-63. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1073/pnas.1510733112. Epub 2015 Jul
6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">EGFR inhibition evokes innate drug
resistance in lung cancer cells by preventing 
</P>
<P STYLE="margin-bottom: 0cm">Akt activity and thus inactivating
Ets-1 function.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Phuchareon J(1), McCormick F(2), Eisele
DW(1), Tetsu O(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Head and Neck Cancer Research
Laboratory, Department of Otolaryngology-Head</P>
<P STYLE="margin-bottom: 0cm">and Neck Surgery, School of Medicine,
University of California, San Francisco</P>
<P STYLE="margin-bottom: 0cm">(UCSF), CA 94115; UCSF Helen Diller
Family Comprehensive Cancer Center, School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, University of California, San
Francisco, CA 94158. (2)UCSF Helen Diller</P>
<P STYLE="margin-bottom: 0cm">Family Comprehensive Cancer Center,
School of Medicine, University of California,</P>
<P STYLE="margin-bottom: 0cm">San Francisco, CA 94158
mccormic@cc.ucsf.edu osamu.tetsu@ucsf.edu. (3)Head and</P>
<P STYLE="margin-bottom: 0cm">Neck Cancer Research Laboratory,
Department of Otolaryngology-Head and Neck</P>
<P STYLE="margin-bottom: 0cm">Surgery, School of Medicine, University
of California, San Francisco (UCSF), CA</P>
<P STYLE="margin-bottom: 0cm">94115; UCSF Helen Diller Family
Comprehensive Cancer Center, School of Medicine, 
</P>
<P STYLE="margin-bottom: 0cm">University of California, San
Francisco, CA 94158 mccormic@cc.ucsf.edu</P>
<P STYLE="margin-bottom: 0cm">osamu.tetsu@ucsf.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nonsmall cell lung cancer (NSCLC) is
the leading cause of cancer death worldwide.</P>
<P STYLE="margin-bottom: 0cm">About 14% of NSCLCs harbor mutations in
epidermal growth factor receptor (EGFR). 
</P>
<P STYLE="margin-bottom: 0cm">Despite remarkable progress in
treatment with tyrosine kinase inhibitors (TKIs), 
</P>
<P STYLE="margin-bottom: 0cm">only 5% of patients achieve tumor
reduction &gt;90%. The limited primary responses</P>
<P STYLE="margin-bottom: 0cm">are attributed partly to drug
resistance inherent in the tumor cells before</P>
<P STYLE="margin-bottom: 0cm">therapy begins. Recent reports showed
that activation of receptor tyrosine</P>
<P STYLE="margin-bottom: 0cm">kinases (RTKs) is an important
determinant of this innate drug resistance. In</P>
<P STYLE="margin-bottom: 0cm">contrast, we demonstrate that EGFR
inhibition promotes innate drug resistance</P>
<P STYLE="margin-bottom: 0cm">despite blockade of RTK activity in
NSCLC cells. EGFR TKIs decrease both the</P>
<P STYLE="margin-bottom: 0cm">mitogen-activated protein kinase (MAPK)
and Akt protein kinase pathways for a</P>
<P STYLE="margin-bottom: 0cm">short time, after which the Ras/MAPK
pathway becomes reactivated. Akt inhibition 
</P>
<P STYLE="margin-bottom: 0cm">selectively blocks the transcriptional
activation of Ets-1, which inhibits its</P>
<P STYLE="margin-bottom: 0cm">target gene, dual specificity
phosphatase 6 (DUSP6), a negative regulator</P>
<P STYLE="margin-bottom: 0cm">specific for ERK1/2. As a result,
ERK1/2 is activated. Furthermore, elevated</P>
<P STYLE="margin-bottom: 0cm">c-Src stimulates Ras GTP-loading and
activates Raf and MEK kinases. These</P>
<P STYLE="margin-bottom: 0cm">observations suggest that not only
ERK1/2 but also Akt activity is essential to</P>
<P STYLE="margin-bottom: 0cm">maintain Ets-1 in an active state.
Therefore, despite high levels of ERK1/2,</P>
<P STYLE="margin-bottom: 0cm">Ets-1 target genes including DUSP6 and
cyclins D1, D3, and E2 remain suppressed</P>
<P STYLE="margin-bottom: 0cm">by Akt inhibition. Reduction of DUSP6
in combination with elevated c-Src renews</P>
<P STYLE="margin-bottom: 0cm">activation of the Ras/MAPK pathway,
which enhances cell survival by accelerating 
</P>
<P STYLE="margin-bottom: 0cm">Bim protein turnover. Thus, EGFR TKIs
evoke innate drug resistance by preventing 
</P>
<P STYLE="margin-bottom: 0cm">Akt activity and inactivating Ets-1
function in NSCLC cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26150526 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">18. JAMA Oncol. 2015 Jun;1(3):359-368.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Association Between NRAS and BRAF
Mutational Status and Melanoma-Specific</P>
<P STYLE="margin-bottom: 0cm">Survival Among Patients With Higher
Risk Primary Melanoma.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Thomas NE(1), Edmiston SN(1), Alexander
A(1), Groben PA(1), Parrish E(1), Kricker</P>
<P STYLE="margin-bottom: 0cm">A(1), Armstrong BK(1), Anton-Culver
H(1), Gruber SB(1), From L(1), Busam KJ(1),</P>
<P STYLE="margin-bottom: 0cm">Hao H(1), Orlow I(1), Kanetsky PA(1),
Luo L(1), Reiner AS(1), Paine S(1), Frank</P>
<P STYLE="margin-bottom: 0cm">JS(1), Bramson JI(1), Marrett LD(1),
Gallagher RP(1), Zanetti R(1), Rosso S(1),</P>
<P STYLE="margin-bottom: 0cm">Dwyer T(1), Cust AE(1), Ollila DW(1),
Begg CB(1), Berwick M(1), Conway K(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Departments of Dermatology (Dr.
Thomas and Ms. Hao), Epidemiology (Dr.</P>
<P STYLE="margin-bottom: 0cm">Conway), Pathology and Laboratory
Medicine (Dr. Groben), and Surgery (Dr. Ollila,</P>
<P STYLE="margin-bottom: 0cm">Ms. Frank, Ms. Bramson), Lineberger
Comprehensive Cancer Center (Drs. Thomas,</P>
<P STYLE="margin-bottom: 0cm">Ollila, and Conway and Ms. Edmiston,
Ms. Alexander, and Ms. Parrish), University 
</P>
<P STYLE="margin-bottom: 0cm">of North Carolina, Chapel Hill, North
Carolina; Sydney School of Public Health</P>
<P STYLE="margin-bottom: 0cm">(Drs. Armstrong, Kricker, and Cust),
The University of Sydney, Sydney, New South 
</P>
<P STYLE="margin-bottom: 0cm">Wales, Australia; Women's College
Hospital (Dr. From), Toronto, Ontario, Canada; 
</P>
<P STYLE="margin-bottom: 0cm">Departments of Pathology (Dr. Busam)
and Epidemiology and Biostatistics (Drs.</P>
<P STYLE="margin-bottom: 0cm">Orlow and Begg and Ms. Reiner),
Memorial Sloan Kettering Cancer Center, New York,</P>
<P STYLE="margin-bottom: 0cm">New York; University of California (Dr.
Anton-Culver), Irvine, California; USC</P>
<P STYLE="margin-bottom: 0cm">Norris Comprehensive Cancer Center (Dr.
Gruber), University of Southern</P>
<P STYLE="margin-bottom: 0cm">California, Los Angeles, California;
Department of Cancer Epidemiology, H. Lee</P>
<P STYLE="margin-bottom: 0cm">Moffitt Cancer Center &amp; Research
Institute, Tampa, FL (Dr. Kanetsky); Cancer Care</P>
<P STYLE="margin-bottom: 0cm">Ontario, Toronto, Ontario, Canada (Dr.
Marrett); British Columbia Cancer Agency, 
</P>
<P STYLE="margin-bottom: 0cm">Vancouver, British Columbia, Canada(Dr.
Gallagher); Piedmont Cancer Registry,</P>
<P STYLE="margin-bottom: 0cm">Centre for Epidemiology and Prevention
in Oncology in Piedmont, Turin, Italy</P>
<P STYLE="margin-bottom: 0cm">(Drs. Rosso and Zanetti); The George
Institute for Global Health, Oxford Martin</P>
<P STYLE="margin-bottom: 0cm">School, &amp; Nuffield Department of
Population Health, Oxford University, United</P>
<P STYLE="margin-bottom: 0cm">Kingdom (Dr. Dwyer); Department of
Medicine, Division of Epidemiology (Ms. Paine 
</P>
<P STYLE="margin-bottom: 0cm">and Drs. Luo and Berwick) University of
New Mexico, Albuquerque, New Mexico.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">IMPORTANCE: NRAS and BRAF mutations in
melanoma inform current treatment</P>
<P STYLE="margin-bottom: 0cm">paradigms but their role in survival
from primary melanoma has not been</P>
<P STYLE="margin-bottom: 0cm">established. Identification of patients
at high risk of melanoma-related death</P>
<P STYLE="margin-bottom: 0cm">based on their primary melanoma
characteristics before evidence of recurrence</P>
<P STYLE="margin-bottom: 0cm">could inform recommendations for
patient follow-up and eligibility for adjuvant</P>
<P STYLE="margin-bottom: 0cm">trials.</P>
<P STYLE="margin-bottom: 0cm">OBJECTIVE: To determine tumor
characteristics and survival from primary melanoma 
</P>
<P STYLE="margin-bottom: 0cm">by somatic NRAS and BRAF status.</P>
<P STYLE="margin-bottom: 0cm">DESIGN SETTING AND PARTICIPANTS: A
population-based study with median follow-up</P>
<P STYLE="margin-bottom: 0cm">of 7.6 years for 912 patients with
first primary cutaneous melanoma analyzed for 
</P>
<P STYLE="margin-bottom: 0cm">NRAS and BRAF mutations diagnosed in
the year 2000 from the United States and</P>
<P STYLE="margin-bottom: 0cm">Australia in the Genes, Environment and
Melanoma Study and followed through 2007.</P>
<P STYLE="margin-bottom: 0cm">MAIN OUTCOMES AND MEASURES: Tumor
characteristics and melanoma-specific survival 
</P>
<P STYLE="margin-bottom: 0cm">of primary melanoma by NRAS and BRAF
mutational status.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: The melanomas were 13% NRAS+,
30% BRAF+, and 57% with neither NRAS nor</P>
<P STYLE="margin-bottom: 0cm">BRAF mutation (wildtype). In a
multivariable model including clinicopathologic</P>
<P STYLE="margin-bottom: 0cm">characteristics, NRAS+ melanoma was
associated (P&lt;.05) with mitoses, lower tumor 
</P>
<P STYLE="margin-bottom: 0cm">infiltrating lymphocyte (TIL) grade,
and anatomic site other than scalp/neck and 
</P>
<P STYLE="margin-bottom: 0cm">BRAF+ melanoma was associated with
younger age, superficial spreading subtype,</P>
<P STYLE="margin-bottom: 0cm">and mitoses, relative to wildtype
melanoma. There was no significant difference</P>
<P STYLE="margin-bottom: 0cm">in melanoma-specific survival for
melanoma harboring mutations in NRAS (HR 1.7,</P>
<P STYLE="margin-bottom: 0cm">95% CI, 0.8-3.4) or BRAF (HR, 1.5, 95%
CI, 0.8-2.9) compared to wildtype melanoma</P>
<P STYLE="margin-bottom: 0cm">adjusted for age, sex, site, AJCC tumor
stage, TIL grade, and study center.</P>
<P STYLE="margin-bottom: 0cm">However, melanoma-specific survival was
significantly poorer for higher risk (T2b</P>
<P STYLE="margin-bottom: 0cm">or higher stage) tumors with NRAS (HR
2.9; 95% CI 1.1-7.7) or BRAF (HR 3.1; 95%</P>
<P STYLE="margin-bottom: 0cm">CI 1.2-8.5) mutations but not for lower
risk (T2a or lower) tumors (P=.65)</P>
<P STYLE="margin-bottom: 0cm">adjusted for age, sex, site, AJCC tumor
stage, TIL grade, and study center.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS AND RELEVANCE: Lower TIL
grade for NRAS+ melanoma suggests it has a</P>
<P STYLE="margin-bottom: 0cm">more immunosuppressed microenvironment,
which may impact its response to</P>
<P STYLE="margin-bottom: 0cm">immunotherapies. Further, the
approximately three-fold increased death rate for</P>
<P STYLE="margin-bottom: 0cm">higher risk tumors harboring NRAS or
BRAF mutations compared to wildtype</P>
<P STYLE="margin-bottom: 0cm">melanomas after adjusting for other
prognostic factors indicates that the</P>
<P STYLE="margin-bottom: 0cm">prognostic implication of NRAS and BRAF
mutations deserves further investigation,</P>
<P STYLE="margin-bottom: 0cm">particularly in higher AJCC stage
primary melanomas.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4486299 [Available on
2016-06-01]</P>
<P STYLE="margin-bottom: 0cm">PMID: 26146664 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">19. Int J Oncol. 2015 Jul 2. doi:
10.3892/ijo.2015.3071. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Bcl-xl and Mcl-1 are the major
determinants of the apoptotic response to dual</P>
<P STYLE="margin-bottom: 0cm">PI3K and MEK blockage.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Jokinen E(1), Koivunen JP(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Medical Oncology and
Radiotherapy and Medical Research Center</P>
<P STYLE="margin-bottom: 0cm">Oulu, Oulu University Hospital and
University of Oulu, Oulu, PB22 90029 OYS,</P>
<P STYLE="margin-bottom: 0cm">Finland.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The dual targeting of PI3K-AKT-mTOR and
Ras-Raf-MEK-ERK pathways is a potential</P>
<P STYLE="margin-bottom: 0cm">anticancer therapy, but unfortunately,
the response rate has been low in early</P>
<P STYLE="margin-bottom: 0cm">phase clinical trials. Pre-clinical
models have suggested that an apoptotic</P>
<P STYLE="margin-bottom: 0cm">response to dual PI3K and MEK targeting
is relatively rare and understanding</P>
<P STYLE="margin-bottom: 0cm">apoptotic avoidance could lead to
increased clinical efficiency. This study</P>
<P STYLE="margin-bottom: 0cm">investigated solid cancer cell lines,
which are known to be sensitive to dual</P>
<P STYLE="margin-bottom: 0cm">PI3K and MEK inhibition but to have a
limited apoptotic response. The cells were 
</P>
<P STYLE="margin-bottom: 0cm">exposed to dual PI3K and MEK blockage
in combination with a panel of additional</P>
<P STYLE="margin-bottom: 0cm">pharmacological agents and cytotoxicity
and apoptosis were analyzed. Our results 
</P>
<P STYLE="margin-bottom: 0cm">indicated that the BH3 mimetic ABT-263,
the HDAC inhibitor entinostat and the</P>
<P STYLE="margin-bottom: 0cm">multikinase inhibitor dasatinib
increased the cytotoxicity and apoptotic response</P>
<P STYLE="margin-bottom: 0cm">of dual PI3K and MEK targeting.
Furthermore, ABT-263 and entinostat was able to</P>
<P STYLE="margin-bottom: 0cm">induce apoptosis in combination with
single agent PI3K and MEK inhibitors.</P>
<P STYLE="margin-bottom: 0cm">Protein expression, immunoprecipitation
and siRNA knockdown models suggested that</P>
<P STYLE="margin-bottom: 0cm">Bcl-xl and Mcl-1 were the most
important factors circumventing PI3K and/or MEK</P>
<P STYLE="margin-bottom: 0cm">inhibition-mediated apoptosis. The
results suggest that the cytotoxicity of PI3K 
</P>
<P STYLE="margin-bottom: 0cm">and/or MEK inhibitor treatments can be
augmented by combinatory approaches</P>
<P STYLE="margin-bottom: 0cm">targeting anti-apoptotic mediators
Bcl-xl and Mcl-1.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26135106 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">20. Int J Clin Exp Med. 2015 Apr
15;8(4):5553-8. eCollection 2015.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The role of leptin in the ventricular
remodeling process and its mechanism.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zuo G(1), Du X(1), Zheng L(1), Wang
C(1), Wang K(1), Li Y(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Cardiology, Tianjin
Fifth Central Hospital No. 41 Zhejiang Road,</P>
<P STYLE="margin-bottom: 0cm">Tianjin 300450, P. R. China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">OBJECTIVE: This study aims to explore
the role of leptin in the ventricular</P>
<P STYLE="margin-bottom: 0cm">remodeling process and its mechanism in
the diabetic rats' model.</P>
<P STYLE="margin-bottom: 0cm">METHODS: The diabetic SD rats model
induced by streptozotocin was established.</P>
<P STYLE="margin-bottom: 0cm">The SD rats were randomly divided into
4 groups: control group (20 rats treated</P>
<P STYLE="margin-bottom: 0cm">with citric acid/sodium citrate
buffer); M0 group (10 rats treated with</P>
<P STYLE="margin-bottom: 0cm">physiological saline); M1 group (10
rats treated with 50 μg/kg LP); M2 group (10 
</P>
<P STYLE="margin-bottom: 0cm">rats treated with 100 μg/kg LP).
Ang-II was detected by ELISA. The expression</P>
<P STYLE="margin-bottom: 0cm">levels of LP and Ob-Rb were detected by
RT-PCR. MAPK phosphorylation changes were</P>
<P STYLE="margin-bottom: 0cm">detected by western blotting.
Myocardial morphology was observed.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: Compared with control group,
the blood glucose concentration and Ang-II 
</P>
<P STYLE="margin-bottom: 0cm">significantly increased in diabetic
model groups (P &lt; 0.01) and body weight</P>
<P STYLE="margin-bottom: 0cm">decreased (P &lt; 0.05). The expression
levels of LP and Ob-Rb increased and heart</P>
<P STYLE="margin-bottom: 0cm">function decreased in diabetic model
groups.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: LP may be involved in the
myocardial cell hypertrophy through the</P>
<P STYLE="margin-bottom: 0cm">neuroendocrine system and associated
with the JAK-STAT, Ras-Raf-MEK-MAPK and</P>
<P STYLE="margin-bottom: 0cm">PI-3K signaling pathway, which provides
a new concept for the pathogenesis of</P>
<P STYLE="margin-bottom: 0cm">cardiac hypertrophy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4483875</P>
<P STYLE="margin-bottom: 0cm">PMID: 26131137 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Nat Commun. 2015 Jun 24;6:7354. doi:
10.1038/ncomms8354.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Grb2 monomer-dimer equilibrium
determines normal versus oncogenic function.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ahmed Z(1), Timsah Z(2), Suen KM(2),
Cook NP(3), Lee GR 4th(4), Lin CC(2), Gagea 
</P>
<P STYLE="margin-bottom: 0cm">M(5), Marti AA(3), Ladbury JE(6).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)1] Department of Biochemistry and
Molecular Biology, University of Texas, M.D.</P>
<P STYLE="margin-bottom: 0cm">Anderson Cancer Center, Unit 1000, 1515
Holcombe Boulevard, Houston, Texas 77030,</P>
<P STYLE="margin-bottom: 0cm">USA [2] Center for Biomolecular
Structure and Function, University of Texas, M.D.</P>
<P STYLE="margin-bottom: 0cm">Anderson Cancer Center, Unit 1000, 1515
Holcombe Boulevard, Houston, Texas 77030,</P>
<P STYLE="margin-bottom: 0cm">USA. (2)1] Department of Biochemistry
and Molecular Biology, University of Texas,</P>
<P STYLE="margin-bottom: 0cm">M.D. Anderson Cancer Center, Unit 1000,
1515 Holcombe Boulevard, Houston, Texas</P>
<P STYLE="margin-bottom: 0cm">77030, USA [2] School of Molecular and
Cellular Biology, University of Leeds,</P>
<P STYLE="margin-bottom: 0cm">Leeds LS2 9JT, UK. (3)Department of
Chemistry, Rice University, Houston, Texas</P>
<P STYLE="margin-bottom: 0cm">77005, USA. (4)Center for Biomolecular
Structure and Function, University of</P>
<P STYLE="margin-bottom: 0cm">Texas, M.D. Anderson Cancer Center,
Unit 1000, 1515 Holcombe Boulevard, Houston, 
</P>
<P STYLE="margin-bottom: 0cm">Texas 77030, USA. (5)Department of
Veterinary Medicine and Surgery, University of</P>
<P STYLE="margin-bottom: 0cm">Texas, M.D. Anderson Cancer Center,
Unit 63, 1515 Holcombe Boulevard, Houston,</P>
<P STYLE="margin-bottom: 0cm">Texas 77030, USA. (6)1] Department of
Biochemistry and Molecular Biology,</P>
<P STYLE="margin-bottom: 0cm">University of Texas, M.D. Anderson
Cancer Center, Unit 1000, 1515 Holcombe</P>
<P STYLE="margin-bottom: 0cm">Boulevard, Houston, Texas 77030, USA
[2] Center for Biomolecular Structure and</P>
<P STYLE="margin-bottom: 0cm">Function, University of Texas, M.D.
Anderson Cancer Center, Unit 1000, 1515</P>
<P STYLE="margin-bottom: 0cm">Holcombe Boulevard, Houston, Texas
77030, USA [3] School of Molecular and</P>
<P STYLE="margin-bottom: 0cm">Cellular Biology, University of Leeds,
Leeds LS2 9JT, UK.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The adaptor protein growth factor
receptor-bound protein 2 (Grb2) is ubiquitously</P>
<P STYLE="margin-bottom: 0cm">expressed in eukaryotic cells and
involved in a multitude of intracellular</P>
<P STYLE="margin-bottom: 0cm">protein interactions. Grb2 plays a
pivotal role in tyrosine kinase-mediated</P>
<P STYLE="margin-bottom: 0cm">signal transduction including linking
receptor tyrosine kinases to the</P>
<P STYLE="margin-bottom: 0cm">Ras/mitogen-activated protein (MAP)
kinase pathway, which is implicated in</P>
<P STYLE="margin-bottom: 0cm">oncogenic outcome. Grb2 exists in a
constitutive equilibrium between monomeric</P>
<P STYLE="margin-bottom: 0cm">and dimeric states. Here we show that
only monomeric Grb2 is capable of binding</P>
<P STYLE="margin-bottom: 0cm">to SOS and upregulating MAP kinase
signalling and that the dimeric state is</P>
<P STYLE="margin-bottom: 0cm">inhibitory to this process.
Phosphorylation of tyrosine 160 (Y160) on Grb2, or</P>
<P STYLE="margin-bottom: 0cm">binding of a
tyrosylphosphate-containing ligand to the SH2 domain of Grb2,</P>
<P STYLE="margin-bottom: 0cm">results in dimer dissociation.
Phosphorylation of Y160 on Grb2 is readily</P>
<P STYLE="margin-bottom: 0cm">detectable in the malignant forms of
human prostate, colon and breast cancers.</P>
<P STYLE="margin-bottom: 0cm">The self-association/dissociation of
Grb2 represents a switch that regulates MAP 
</P>
<P STYLE="margin-bottom: 0cm">kinase activity and hence controls
cancer progression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4491180</P>
<P STYLE="margin-bottom: 0cm">PMID: 26103942 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. Eur Heart J. 2015 Jun 11. pii:
ehv268. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Association between renin-angiotensin
system antagonist use and mortality in</P>
<P STYLE="margin-bottom: 0cm">heart failure with severe renal
insufficiency: a prospective propensity</P>
<P STYLE="margin-bottom: 0cm">score-matched cohort study.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Edner M(1), Benson L(2), Dahlström
U(3), Lund LH(4).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Medicine, Unit of
Cardiology, Karolinska Institutet, 17177</P>
<P STYLE="margin-bottom: 0cm">Stockholm, Sweden. (2)Department of
Clinical Science and Education, SöS,</P>
<P STYLE="margin-bottom: 0cm">Karolinska Institutet, 11883 Stockholm,
Sweden. (3)Division of Cardiovascular</P>
<P STYLE="margin-bottom: 0cm">Medicine, Faculty of Health Sciences,
Department of Medicine and Health Sciences,</P>
<P STYLE="margin-bottom: 0cm">Department of Cardiology UHL, Linköping
University, County Council of</P>
<P STYLE="margin-bottom: 0cm">Östergötland, 58191 Linköping,
Sweden. (4)Department of Medicine, Unit of</P>
<P STYLE="margin-bottom: 0cm">Cardiology, Karolinska Institutet,
17177 Stockholm, Sweden Department of</P>
<P STYLE="margin-bottom: 0cm">Cardiology, N3:06, Karolinska
University Hospital, 17176 Stockholm, Sweden</P>
<P STYLE="margin-bottom: 0cm">lars.lund@alumni.duke.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">AIMS: In heart failure (HF) with
reduced ejection fraction (EF),</P>
<P STYLE="margin-bottom: 0cm">renin-angiotensin receptor (RAS)
antagonists reduce mortality. However, severe</P>
<P STYLE="margin-bottom: 0cm">renal insufficiency was an exclusion
criterion in trials. We tested the</P>
<P STYLE="margin-bottom: 0cm">hypothesis that RAS antagonists are
associated with reduced mortality also in HF 
</P>
<P STYLE="margin-bottom: 0cm">with severe renal insufficiency.</P>
<P STYLE="margin-bottom: 0cm">METHODS AND RESULTS: We studied
patients with EF ≤39% registered in the</P>
<P STYLE="margin-bottom: 0cm">prospective Swedish Heart Failure
Registry. In patients with creatinine &gt;221</P>
<P STYLE="margin-bottom: 0cm">µmol/L or creatinine clearance &lt;30
mL/min, propensity scores for RAS-antagonist</P>
<P STYLE="margin-bottom: 0cm">use were derived from 36 variables. The
association between RAS antagonist use</P>
<P STYLE="margin-bottom: 0cm">and all-cause mortality was assessed
with Cox regression in a cohort matched 1:1 
</P>
<P STYLE="margin-bottom: 0cm">based on age and propensity score. To
assess consistency, we performed the same</P>
<P STYLE="margin-bottom: 0cm">analysis as a 'positive control' in
patients without severe renal insufficiency. 
</P>
<P STYLE="margin-bottom: 0cm">Between 2000 and 2013, there were 24
283 patients of which 2410 [age, mean (SD), 
</P>
<P STYLE="margin-bottom: 0cm">82 (9), 45% women] had creatinine &gt;221
µmol/L or creatinine clearance &lt;30 mL/min 
</P>
<P STYLE="margin-bottom: 0cm">and were treated (n = 1602) or not
treated (n = 808) with RAS antagonists. In the</P>
<P STYLE="margin-bottom: 0cm">matched cohort of 602 vs. 602 patients
[age 83 (8), 42% women], RAS antagonist</P>
<P STYLE="margin-bottom: 0cm">use was associated with 55% [95%
confidence interval (CI) 51-59] vs. 45% (41-49) 
</P>
<P STYLE="margin-bottom: 0cm">1-year survival, P &lt; 0.001, with a
hazard ratio (HR) for mortality of 0.76 (95%</P>
<P STYLE="margin-bottom: 0cm">CI 0.67-0.86, P &lt; 0.001). In
positive control patients without severe renal</P>
<P STYLE="margin-bottom: 0cm">insufficiency [n = 21 873; age 71 (12),
27% women], the matched HR was 0.79 (95% 
</P>
<P STYLE="margin-bottom: 0cm">CI 0.72-0.86, P &lt; 0.001).</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: In HF with severe renal
insufficiency, the use of RAS antagonists was</P>
<P STYLE="margin-bottom: 0cm">associated with lower all-cause
mortality. Prospective randomized trials are</P>
<P STYLE="margin-bottom: 0cm">needed before these findings can be
applied to clinical practice.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Published on behalf of the European
Society of Cardiology. All rights reserved. ©</P>
<P STYLE="margin-bottom: 0cm">The Author 2015. For permissions please
email: journals.permissions@oup.com.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26069212 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. Eur J Immunol. 2015 May 14. doi:
10.1002/eji.201445226. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Absence of both Sos-1 and Sos-2 in
peripheral CD4(+) T cells leads to PI3K</P>
<P STYLE="margin-bottom: 0cm">pathway activation and defects in
migration.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Guittard G(1), Kortum RL(1),
Balagopalan L(1), Çuburu N(2), Nguyen P(1), Sommers 
</P>
<P STYLE="margin-bottom: 0cm">CL(1), Samelson LE(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Laboratory of Cellular and Molecular
Biology, Center for Cancer Research,</P>
<P STYLE="margin-bottom: 0cm">National Cancer Institute, Bethesda,
MD, USA. (2)Laboratory of Cellular Oncology,</P>
<P STYLE="margin-bottom: 0cm">Center for Cancer Research, National
Cancer Institute, Bethesda, MD, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sos-1 and Sos-2 are ubiquitously
expressed Ras-guanine exchange factors involved 
</P>
<P STYLE="margin-bottom: 0cm">in Erk-MAP kinase pathway activation.
Using mice lacking genes encoding Sos-1 and</P>
<P STYLE="margin-bottom: 0cm">Sos-2, we evaluated the role of these
proteins in peripheral T-cell signaling and</P>
<P STYLE="margin-bottom: 0cm">function. Our results confirmed that
TCR-mediated Erk activation in peripheral</P>
<P STYLE="margin-bottom: 0cm">CD4(+) T cells does not depend on Sos-1
and Sos-2, although IL-2-mediated Erk</P>
<P STYLE="margin-bottom: 0cm">activation does. Unexpectedly, however,
we show an increase in AKT</P>
<P STYLE="margin-bottom: 0cm">phosphorylation in Sos-1/2dKO CD4(+) T
cells upon TCR and IL-2 stimulation.</P>
<P STYLE="margin-bottom: 0cm">Activation of AKT was likely a
consequence of increased recruitment of PI3K to</P>
<P STYLE="margin-bottom: 0cm">Grb2 upon TCR and/or IL-2 stimulation
in Sos-1/2dKO CD4(+) T cells. The increased</P>
<P STYLE="margin-bottom: 0cm">activity of the PI3K/AKT pathway led to
downregulation of the surface receptor</P>
<P STYLE="margin-bottom: 0cm">CD62L in Sos-1/2dKO T cells and a
subsequent impairment in T-cell migration.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Published 2015. This article is a U.S.
Government work and is in the public</P>
<P STYLE="margin-bottom: 0cm">domain in the USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25973715 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">4. J Immunol. 2015 Apr
15;194(8):3852-60. doi: 10.4049/jimmunol.1401996. Epub 2015</P>
<P STYLE="margin-bottom: 0cm">Mar 18.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Inhibition of CD40-induced N-Ras
activation reduces leishmania major infection.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Chakraborty S(1), Srivastava A(1), Jha
MK(1), Nair A(1), Pandey SP(1), Srivastava</P>
<P STYLE="margin-bottom: 0cm">N(1), Kumari S(1), Singh S(1),
Krishnasastry MV(1), Saha B(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)National Centre for Cell Science,
Ganeshkhind, Pune 411007, India. (2)National</P>
<P STYLE="margin-bottom: 0cm">Centre for Cell Science, Ganeshkhind,
Pune 411007, India sahab@nccs.res.in.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Leishmania major is a parasite that
resides and replicates in macrophages. We</P>
<P STYLE="margin-bottom: 0cm">previously showed that the parasite
enhanced CD40-induced Raf-MEK-ERK signaling</P>
<P STYLE="margin-bottom: 0cm">but inhibited PI3K-MKK-p38MAPK
signaling to proleishmanial effects. As Raf and</P>
<P STYLE="margin-bottom: 0cm">PI3K have a Ras-binding domain but
exert opposite effects on Leishmania</P>
<P STYLE="margin-bottom: 0cm">infection, we examined whether Ras
isoforms had differential roles in Leishmania 
</P>
<P STYLE="margin-bottom: 0cm">infection. We observed that L. major
enhanced N-Ras and H-Ras expression but</P>
<P STYLE="margin-bottom: 0cm">inhibited K-Ras expression in
macrophages. L. major infection enhanced N-Ras</P>
<P STYLE="margin-bottom: 0cm">activity but inhibited H-Ras and K-Ras
activity. TLR2 short hairpin RNA or</P>
<P STYLE="margin-bottom: 0cm">anti-TLR2 or anti-lipophosphoglycan Abs
reversed the L. major-altered N-Ras and</P>
<P STYLE="margin-bottom: 0cm">K-Ras expressions. Pam3CSK4, a TLR2
ligand, enhanced N-Ras expression but reduced</P>
<P STYLE="margin-bottom: 0cm">K-Ras expression, indicating
TLR2-regulated Ras expression in L. major infection.</P>
<P STYLE="margin-bottom: 0cm">Whereas N-Ras silencing reduced L.
major infection, K-Ras and H-Ras silencing</P>
<P STYLE="margin-bottom: 0cm">enhanced the infection both in
macrophages in vitro and in C57BL/6 mice.</P>
<P STYLE="margin-bottom: 0cm">BALB/c-derived macrophages transduced
with lentivirally expressed N-Ras short</P>
<P STYLE="margin-bottom: 0cm">hairpin RNA and pulsed with L.
major-expressed MAPK10 enhanced MAPK10-specific</P>
<P STYLE="margin-bottom: 0cm">Th1-type response. CD40-deficient mice
primed with these macrophages had reduced 
</P>
<P STYLE="margin-bottom: 0cm">L. major infection, accompanied by
higher IFN-γ but less IL-4 production. As</P>
<P STYLE="margin-bottom: 0cm">N-Ras is activated by Sos, a guanine
nucleotide exchange factor, we modeled the</P>
<P STYLE="margin-bottom: 0cm">N-Ras-Sos interaction and designed two
peptides from their interface. Both the</P>
<P STYLE="margin-bottom: 0cm">cell-permeable peptides reduced L.
major infection in BALB/c mice but not in</P>
<P STYLE="margin-bottom: 0cm">CD40-deficient mice. These data reveal
the L. major-enhanced CD40-induced N-Ras</P>
<P STYLE="margin-bottom: 0cm">activation as a novel immune evasion
strategy and the potential for Ras</P>
<P STYLE="margin-bottom: 0cm">isoform-targeted antileishmanial
immunotherapy and immunoprophylaxis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015 by The American
Association of Immunologists, Inc.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25786685 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">5. Biol Chem. 2015 Aug 1;396(8):831-48.
doi: 10.1515/hsz-2014-0257.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ras activation revisited: role of GEF
and GAP systems.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hennig A, Markwart R, Esparza-Franco
MA, Ladds G, Rubio I.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ras is a prototypical small G-protein
and a central regulator of growth,</P>
<P STYLE="margin-bottom: 0cm">proliferation and differentiation
processes in virtually every nucleated cell. As</P>
<P STYLE="margin-bottom: 0cm">such, Ras becomes engaged and activated
by multiple growth factors, mitogens,</P>
<P STYLE="margin-bottom: 0cm">cytokines or adhesion receptors. Ras
activation comes about by changes in the</P>
<P STYLE="margin-bottom: 0cm">steady-state equilibrium between the
inactive guanosine diphosphate (GDP)-bound</P>
<P STYLE="margin-bottom: 0cm">and active guanosine triphosphate
(GTP)-bound states of Ras, resulting in the</P>
<P STYLE="margin-bottom: 0cm">mostly transient accumulation of
Ras-GTP. Three decades of intense Ras research</P>
<P STYLE="margin-bottom: 0cm">have disclosed various families of
guanine nucleotide exchange factors (GEFs) and</P>
<P STYLE="margin-bottom: 0cm">GTPase activating proteins (GAPs) as
the two principal regulatory elements of the</P>
<P STYLE="margin-bottom: 0cm">Ras-GDP/GTP loading status. However,
with the possible exception of the GEF Sos, 
</P>
<P STYLE="margin-bottom: 0cm">we still have only a rudimentary
knowledge of the precise role played by many GEF</P>
<P STYLE="margin-bottom: 0cm">and GAP members in the signalling
network upstream of Ras. As for GAPs, we even</P>
<P STYLE="margin-bottom: 0cm">lack the fundamental understanding of
whether they function as genuine signal</P>
<P STYLE="margin-bottom: 0cm">transducers in the context of growth
factor-elicited Ras activation or rather act</P>
<P STYLE="margin-bottom: 0cm">as passive modulators of the
Ras-GDP/GTP cycle. Here we sift through the large</P>
<P STYLE="margin-bottom: 0cm">body of Ras literature and review the
relevant data for understanding the</P>
<P STYLE="margin-bottom: 0cm">participation and precise role played
by GEFs and GAPs in the process of Ras</P>
<P STYLE="margin-bottom: 0cm">activation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25781681 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">6. Int J Mol Med. 2015
Apr;35(4):909-14. doi: 10.3892/ijmm.2015.2111. Epub 2015 Feb 
</P>
<P STYLE="margin-bottom: 0cm">26.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The proliferative effects of Pyropia
yezoensis peptide on IEC-6 cells are</P>
<P STYLE="margin-bottom: 0cm">mediated through the epidermal growth
factor receptor signaling pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lee MK(1), Kim IH(2), Choi YH(2), Choi
JW(1), Kim YM(2), Nam TJ(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Food Science and
Nutrition, Pukyong National University, Busan</P>
<P STYLE="margin-bottom: 0cm">608-737, Republic of Korea.
(2)Institute of Fisheries Science, Pukyong National</P>
<P STYLE="margin-bottom: 0cm">University, Busan 619-911, Republic of
Korea.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">For a number of years, seaweed has been
used as a functional food in Asian</P>
<P STYLE="margin-bottom: 0cm">countries, particularly in Korea, Japan
and China. Pyropia yezoensis is a marine 
</P>
<P STYLE="margin-bottom: 0cm">red alga that has potentially
beneficial biological activities. In this study, we</P>
<P STYLE="margin-bottom: 0cm">examined the mechanisms through which a
Pyropia yezoensis peptide [PYP1 (1-20)]</P>
<P STYLE="margin-bottom: 0cm">induces the proliferation of IEC-6
cells, a rat intestinal epithelial cell line, 
</P>
<P STYLE="margin-bottom: 0cm">and the involvement of the epidermal
growth factor receptor (EGFR) signaling</P>
<P STYLE="margin-bottom: 0cm">pathway. First, cell viability assay
revealed that PYP1 (1-20) induced cell</P>
<P STYLE="margin-bottom: 0cm">proliferation in a
concentration-dependent manner. Subsequently, we examined the 
</P>
<P STYLE="margin-bottom: 0cm">mechanisms responsible for this
induction of proliferation induced by PYP1</P>
<P STYLE="margin-bottom: 0cm">(1-20). EGFR is widely expressed in
mammalian epithelial tissues, and the binding</P>
<P STYLE="margin-bottom: 0cm">of this ligand affects a variety of
cell physiological parameters, such as cell</P>
<P STYLE="margin-bottom: 0cm">growth and proliferation. PYP1 (1-20)
increased the expression of EGFR, Shc,</P>
<P STYLE="margin-bottom: 0cm">growth factor receptor-bound protein 2
(Grb2) and son of sevenless (SOS). EGFR</P>
<P STYLE="margin-bottom: 0cm">also induced the activation of the Ras
signaling pathway through Raf, MEK and</P>
<P STYLE="margin-bottom: 0cm">extracellular signal-regulated kinase
(ERK) phosphorylation. In addition, cell</P>
<P STYLE="margin-bottom: 0cm">cycle analysis revealed the expression
of cell cycle-related proteins. The</P>
<P STYLE="margin-bottom: 0cm">results demonstrated an increased
number of cells in the G1 phase and an enhanced</P>
<P STYLE="margin-bottom: 0cm">cell proliferation. In addition, the
upregulation of cyclin D, cyclin E, Cdk2,</P>
<P STYLE="margin-bottom: 0cm">Cdk4 and Cdk6 was observed accompanied
by a decreased in p21 and p27 expression. 
</P>
<P STYLE="margin-bottom: 0cm">These findings suggest that PYP1 (1-20)
stimulates the proliferation of rat IEC-6</P>
<P STYLE="margin-bottom: 0cm">cells by activating the EGFR signaling
pathway. Therefore, PYP1 (1-20) may be a</P>
<P STYLE="margin-bottom: 0cm">potential source for the development of
bio-functional foods which promotes the</P>
<P STYLE="margin-bottom: 0cm">proliferation of intestinal epithelial
cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4356455</P>
<P STYLE="margin-bottom: 0cm">PMID: 25716690 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">7. J Med Chem. 2015 Mar
12;58(5):2265-74. doi: 10.1021/jm501660t. Epub 2015 Feb 26.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Small molecule binding sites on the
Ras:SOS complex can be exploited for</P>
<P STYLE="margin-bottom: 0cm">inhibition of Ras activation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Winter JJ(1), Anderson M, Blades K,
Brassington C, Breeze AL, Chresta C, Embrey</P>
<P STYLE="margin-bottom: 0cm">K, Fairley G, Faulder P, Finlay MR,
Kettle JG, Nowak T, Overman R, Patel SJ,</P>
<P STYLE="margin-bottom: 0cm">Perkins P, Spadola L, Tart J, Tucker
JA, Wrigley G.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)AstraZeneca , Alderley Park,
Macclesfield, Cheshire, SK10 4TG, United Kingdom.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Constitutively active mutant KRas
displays a reduced rate of GTP hydrolysis via</P>
<P STYLE="margin-bottom: 0cm">both intrinsic and GTPase-activating
protein-catalyzed mechanisms, resulting in</P>
<P STYLE="margin-bottom: 0cm">the perpetual activation of Ras
pathways. We describe a fragment screening</P>
<P STYLE="margin-bottom: 0cm">campaign using X-ray crystallography
that led to the discovery of three fragment 
</P>
<P STYLE="margin-bottom: 0cm">binding sites on the Ras:SOS complex.
The identification of tool compounds</P>
<P STYLE="margin-bottom: 0cm">binding at each of these sites allowed
exploration of two new approaches to Ras</P>
<P STYLE="margin-bottom: 0cm">pathway inhibition by stabilizing or
covalently modifying the Ras:SOS complex to 
</P>
<P STYLE="margin-bottom: 0cm">prevent the reloading of Ras with GTP.
Initially, we identified ligands that</P>
<P STYLE="margin-bottom: 0cm">bound reversibly to the Ras:SOS complex
in two distinct sites, but these</P>
<P STYLE="margin-bottom: 0cm">compounds were not sufficiently potent
inhibitors to validate our stabilization</P>
<P STYLE="margin-bottom: 0cm">hypothesis. We conclude by
demonstrating that covalent modification of Cys118 on 
</P>
<P STYLE="margin-bottom: 0cm">Ras leads to a novel mechanism of
inhibition of the SOS-mediated interaction</P>
<P STYLE="margin-bottom: 0cm">between Ras and Raf and is effective at
inhibiting the exchange of labeled GDP in</P>
<P STYLE="margin-bottom: 0cm">both mutant (G12C and G12V) and wild
type Ras.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25695162 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">8. Development. 2014
Nov;141(22):4279-84. doi: 10.1242/dev.112045.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A non-cell-autonomous role for Ras
signaling in C. elegans neuroblast</P>
<P STYLE="margin-bottom: 0cm">delamination.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Parry JM(1), Sundaram MV(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Genetics, University
of Pennsylvania Perelman School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, 415 Curie Boulevard,
Philadelphia, PA 19104, USA Department of Biology,</P>
<P STYLE="margin-bottom: 0cm">Georgian Court University, 900 Lakewood
Avenue, Lakewood, NJ 08701, USA.</P>
<P STYLE="margin-bottom: 0cm">(2)Department of Genetics, University
of Pennsylvania Perelman School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, 415 Curie Boulevard,
Philadelphia, PA 19104, USA</P>
<P STYLE="margin-bottom: 0cm">sundaram@mail.med.upenn.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Receptor tyrosine kinase (RTK)
signaling through Ras influences many aspects of</P>
<P STYLE="margin-bottom: 0cm">normal cell behavior, including
epithelial-to-mesenchymal transition, and</P>
<P STYLE="margin-bottom: 0cm">aberrant signaling promotes both
tumorigenesis and metastasis. Although many such</P>
<P STYLE="margin-bottom: 0cm">effects are cell-autonomous, here we
show a non-cell-autonomous role for RTK-Ras 
</P>
<P STYLE="margin-bottom: 0cm">signaling in the delamination of a
neuroblast from an epithelial organ. The C.</P>
<P STYLE="margin-bottom: 0cm">elegans renal-like excretory organ is
initially composed of three unicellular</P>
<P STYLE="margin-bottom: 0cm">epithelial tubes, namely the canal,
duct and G1 pore cells; however, the G1 cell 
</P>
<P STYLE="margin-bottom: 0cm">later delaminates from the excretory
system to become a neuroblast and is</P>
<P STYLE="margin-bottom: 0cm">replaced by the G2 cell. G1
delamination and G2 intercalation involve</P>
<P STYLE="margin-bottom: 0cm">cytoskeletal remodeling,
interconversion of autocellular and intercellular</P>
<P STYLE="margin-bottom: 0cm">junctions and migration over a luminal
extracellular matrix, followed by G1</P>
<P STYLE="margin-bottom: 0cm">junction loss. LET-23/EGFR and SOS-1,
an exchange factor for Ras, are required</P>
<P STYLE="margin-bottom: 0cm">for G1 junction loss but not for
initial cytoskeletal or junction remodeling.</P>
<P STYLE="margin-bottom: 0cm">Surprisingly, expression of activated
LET-60/Ras in the neighboring duct cell,</P>
<P STYLE="margin-bottom: 0cm">but not in the G1 or G2 cells, is
sufficient to rescue sos-1 delamination</P>
<P STYLE="margin-bottom: 0cm">defects, revealing that Ras acts
non-cell-autonomously to permit G1 delamination.</P>
<P STYLE="margin-bottom: 0cm">We suggest that, similarly, oncogenic
mutations in cells within a tumor might</P>
<P STYLE="margin-bottom: 0cm">help create a microenvironment that is
permissive for other cells to detach and</P>
<P STYLE="margin-bottom: 0cm">ultimately metastasize.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2014. Published by The Company of
Biologists Ltd.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4302911 [Available on
2015-11-15]</P>
<P STYLE="margin-bottom: 0cm">PMID: 25371363 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">9. Adv Bioinformatics.
2014;2014:431696. doi: 10.1155/2014/431696. Epub 2014 Sep 21.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">In Silico Screening of Mutated K-Ras
Inhibitors from Malaysian Typhonium</P>
<P STYLE="margin-bottom: 0cm">flagelliforme for Non-Small Cell Lung
Cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Fatima A(1), Yee HF(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Pharmaceutical
Technology, Faculty of Pharmaceutical Sciences,</P>
<P STYLE="margin-bottom: 0cm">UCSI University, Jalan Menara Gading 1,
Taman Connaught, Cheras, 56000 Kuala</P>
<P STYLE="margin-bottom: 0cm">Lumpur, Malaysia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">K-ras is an oncogenic GTPase
responsible for at least 15-25% of all non-small</P>
<P STYLE="margin-bottom: 0cm">cell lung cancer cases worldwide. Lung
cancer of both types is increasing with an</P>
<P STYLE="margin-bottom: 0cm">alarming rate due to smoking habits in
Malaysia among men and women. Natural</P>
<P STYLE="margin-bottom: 0cm">products always offer alternate
treatment therapies that are safe and effective. 
</P>
<P STYLE="margin-bottom: 0cm">Typhonium flagelliforme or Keladi Tikus
is a local plant known to possess</P>
<P STYLE="margin-bottom: 0cm">anticancer properties. The whole
extract is considered more potent than</P>
<P STYLE="margin-bottom: 0cm">individual constituents. Since K-ras is
the key protein in lung cancer, our aim</P>
<P STYLE="margin-bottom: 0cm">was to identify the constituents of the
plant that could target the mutated</P>
<P STYLE="margin-bottom: 0cm">K-ras. Using docking strategies,
reported potentially active compounds of</P>
<P STYLE="margin-bottom: 0cm">Typhonium flagelliforme were docked
into the allosteric surface pockets and</P>
<P STYLE="margin-bottom: 0cm">switch regions of the K-ras protein to
identify possible inhibitors. The selected</P>
<P STYLE="margin-bottom: 0cm">ligands were found to have a high
binding affinity for the switch II and the</P>
<P STYLE="margin-bottom: 0cm">interphase region of the ras-SOS
binding surface.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4189522</P>
<P STYLE="margin-bottom: 0cm">PMID: 25309590 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">10. Cancer Res. 2014 Oct
15;74(20):5866-77. doi: 10.1158/0008-5472.CAN-14-0806. Epub 
</P>
<P STYLE="margin-bottom: 0cm">2014 Aug 28.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Dsh homolog DVL3 mediates resistance to
IGFIR inhibition by regulating IGF-RAS</P>
<P STYLE="margin-bottom: 0cm">signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gao S(1), Bajrami I(2), Verrill C(3),
Kigozi A(2), Ouaret D(1), Aleksic T(1),</P>
<P STYLE="margin-bottom: 0cm">Asher R(3), Han C(1), Allen P(4),
Bailey D(4), Feller S(1), Kashima T(1),</P>
<P STYLE="margin-bottom: 0cm">Athanasou N(5), Blay JY(6), Schmitz
S(7), Machiels JP(7), Upile N(8), Jones</P>
<P STYLE="margin-bottom: 0cm">TM(8), Thalmann G(9), Ashraf SQ(1),
Wilding JL(1), Bodmer WF(1), Middleton</P>
<P STYLE="margin-bottom: 0cm">MR(10), Ashworth A(2), Lord CJ(2),
Macaulay VM(11).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Oncology, Weatherall
Institute of Molecular Medicine, John</P>
<P STYLE="margin-bottom: 0cm">Radcliffe Hospital, University of
Oxford, Oxford, United Kingdom. (2)Breakthrough</P>
<P STYLE="margin-bottom: 0cm">Breast Cancer Research Centre, The
Institute of Cancer Research, London, United</P>
<P STYLE="margin-bottom: 0cm">Kingdom. (3)Department of Cellular
Pathology and NIHR Oxford Biomedical Research 
</P>
<P STYLE="margin-bottom: 0cm">Centre, Oxford University Hospitals NHS
Trust, John Radcliffe Hospital, Oxford,</P>
<P STYLE="margin-bottom: 0cm">United Kingdom. (4)Department of
Cellular Pathology, Oxford University Hospitals 
</P>
<P STYLE="margin-bottom: 0cm">NHS Trust, John Radcliffe Hospital,
Oxford, United Kingdom. (5)Nuffield</P>
<P STYLE="margin-bottom: 0cm">Department of Orthopaedics,
Rheumatology and Musculoskeletal Science, Department 
</P>
<P STYLE="margin-bottom: 0cm">of Pathology, Nuffield Orthopaedic
Centre, Oxford, United Kingdom. (6)University 
</P>
<P STYLE="margin-bottom: 0cm">Claude Bernard Lyon I, Centre Léon
Bérard, Department of Medicine, Lyon, France. 
</P>
<P STYLE="margin-bottom: 0cm">(7)Service d'oncologie médicale,
Cliniques universitaires Saint-Luc, Université</P>
<P STYLE="margin-bottom: 0cm">catholique de Louvain, Brussels,
Belgium. (8)Liverpool CR-UK Centre, Department</P>
<P STYLE="margin-bottom: 0cm">of Molecular and Clinical Cancer
Medicine, Royal Liverpool University Hospital,</P>
<P STYLE="margin-bottom: 0cm">Liverpool, United Kingdom.
(9)Department of Urology, Inselspital, Bern, Bern,</P>
<P STYLE="margin-bottom: 0cm">Switzerland. (10)Oxford Cancer and
Haematology Centre, Oxford University</P>
<P STYLE="margin-bottom: 0cm">Hospitals NHS Trust, Churchill
Hospital, Oxford, Liverpool, United Kingdom.</P>
<P STYLE="margin-bottom: 0cm">(11)Department of Oncology, Weatherall
Institute of Molecular Medicine, John</P>
<P STYLE="margin-bottom: 0cm">Radcliffe Hospital, University of
Oxford, Oxford, United Kingdom. Oxford Cancer</P>
<P STYLE="margin-bottom: 0cm">and Haematology Centre, Oxford
University Hospitals NHS Trust, Churchill</P>
<P STYLE="margin-bottom: 0cm">Hospital, Oxford, Liverpool, United
Kingdom.</P>
<P STYLE="margin-bottom: 0cm">valentine.macaulay@oncology.ox.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Drugs that inhibit insulin-like growth
factor 1 (IGFI) receptor IGFIR were</P>
<P STYLE="margin-bottom: 0cm">encouraging in early trials, but
predictive biomarkers were lacking and the drugs</P>
<P STYLE="margin-bottom: 0cm">provided insufficient benefit in
unselected patients. In this study, we used</P>
<P STYLE="margin-bottom: 0cm">genetic screening and downstream
validation to identify the WNT pathway element</P>
<P STYLE="margin-bottom: 0cm">DVL3 as a mediator of resistance to
IGFIR inhibition. Sensitivity to IGFIR</P>
<P STYLE="margin-bottom: 0cm">inhibition was enhanced specifically in
vitro and in vivo by genetic or</P>
<P STYLE="margin-bottom: 0cm">pharmacologic blockade of DVL3. In
breast and prostate cancer cells,</P>
<P STYLE="margin-bottom: 0cm">sensitization tracked with enhanced
MEK-ERK activation and relied upon MEK</P>
<P STYLE="margin-bottom: 0cm">activity and DVL3 expression.
Mechanistic investigations showed that DVL3 is</P>
<P STYLE="margin-bottom: 0cm">present in an adaptor complex that
links IGFIR to RAS, which includes Shc, growth</P>
<P STYLE="margin-bottom: 0cm">factor receptor-bound-2 (Grb2),
son-of-sevenless (SOS), and the tumor suppressor 
</P>
<P STYLE="margin-bottom: 0cm">DAB2. Dual DVL and DAB2 blockade
synergized in activating ERKs and sensitizing</P>
<P STYLE="margin-bottom: 0cm">cells to IGFIR inhibition, suggesting a
nonredundant role for DVL3 in the</P>
<P STYLE="margin-bottom: 0cm">Shc-Grb2-SOS complex. Clinically,
tumors that responded to IGFIR inhibition</P>
<P STYLE="margin-bottom: 0cm">contained relatively lower levels of
DVL3 protein than resistant tumors, and DVL3</P>
<P STYLE="margin-bottom: 0cm">levels in tumors correlated inversely
with progression-free survival in patients 
</P>
<P STYLE="margin-bottom: 0cm">treated with IGFIR antibodies. Because
IGFIR does not contain activating</P>
<P STYLE="margin-bottom: 0cm">mutations analogous to EGFR variants
associated with response to EGFR inhibitors,</P>
<P STYLE="margin-bottom: 0cm">we suggest that IGF signaling achieves
an equivalent integration at the</P>
<P STYLE="margin-bottom: 0cm">postreceptor level through adaptor
protein complexes, influencing cellular</P>
<P STYLE="margin-bottom: 0cm">dependence on the IGF axis and
identifying a patient population with potential to</P>
<P STYLE="margin-bottom: 0cm">benefit from IGFIR inhibition.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">©2014 American Association for Cancer
Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25168481 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">11. Cell Rep. 2014 Aug 21;8(4):1037-48.
doi: 10.1016/j.celrep.2014.07.010. Epub 2014 
</P>
<P STYLE="margin-bottom: 0cm">Aug 7.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Oncogene mimicry as a mechanism of
primary resistance to BRAF inhibitors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sos ML(1), Levin RS(2), Gordan JD(3),
Oses-Prieto JA(4), Webber JT(5), Salt M(6),</P>
<P STYLE="margin-bottom: 0cm">Hann B(6), Burlingame AL(4), McCormick
F(6), Bandyopadhyay S(5), Shokat KM(7).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Howard Hughes Medical Institute and
Department of Cellular and Molecular</P>
<P STYLE="margin-bottom: 0cm">Pharmacology, University of California,
San Francisco, San Francisco, CA 94158,</P>
<P STYLE="margin-bottom: 0cm">USA. (2)Howard Hughes Medical Institute
and Department of Cellular and Molecular 
</P>
<P STYLE="margin-bottom: 0cm">Pharmacology, University of California,
San Francisco, San Francisco, CA 94158,</P>
<P STYLE="margin-bottom: 0cm">USA; Department of Pharmaceutical
Chemistry, University of California, San</P>
<P STYLE="margin-bottom: 0cm">Francisco, San Francisco, California,
CA 94158, USA. (3)Howard Hughes Medical</P>
<P STYLE="margin-bottom: 0cm">Institute and Department of Cellular
and Molecular Pharmacology, University of</P>
<P STYLE="margin-bottom: 0cm">California, San Francisco, San
Francisco, CA 94158, USA; Department of Medicine, 
</P>
<P STYLE="margin-bottom: 0cm">Helen Diller Family Comprehensive
Cancer Center, University of California, San</P>
<P STYLE="margin-bottom: 0cm">Francisco, San Francisco, CA 94143,
USA. (4)Department of Pharmaceutical</P>
<P STYLE="margin-bottom: 0cm">Chemistry, University of California,
San Francisco, San Francisco, California, CA</P>
<P STYLE="margin-bottom: 0cm">94158, USA. (5)Department of
Bioengineering and Therapeutic Sciences, University 
</P>
<P STYLE="margin-bottom: 0cm">of California, San Francisco, San
Francisco, CA 94158, USA. (6)Department of</P>
<P STYLE="margin-bottom: 0cm">Medicine, Helen Diller Family
Comprehensive Cancer Center, University of</P>
<P STYLE="margin-bottom: 0cm">California, San Francisco, San
Francisco, CA 94143, USA. (7)Howard Hughes Medical</P>
<P STYLE="margin-bottom: 0cm">Institute and Department of Cellular
and Molecular Pharmacology, University of</P>
<P STYLE="margin-bottom: 0cm">California, San Francisco, San
Francisco, CA 94158, USA. Electronic address:</P>
<P STYLE="margin-bottom: 0cm">kevan.shokat@ucsf.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Despite the development of potent
RAF/mitogen-activated protein kinase (MAPK)</P>
<P STYLE="margin-bottom: 0cm">pathway inhibitors, only a fraction of
BRAF-mutant patients benefit from</P>
<P STYLE="margin-bottom: 0cm">treatment with these drugs. Using a
combined chemogenomics and chemoproteomics</P>
<P STYLE="margin-bottom: 0cm">approach, we identify drug-induced
RAS-RAF-MEK complex formation in a subset of</P>
<P STYLE="margin-bottom: 0cm">BRAF-mutant cancer cells characterized
by primary resistance to vemurafenib. In</P>
<P STYLE="margin-bottom: 0cm">these cells, autocrine interleukin-6
(IL-6) secretion may contribute to the</P>
<P STYLE="margin-bottom: 0cm">primary resistance phenotype via
induction of JAK/STAT3 and MAPK signaling. In a 
</P>
<P STYLE="margin-bottom: 0cm">subset of cell lines, combined
IL-6/MAPK inhibition is able to overcome primary</P>
<P STYLE="margin-bottom: 0cm">resistance to BRAF-targeted therapy.
Overall, we show that the signaling</P>
<P STYLE="margin-bottom: 0cm">plasticity exerted by primary resistant
BRAF-mutant cells is achieved by their</P>
<P STYLE="margin-bottom: 0cm">ability to mimic signaling features of
oncogenic RAS, a strategy that we term</P>
<P STYLE="margin-bottom: 0cm">&quot;oncogene mimicry.&quot; This
model may guide future strategies for overcoming primary</P>
<P STYLE="margin-bottom: 0cm">resistance observed in these tumors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2014 The Authors.
Published by Elsevier Inc. All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4294625</P>
<P STYLE="margin-bottom: 0cm">PMID: 25127139 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">12. Proc Natl Acad Sci U S A. 2014 Aug
26;111(34):12544-9. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1073/pnas.1403450111. Epub 2014 Aug
6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">DRK/DOS/SOS converge with
Crk/Mbc/dCed-12 to activate Rac1 during glial</P>
<P STYLE="margin-bottom: 0cm">engulfment of axonal debris.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lu TY(1), Doherty J(1), Freeman MR(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Neurobiology and
Howard Hughes Medical Institute, University of 
</P>
<P STYLE="margin-bottom: 0cm">Massachusetts Medical School,
Worcester, MA 01605. (2)Department of Neurobiology 
</P>
<P STYLE="margin-bottom: 0cm">and Howard Hughes Medical Institute,
University of Massachusetts Medical School, 
</P>
<P STYLE="margin-bottom: 0cm">Worcester, MA 01605
marc.freeman@umassmed.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nervous system injury or disease leads
to activation of glia, which govern</P>
<P STYLE="margin-bottom: 0cm">postinjury responses in the nervous
system. Axonal injury in Drosophila results</P>
<P STYLE="margin-bottom: 0cm">in transcriptional up-regulation of the
glial engulfment receptor Draper; there</P>
<P STYLE="margin-bottom: 0cm">is extension of glial membranes to the
injury site (termed activation), and then 
</P>
<P STYLE="margin-bottom: 0cm">axonal debris is internalized and
degraded. Loss of the small GTPase Rac1 from</P>
<P STYLE="margin-bottom: 0cm">glia completely suppresses glial
responses to injury, but upstream activators</P>
<P STYLE="margin-bottom: 0cm">remain poorly defined. Loss of the Rac
guanine nucleotide exchange factor (GEF)</P>
<P STYLE="margin-bottom: 0cm">Crk/myoblast city (Mbc)/dCed-12 has no
effect on glial activation, but blocks</P>
<P STYLE="margin-bottom: 0cm">internalization and degradation of
debris. Here we show that the signaling</P>
<P STYLE="margin-bottom: 0cm">molecules downstream of receptor kinase
(DRK) and daughter of sevenless (DOS)</P>
<P STYLE="margin-bottom: 0cm">(mammalian homologs, Grb2 and Gab2,
respectively) and the GEF son of sevenless</P>
<P STYLE="margin-bottom: 0cm">(SOS) (mammalian homolog, mSOS) are
required for efficient activation of glia</P>
<P STYLE="margin-bottom: 0cm">after axotomy and
internalization/degradation of axonal debris. At the earliest</P>
<P STYLE="margin-bottom: 0cm">steps of glial activation, DRK/DOS/SOS
function in a partially redundant manner</P>
<P STYLE="margin-bottom: 0cm">with Crk/Mbc/dCed-12, with blockade of
both complexes strongly suppressing all</P>
<P STYLE="margin-bottom: 0cm">glial responses, similar to loss of
Rac1. This work identifies DRK/DOS/SOS as the</P>
<P STYLE="margin-bottom: 0cm">upstream Rac GEF complex required for
glial responses to axonal injury, and</P>
<P STYLE="margin-bottom: 0cm">demonstrates a critical requirement for
multiple GEFs in efficient glial</P>
<P STYLE="margin-bottom: 0cm">activation after injury and
internalization/degradation of axonal debris.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4151738</P>
<P STYLE="margin-bottom: 0cm">PMID: 25099352 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">13. Science. 2014 Jul 4;345(6192):50-4.
doi: 10.1126/science.1250373.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Molecular kinetics. Ras activation by
SOS: allosteric regulation by altered</P>
<P STYLE="margin-bottom: 0cm">fluctuation dynamics.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Iversen L(1), Tu HL(1), Lin WC(1),
Christensen SM(1), Abel SM(2), Iwig J(3), Wu</P>
<P STYLE="margin-bottom: 0cm">HJ(1), Gureasko J(3), Rhodes C(4),
Petit RS(1), Hansen SD(1), Thill P(5), Yu</P>
<P STYLE="margin-bottom: 0cm">CH(6), Stamou D(7), Chakraborty AK(8),
Kuriyan J(9), Groves JT(10).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Howard Hughes Medical Institute,
Department of Chemistry, University of</P>
<P STYLE="margin-bottom: 0cm">California, Berkeley, Berkeley, CA
94720, USA. (2)Department of Chemical</P>
<P STYLE="margin-bottom: 0cm">Engineering, Massachusetts Institute of
Technology (MIT), Cambridge, MA 02139,</P>
<P STYLE="margin-bottom: 0cm">USA. (3)Howard Hughes Medical
Institute, Department of Molecular and Cell</P>
<P STYLE="margin-bottom: 0cm">Biology, University of California,
Berkeley, Berkeley, CA 94720, USA.</P>
<P STYLE="margin-bottom: 0cm">(4)Department of Mechanical
Engineering, University of California, Berkeley,</P>
<P STYLE="margin-bottom: 0cm">Berkeley, CA 94720, USA. (5)Department
of Chemistry, MIT, Cambridge, MA 02139,</P>
<P STYLE="margin-bottom: 0cm">USA. (6)Mechanobiology Institute,
National University of Singapore, Singapore.</P>
<P STYLE="margin-bottom: 0cm">(7)Department of Chemistry and
Nano-Science Center, University of Copenhagen,</P>
<P STYLE="margin-bottom: 0cm">Copenhagen, Denmark. (8)Department of
Chemical Engineering, Massachusetts</P>
<P STYLE="margin-bottom: 0cm">Institute of Technology (MIT),
Cambridge, MA 02139, USA. Department of Chemistry,</P>
<P STYLE="margin-bottom: 0cm">MIT, Cambridge, MA 02139, USA.
Department of Biological Engineering, MIT,</P>
<P STYLE="margin-bottom: 0cm">Cambridge, MA 02139, USA. Ragon
Institute of Massachusetts General Hospital, MIT,</P>
<P STYLE="margin-bottom: 0cm">and Harvard, Cambridge, MA 02139, USA.
Department of Physics, MIT, Cambridge, MA 
</P>
<P STYLE="margin-bottom: 0cm">02139, USA. Institute for Medical
Engineering and Science, MIT, Cambridge, MA</P>
<P STYLE="margin-bottom: 0cm">02139, USA. (9)Howard Hughes Medical
Institute, Department of Chemistry,</P>
<P STYLE="margin-bottom: 0cm">University of California, Berkeley,
Berkeley, CA 94720, USA. Howard Hughes</P>
<P STYLE="margin-bottom: 0cm">Medical Institute, Department of
Molecular and Cell Biology, University of</P>
<P STYLE="margin-bottom: 0cm">California, Berkeley, Berkeley, CA
94720, USA. Physical Biosciences and Materials</P>
<P STYLE="margin-bottom: 0cm">Sciences Divisions, Lawrence Berkeley
National Laboratory, Berkeley, CA 94720,</P>
<P STYLE="margin-bottom: 0cm">USA. (10)Howard Hughes Medical
Institute, Department of Chemistry, University of 
</P>
<P STYLE="margin-bottom: 0cm">California, Berkeley, Berkeley, CA
94720, USA. Mechanobiology Institute, National</P>
<P STYLE="margin-bottom: 0cm">University of Singapore, Singapore.
Physical Biosciences and Materials Sciences</P>
<P STYLE="margin-bottom: 0cm">Divisions, Lawrence Berkeley National
Laboratory, Berkeley, CA 94720, USA.</P>
<P STYLE="margin-bottom: 0cm">Berkeley Education Alliance for
Research in Singapore, 1 Create Way, CREATE tower</P>
<P STYLE="margin-bottom: 0cm">level 11, University Town, Singapore
138602. jtgroves@lbl.gov.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Activation of the small guanosine
triphosphatase H-Ras by the exchange factor Son</P>
<P STYLE="margin-bottom: 0cm">of Sevenless (SOS) is an important hub
for signal transduction. Multiple layers</P>
<P STYLE="margin-bottom: 0cm">of regulation, through protein and
membrane interactions, govern activity of SOS.</P>
<P STYLE="margin-bottom: 0cm">We characterized the specific activity
of individual SOS molecules catalyzing</P>
<P STYLE="margin-bottom: 0cm">nucleotide exchange in H-Ras.
Single-molecule kinetic traces revealed that SOS</P>
<P STYLE="margin-bottom: 0cm">samples a broad distribution of
turnover rates through stochastic fluctuations</P>
<P STYLE="margin-bottom: 0cm">between distinct, long-lived (more than
100 seconds), functional states. The</P>
<P STYLE="margin-bottom: 0cm">expected allosteric activation of SOS
by Ras-guanosine triphosphate (GTP) was</P>
<P STYLE="margin-bottom: 0cm">conspicuously absent in the mean rate.
However, fluctuations into highly active</P>
<P STYLE="margin-bottom: 0cm">states were modulated by Ras-GTP. This
reveals a mechanism in which functional</P>
<P STYLE="margin-bottom: 0cm">output may be determined by the
dynamical spectrum of rates sampled by a small</P>
<P STYLE="margin-bottom: 0cm">number of enzymes, rather than the
ensemble average.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2014, American Association
for the Advancement of Science.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4255705</P>
<P STYLE="margin-bottom: 0cm">PMID: 24994643 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">14. Oncogene. 2015 Mar
26;34(13):1729-35. doi: 10.1038/onc.2014.110. Epub 2014 May</P>
<P STYLE="margin-bottom: 0cm">19.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The ShcA adaptor activates AKT
signaling to potentiate breast tumor angiogenesis 
</P>
<P STYLE="margin-bottom: 0cm">by stimulating VEGF mRNA translation in
a 4E-BP-dependent manner.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Im YK(1), La Selva R(1), Gandin V(1),
Ha JR(1), Sabourin V(1), Sonenberg N(2),</P>
<P STYLE="margin-bottom: 0cm">Pawson T(3), Topisirovic I(1),
Ursini-Siegel J(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Oncology, Lady Davis
Institute for Medical Research, McGill</P>
<P STYLE="margin-bottom: 0cm">University, Montreal, Quebec, Canada.
(2)Goodman Cancer Research Centre,</P>
<P STYLE="margin-bottom: 0cm">Montreal, Quebec, Canada. (3)Samuel
Lunenfeld Research Institute, Mount Sinai</P>
<P STYLE="margin-bottom: 0cm">Hospital, University of Toronto,
Toronto, Ontario, Canada.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The ShcA adaptor protein is engaged by
numerous receptor tyrosine kinases (RTKs) 
</P>
<P STYLE="margin-bottom: 0cm">in breast cancer cells. Once activated,
RTKs phosphorylate three key tyrosine</P>
<P STYLE="margin-bottom: 0cm">phosphorylation sites (Y239, Y240 and
Y317) within ShcA that creates a docking</P>
<P STYLE="margin-bottom: 0cm">site for Grb2/SOS and
Grb2/Gab-containing complexes to activate the MAPK and AKT 
</P>
<P STYLE="margin-bottom: 0cm">signaling pathways, respectively. We
previously demonstrated that a tyrosine to</P>
<P STYLE="margin-bottom: 0cm">phenylalanine substitution of the ShcA
tyrosine phosphorylation sites</P>
<P STYLE="margin-bottom: 0cm">(Shc3F-Y239/240/313F) significantly
impairs breast tumor growth and angiogenesis 
</P>
<P STYLE="margin-bottom: 0cm">in transgenic mouse models, in part,
through the regulation of vascular</P>
<P STYLE="margin-bottom: 0cm">endothelial growth factor (VEGF)
production. Despite this fact, the underlying</P>
<P STYLE="margin-bottom: 0cm">molecular mechanisms by which ShcA
transduces pro-tumorigenic signals in breast</P>
<P STYLE="margin-bottom: 0cm">cancer cells remain poorly defined. In
this study, we demonstrate that</P>
<P STYLE="margin-bottom: 0cm">ShcA-dependent activation of AKT, but
not the RAS/MAPK pathway, induces VEGF</P>
<P STYLE="margin-bottom: 0cm">production by bolstering VEGF mRNA
translation. Accordingly, ShcA drives breast</P>
<P STYLE="margin-bottom: 0cm">tumor growth and angiogenesis in vivo
in a 4E-BP-dependent manner. These findings</P>
<P STYLE="margin-bottom: 0cm">establish ShcA as a biological bridge
that links AKT activation downstream of</P>
<P STYLE="margin-bottom: 0cm">RTKs to cap-dependent VEGF mRNA
translation in order to promote mammary</P>
<P STYLE="margin-bottom: 0cm">tumorigenesis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24837366 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">15. Front Biol (Beijing). 2013 Oct
1;8(5):508-532.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">RasGRP Ras guanine nucleotide exchange
factors in cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ksionda O(1), Limnander A(1), Roose
JP(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Anatomy, University of
California, San Francisco, San Francisco,</P>
<P STYLE="margin-bottom: 0cm">CA 94143, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">RasGRP proteins are activators of Ras
and other related small GTPases by the</P>
<P STYLE="margin-bottom: 0cm">virtue of functioning as guanine
nucleotide exchange factors (GEFs). In</P>
<P STYLE="margin-bottom: 0cm">vertebrates, four RasGRP family members
have been described. RasGRP-1 through -4 
</P>
<P STYLE="margin-bottom: 0cm">share many structural domains but there
are also subtle differences between each 
</P>
<P STYLE="margin-bottom: 0cm">of the different family members.
Whereas SOS RasGEFs are ubiquitously expressed, 
</P>
<P STYLE="margin-bottom: 0cm">RasGRP proteins are expressed in
distinct patterns, such as in different cells of</P>
<P STYLE="margin-bottom: 0cm">the hematopoietic system and in the
brain. Most studies have concentrated on the 
</P>
<P STYLE="margin-bottom: 0cm">role of RasGRP proteins in the
development and function of immune cell types</P>
<P STYLE="margin-bottom: 0cm">because of the predominant RasGRP
expression profiles in these cells and the</P>
<P STYLE="margin-bottom: 0cm">immune phenotypes of mice deficient for
Rasgrp genes. However, more recent</P>
<P STYLE="margin-bottom: 0cm">studies demonstrate that RasGRPs also
play an important role in tumorigenesis.</P>
<P STYLE="margin-bottom: 0cm">Examples are skin- and
hematological-cancers but also solid malignancies such as 
</P>
<P STYLE="margin-bottom: 0cm">melanoma or prostate cancer. These
novel studies bring up many new and unanswered</P>
<P STYLE="margin-bottom: 0cm">questions related to the molecular
mechanism of RasGRP-driven oncogenesis, such</P>
<P STYLE="margin-bottom: 0cm">as new receptor systems that RasGRP
appears to respond to as well as regulatory</P>
<P STYLE="margin-bottom: 0cm">mechanism for RasGRP expression that
appear to be perturbed in these cancers.</P>
<P STYLE="margin-bottom: 0cm">Here we will review some of the known
aspects of RasGRP biology in lymphocytes</P>
<P STYLE="margin-bottom: 0cm">and will discuss the exciting new
notion that RasGRP Ras exchange factors play a 
</P>
<P STYLE="margin-bottom: 0cm">role in oncogenesis downstream of
various growth factor receptors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3987922</P>
<P STYLE="margin-bottom: 0cm">PMID: 24744772 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">16. Proc Natl Acad Sci U S A. 2014 Mar
4;111(9):3401-6. doi: 10.1073/pnas.1315798111.</P>
<P STYLE="margin-bottom: 0cm">Epub 2014 Feb 18.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Approach for targeting Ras with small
molecules that activate SOS-mediated</P>
<P STYLE="margin-bottom: 0cm">nucleotide exchange.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Burns MC(1), Sun Q, Daniels RN, Camper
D, Kennedy JP, Phan J, Olejniczak ET, Lee 
</P>
<P STYLE="margin-bottom: 0cm">T, Waterson AG, Rossanese OW, Fesik SW.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Departments of Biochemistry,
Pharmacology, and Chemistry, Vanderbilt</P>
<P STYLE="margin-bottom: 0cm">University School of Medicine,
Nashville, TN 37232.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Aberrant activation of the small GTPase
Ras by oncogenic mutation or</P>
<P STYLE="margin-bottom: 0cm">constitutively active upstream receptor
tyrosine kinases results in the</P>
<P STYLE="margin-bottom: 0cm">deregulation of cellular signals
governing growth and survival in ∼30% of all</P>
<P STYLE="margin-bottom: 0cm">human cancers. However, the discovery
of potent inhibitors of Ras has been</P>
<P STYLE="margin-bottom: 0cm">difficult to achieve. Here, we report
the identification of small molecules that 
</P>
<P STYLE="margin-bottom: 0cm">bind to a unique pocket on the Ras:Son
of Sevenless (SOS):Ras complex, increase</P>
<P STYLE="margin-bottom: 0cm">the rate of SOS-catalyzed nucleotide
exchange in vitro, and modulate Ras</P>
<P STYLE="margin-bottom: 0cm">signaling pathways in cells. X-ray
crystallography of Ras:SOS:Ras in complex with</P>
<P STYLE="margin-bottom: 0cm">these molecules reveals that the
compounds bind in a hydrophobic pocket in the</P>
<P STYLE="margin-bottom: 0cm">CDC25 domain of SOS adjacent to the
Switch II region of Ras. The</P>
<P STYLE="margin-bottom: 0cm">structure-activity relationships
exhibited by these compounds can be rationalized</P>
<P STYLE="margin-bottom: 0cm">on the basis of multiple X-ray
cocrystal structures. Mutational analyses</P>
<P STYLE="margin-bottom: 0cm">confirmed the functional relevance of
this binding site and showed it to be</P>
<P STYLE="margin-bottom: 0cm">essential for compound activity. These
molecules increase Ras-GTP levels and</P>
<P STYLE="margin-bottom: 0cm">disrupt MAPK and PI3K signaling in
cells at low micromolar concentrations. These 
</P>
<P STYLE="margin-bottom: 0cm">small molecules represent tools to
study the acute activation of Ras and</P>
<P STYLE="margin-bottom: 0cm">highlight a pocket on SOS that may be
exploited to modulate Ras signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3948241</P>
<P STYLE="margin-bottom: 0cm">PMID: 24550516 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">17. Eur J Immunol. 2014
May;44(5):1535-40. doi: 10.1002/eji.201344046. Epub 2014 Feb 
</P>
<P STYLE="margin-bottom: 0cm">20.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sos1 regulates sustained TCR-mediated
Erk activation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Poltorak M(1), Meinert I, Stone JC,
Schraven B, Simeoni L.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Institute of Molecular and Clinical
Immunology, Otto-von-Guericke University, 
</P>
<P STYLE="margin-bottom: 0cm">Magdeburg, Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The duration and/or the magnitude of
Ras-Erk activation are known to be crucial</P>
<P STYLE="margin-bottom: 0cm">for cell-fate decisions. In T cells,
sustained Erk activation correlates with</P>
<P STYLE="margin-bottom: 0cm">differentiation/proliferation, whereas
transient Erk activation parallels with</P>
<P STYLE="margin-bottom: 0cm">unresponsiveness/apoptosis. The
mechanism by which Son of sevenless (Sos)</P>
<P STYLE="margin-bottom: 0cm">proteins and Ras guanyl-releasing
protein 1 (RasGRP1) contribute to dynamics of</P>
<P STYLE="margin-bottom: 0cm">Erk activation in mature T cells is not
yet known. Here, we have assessed this</P>
<P STYLE="margin-bottom: 0cm">issue using stimuli inducing either
transient or sustained TCR signaling and RNA 
</P>
<P STYLE="margin-bottom: 0cm">interference mediated suppression of
Sos1, Sos2, and RasGRP1 expression in</P>
<P STYLE="margin-bottom: 0cm">primary human T cells. We found that
transient Erk activation depends on RasGRP1 
</P>
<P STYLE="margin-bottom: 0cm">but not on Sos. Conversely, sustained
Erk signaling and T-cell activation depend 
</P>
<P STYLE="margin-bottom: 0cm">on both Sos1 and RasGRP1. In summary,
our data show for the first time that the</P>
<P STYLE="margin-bottom: 0cm">two guanine nucleotide exchange factors
expressed in T cells are differentially</P>
<P STYLE="margin-bottom: 0cm">involved in the regulation of the
duration of Erk phosphorylation and T-cell</P>
<P STYLE="margin-bottom: 0cm">activation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2014 WILEY-VCH Verlag GmbH &amp; Co.
KGaA, Weinheim.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24497027 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">18. Oncogene. 2015 Jan 22;34(4):474-84.
doi: 10.1038/onc.2013.564. Epub 2014 Jan 27.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Casein kinase 1 regulates Sprouty2 in
FGF-ERK signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Yim DG(1), Ghosh S(2), Guy GR(3),
Virshup DM(4).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)1] Program in Cancer and Stem Cell
Biology, Duke-NUS Graduate Medical School, 
</P>
<P STYLE="margin-bottom: 0cm">Singapore, Singapore [2] Signal
Transduction Laboratory, Institute for Molecular 
</P>
<P STYLE="margin-bottom: 0cm">and Cellular Biology, Biopolis,
Singapore [3] Genome Institute of Singapore,</P>
<P STYLE="margin-bottom: 0cm">Biopolis, Singapore. (2)Center for
Computational Biology, Duke-NUS Graduate</P>
<P STYLE="margin-bottom: 0cm">Medical School, Singapore, Singapore.
(3)Signal Transduction Laboratory,</P>
<P STYLE="margin-bottom: 0cm">Institute for Molecular and Cellular
Biology, Biopolis, Singapore. (4)1] Program 
</P>
<P STYLE="margin-bottom: 0cm">in Cancer and Stem Cell Biology,
Duke-NUS Graduate Medical School, Singapore,</P>
<P STYLE="margin-bottom: 0cm">Singapore [2] Department of
Biochemistry, YYL School of Medicine, National</P>
<P STYLE="margin-bottom: 0cm">University of Singapore, Singapore,
Singapore.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sprouty2 (SPRY2) is a potent negative
regulator of receptor tyrosine kinase</P>
<P STYLE="margin-bottom: 0cm">signaling, and is implicated as a tumor
suppressor. SPRY2 inhibits FGF-RAS-ERK</P>
<P STYLE="margin-bottom: 0cm">signaling by binding to growth factor
receptor bound protein 2 (GRB2) during</P>
<P STYLE="margin-bottom: 0cm">fibroblast growth factor receptor
(FGFR) activation, disrupting the GRB2-SOS (son</P>
<P STYLE="margin-bottom: 0cm">of sevenless) complex that transduces
signals from FGFR to RAS. SPRY2 binding to 
</P>
<P STYLE="margin-bottom: 0cm">GRB2 is modulated by phosphorylation
but the key regulatory kinase(s) are not</P>
<P STYLE="margin-bottom: 0cm">known. Prior studies identified the
frequent presence of CK1 phosphorylation</P>
<P STYLE="margin-bottom: 0cm">motifs on SPRY2. We therefore tested if
CK1 has a role in SPRY2 phosphorylation</P>
<P STYLE="margin-bottom: 0cm">and function. Loss of CK1 binding and
inhibition of CK1 activity by two</P>
<P STYLE="margin-bottom: 0cm">structurally distinct small molecules
abrogated SPRY2 inhibition of FGF-ERK</P>
<P STYLE="margin-bottom: 0cm">signaling, leading to decreased SPRY2
interaction with GRB2. Moreover, CK1</P>
<P STYLE="margin-bottom: 0cm">activity and binding are necessary for
SPRY2 inhibition of FGF-stimulated neurite</P>
<P STYLE="margin-bottom: 0cm">outgrowth in PC12 cells. Consistent
with its proposed role as an inhibitor of FGF</P>
<P STYLE="margin-bottom: 0cm">signaling, we find that CSNK1E
transcript abundance negatively correlates with</P>
<P STYLE="margin-bottom: 0cm">FGF1/FGF7 message in human gastric
cancer samples. Modulation of CK1 activity may</P>
<P STYLE="margin-bottom: 0cm">be therapeutically useful in the
treatment of FGF/SPRY2-related diseases.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24469046 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">19. Proc Natl Acad Sci U S A. 2013 Dec
17;110(51):20587-92. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1073/pnas.1222078110. Epub 2013 Dec
2.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Regulation of Son of sevenless by the
membrane-actin linker protein ezrin.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Geissler KJ(1), Jung MJ, Riecken LB,
Sperka T, Cui Y, Schacke S, Merkel U,</P>
<P STYLE="margin-bottom: 0cm">Markwart R, Rubio I, Than ME,
Breithaupt C, Peuker S, Seifert R, Kaupp UB,</P>
<P STYLE="margin-bottom: 0cm">Herrlich P, Morrison H.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)H.M. Laboratory, P.H. Laboratory,
and M.E.T. Laboratory, Leibniz Institute for</P>
<P STYLE="margin-bottom: 0cm">Age Research - Fritz Lipmann Institute,
07745 Jena, Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Receptor tyrosine kinases participate
in several signaling pathways through small</P>
<P STYLE="margin-bottom: 0cm">G proteins such as Ras (rat sarcoma).
An important component in the activation of</P>
<P STYLE="margin-bottom: 0cm">these G proteins is Son of sevenless
(SOS), which catalyzes the nucleotide</P>
<P STYLE="margin-bottom: 0cm">exchange on Ras. For optimal activity,
a second Ras molecule acts as an</P>
<P STYLE="margin-bottom: 0cm">allosteric activator by binding to a
second Ras-binding site within SOS. This</P>
<P STYLE="margin-bottom: 0cm">allosteric Ras-binding site is blocked
by autoinhibitory domains of SOS. We have 
</P>
<P STYLE="margin-bottom: 0cm">reported recently that Ras activation
also requires the actin-binding proteins</P>
<P STYLE="margin-bottom: 0cm">ezrin, radixin, and moesin. Here we
report the mechanism by which ezrin modulates</P>
<P STYLE="margin-bottom: 0cm">SOS activity and thereby Ras
activation. Active ezrin enhances Ras/MAPK signaling</P>
<P STYLE="margin-bottom: 0cm">and interacts with both SOS and Ras in
vivo and in vitro. Moreover, in vitro</P>
<P STYLE="margin-bottom: 0cm">kinetic assays with recombinant
proteins show that ezrin also is important for</P>
<P STYLE="margin-bottom: 0cm">the activity of SOS itself. Ezrin
interacts with GDP-Ras and with the Dbl</P>
<P STYLE="margin-bottom: 0cm">homology (DH)/pleckstrin homology (PH)
domains of SOS, bringing GDP-Ras to the</P>
<P STYLE="margin-bottom: 0cm">proximity of the allosteric site of
SOS. These actions of ezrin are antagonized</P>
<P STYLE="margin-bottom: 0cm">by the neurofibromatosis type 2
tumor-suppressor protein merlin. We propose an</P>
<P STYLE="margin-bottom: 0cm">additional essential step in SOS/Ras
control that is relevant for human cancer as</P>
<P STYLE="margin-bottom: 0cm">well as all physiological processes
involving Ras.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3870676</P>
<P STYLE="margin-bottom: 0cm">PMID: 24297905 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">20. J Med Chem. 2013 Dec
12;56(23):9664-72. doi: 10.1021/jm401291q. Epub 2013 Nov 22.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Bisphenol A binds to Ras proteins and
competes with guanine nucleotide exchange: 
</P>
<P STYLE="margin-bottom: 0cm">implications for GTPase-selective
antagonists.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Schöpel M(1), Jockers KF, Düppe PM,
Autzen J, Potheraveedu VN, Ince S, Yip KT,</P>
<P STYLE="margin-bottom: 0cm">Heumann R, Herrmann C, Scherkenbeck J,
Stoll R.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Faculty of Chemistry and
Biochemistry, Ruhr University of Bochum ,</P>
<P STYLE="margin-bottom: 0cm">Universitätsstraße 150, D-44780
Bochum, Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">We show for the first time that
bisphenol A (10) has the capacity to interact</P>
<P STYLE="margin-bottom: 0cm">directly with K-Ras and that Rheb
weakly binds to bisphenol A (10) and</P>
<P STYLE="margin-bottom: 0cm">4,4'-biphenol derivatives. We have
characterized these interactions at atomic</P>
<P STYLE="margin-bottom: 0cm">resolution suggesting that these
compounds sterically interfere with the</P>
<P STYLE="margin-bottom: 0cm">Sos-mediated nucleotide exchange in H-
and K-Ras. We show that 4,4'-biphenol (5) 
</P>
<P STYLE="margin-bottom: 0cm">selectively inhibits Rheb signaling and
induces cell death suggesting that this</P>
<P STYLE="margin-bottom: 0cm">compound might be a novel candidate for
treatment of tuberous sclerosis-mediated 
</P>
<P STYLE="margin-bottom: 0cm">tumor growth. Our results propose a new
mode of action for bisphenol A (10) that 
</P>
<P STYLE="margin-bottom: 0cm">advocates a reduced exposure to this
compound in our environment. Our data may</P>
<P STYLE="margin-bottom: 0cm">lay the foundation for the future
design of GTPase-selective antagonists with</P>
<P STYLE="margin-bottom: 0cm">higher affinity to benefit of the
treatment of cancer because K-Ras inhibition is</P>
<P STYLE="margin-bottom: 0cm">regarded to be a promising strategy
with a potential therapeutic window for</P>
<P STYLE="margin-bottom: 0cm">targeting Sos in Ras-driven tumors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24266771 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Nat Commun. 2015 Jun 24;6:7354. doi:
10.1038/ncomms8354.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Grb2 monomer-dimer equilibrium
determines normal versus oncogenic function.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ahmed Z(1), Timsah Z(2), Suen KM(2),
Cook NP(3), Lee GR 4th(4), Lin CC(2), Gagea 
</P>
<P STYLE="margin-bottom: 0cm">M(5), Marti AA(3), Ladbury JE(6).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)1] Department of Biochemistry and
Molecular Biology, University of Texas, M.D.</P>
<P STYLE="margin-bottom: 0cm">Anderson Cancer Center, Unit 1000, 1515
Holcombe Boulevard, Houston, Texas 77030,</P>
<P STYLE="margin-bottom: 0cm">USA [2] Center for Biomolecular
Structure and Function, University of Texas, M.D.</P>
<P STYLE="margin-bottom: 0cm">Anderson Cancer Center, Unit 1000, 1515
Holcombe Boulevard, Houston, Texas 77030,</P>
<P STYLE="margin-bottom: 0cm">USA. (2)1] Department of Biochemistry
and Molecular Biology, University of Texas,</P>
<P STYLE="margin-bottom: 0cm">M.D. Anderson Cancer Center, Unit 1000,
1515 Holcombe Boulevard, Houston, Texas</P>
<P STYLE="margin-bottom: 0cm">77030, USA [2] School of Molecular and
Cellular Biology, University of Leeds,</P>
<P STYLE="margin-bottom: 0cm">Leeds LS2 9JT, UK. (3)Department of
Chemistry, Rice University, Houston, Texas</P>
<P STYLE="margin-bottom: 0cm">77005, USA. (4)Center for Biomolecular
Structure and Function, University of</P>
<P STYLE="margin-bottom: 0cm">Texas, M.D. Anderson Cancer Center,
Unit 1000, 1515 Holcombe Boulevard, Houston, 
</P>
<P STYLE="margin-bottom: 0cm">Texas 77030, USA. (5)Department of
Veterinary Medicine and Surgery, University of</P>
<P STYLE="margin-bottom: 0cm">Texas, M.D. Anderson Cancer Center,
Unit 63, 1515 Holcombe Boulevard, Houston,</P>
<P STYLE="margin-bottom: 0cm">Texas 77030, USA. (6)1] Department of
Biochemistry and Molecular Biology,</P>
<P STYLE="margin-bottom: 0cm">University of Texas, M.D. Anderson
Cancer Center, Unit 1000, 1515 Holcombe</P>
<P STYLE="margin-bottom: 0cm">Boulevard, Houston, Texas 77030, USA
[2] Center for Biomolecular Structure and</P>
<P STYLE="margin-bottom: 0cm">Function, University of Texas, M.D.
Anderson Cancer Center, Unit 1000, 1515</P>
<P STYLE="margin-bottom: 0cm">Holcombe Boulevard, Houston, Texas
77030, USA [3] School of Molecular and</P>
<P STYLE="margin-bottom: 0cm">Cellular Biology, University of Leeds,
Leeds LS2 9JT, UK.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The adaptor protein growth factor
receptor-bound protein 2 (Grb2) is ubiquitously</P>
<P STYLE="margin-bottom: 0cm">expressed in eukaryotic cells and
involved in a multitude of intracellular</P>
<P STYLE="margin-bottom: 0cm">protein interactions. Grb2 plays a
pivotal role in tyrosine kinase-mediated</P>
<P STYLE="margin-bottom: 0cm">signal transduction including linking
receptor tyrosine kinases to the</P>
<P STYLE="margin-bottom: 0cm">Ras/mitogen-activated protein (MAP)
kinase pathway, which is implicated in</P>
<P STYLE="margin-bottom: 0cm">oncogenic outcome. Grb2 exists in a
constitutive equilibrium between monomeric</P>
<P STYLE="margin-bottom: 0cm">and dimeric states. Here we show that
only monomeric Grb2 is capable of binding</P>
<P STYLE="margin-bottom: 0cm">to SOS and upregulating MAP kinase
signalling and that the dimeric state is</P>
<P STYLE="margin-bottom: 0cm">inhibitory to this process.
Phosphorylation of tyrosine 160 (Y160) on Grb2, or</P>
<P STYLE="margin-bottom: 0cm">binding of a
tyrosylphosphate-containing ligand to the SH2 domain of Grb2,</P>
<P STYLE="margin-bottom: 0cm">results in dimer dissociation.
Phosphorylation of Y160 on Grb2 is readily</P>
<P STYLE="margin-bottom: 0cm">detectable in the malignant forms of
human prostate, colon and breast cancers.</P>
<P STYLE="margin-bottom: 0cm">The self-association/dissociation of
Grb2 represents a switch that regulates MAP 
</P>
<P STYLE="margin-bottom: 0cm">kinase activity and hence controls
cancer progression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4491180</P>
<P STYLE="margin-bottom: 0cm">PMID: 26103942 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. Eur J Immunol. 2015 May 14. doi:
10.1002/eji.201445226. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Absence of both Sos-1 and Sos-2 in
peripheral CD4(+) T cells leads to PI3K</P>
<P STYLE="margin-bottom: 0cm">pathway activation and defects in
migration.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Guittard G(1), Kortum RL(1),
Balagopalan L(1), Çuburu N(2), Nguyen P(1), Sommers 
</P>
<P STYLE="margin-bottom: 0cm">CL(1), Samelson LE(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Laboratory of Cellular and Molecular
Biology, Center for Cancer Research,</P>
<P STYLE="margin-bottom: 0cm">National Cancer Institute, Bethesda,
MD, USA. (2)Laboratory of Cellular Oncology,</P>
<P STYLE="margin-bottom: 0cm">Center for Cancer Research, National
Cancer Institute, Bethesda, MD, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sos-1 and Sos-2 are ubiquitously
expressed Ras-guanine exchange factors involved 
</P>
<P STYLE="margin-bottom: 0cm">in Erk-MAP kinase pathway activation.
Using mice lacking genes encoding Sos-1 and</P>
<P STYLE="margin-bottom: 0cm">Sos-2, we evaluated the role of these
proteins in peripheral T-cell signaling and</P>
<P STYLE="margin-bottom: 0cm">function. Our results confirmed that
TCR-mediated Erk activation in peripheral</P>
<P STYLE="margin-bottom: 0cm">CD4(+) T cells does not depend on Sos-1
and Sos-2, although IL-2-mediated Erk</P>
<P STYLE="margin-bottom: 0cm">activation does. Unexpectedly, however,
we show an increase in AKT</P>
<P STYLE="margin-bottom: 0cm">phosphorylation in Sos-1/2dKO CD4(+) T
cells upon TCR and IL-2 stimulation.</P>
<P STYLE="margin-bottom: 0cm">Activation of AKT was likely a
consequence of increased recruitment of PI3K to</P>
<P STYLE="margin-bottom: 0cm">Grb2 upon TCR and/or IL-2 stimulation
in Sos-1/2dKO CD4(+) T cells. The increased</P>
<P STYLE="margin-bottom: 0cm">activity of the PI3K/AKT pathway led to
downregulation of the surface receptor</P>
<P STYLE="margin-bottom: 0cm">CD62L in Sos-1/2dKO T cells and a
subsequent impairment in T-cell migration.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Published 2015. This article is a U.S.
Government work and is in the public</P>
<P STYLE="margin-bottom: 0cm">domain in the USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25973715 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. Int J Mol Med. 2015
Apr;35(4):909-14. doi: 10.3892/ijmm.2015.2111. Epub 2015 Feb 
</P>
<P STYLE="margin-bottom: 0cm">26.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The proliferative effects of Pyropia
yezoensis peptide on IEC-6 cells are</P>
<P STYLE="margin-bottom: 0cm">mediated through the epidermal growth
factor receptor signaling pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lee MK(1), Kim IH(2), Choi YH(2), Choi
JW(1), Kim YM(2), Nam TJ(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Food Science and
Nutrition, Pukyong National University, Busan</P>
<P STYLE="margin-bottom: 0cm">608-737, Republic of Korea.
(2)Institute of Fisheries Science, Pukyong National</P>
<P STYLE="margin-bottom: 0cm">University, Busan 619-911, Republic of
Korea.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">For a number of years, seaweed has been
used as a functional food in Asian</P>
<P STYLE="margin-bottom: 0cm">countries, particularly in Korea, Japan
and China. Pyropia yezoensis is a marine 
</P>
<P STYLE="margin-bottom: 0cm">red alga that has potentially
beneficial biological activities. In this study, we</P>
<P STYLE="margin-bottom: 0cm">examined the mechanisms through which a
Pyropia yezoensis peptide [PYP1 (1-20)]</P>
<P STYLE="margin-bottom: 0cm">induces the proliferation of IEC-6
cells, a rat intestinal epithelial cell line, 
</P>
<P STYLE="margin-bottom: 0cm">and the involvement of the epidermal
growth factor receptor (EGFR) signaling</P>
<P STYLE="margin-bottom: 0cm">pathway. First, cell viability assay
revealed that PYP1 (1-20) induced cell</P>
<P STYLE="margin-bottom: 0cm">proliferation in a
concentration-dependent manner. Subsequently, we examined the 
</P>
<P STYLE="margin-bottom: 0cm">mechanisms responsible for this
induction of proliferation induced by PYP1</P>
<P STYLE="margin-bottom: 0cm">(1-20). EGFR is widely expressed in
mammalian epithelial tissues, and the binding</P>
<P STYLE="margin-bottom: 0cm">of this ligand affects a variety of
cell physiological parameters, such as cell</P>
<P STYLE="margin-bottom: 0cm">growth and proliferation. PYP1 (1-20)
increased the expression of EGFR, Shc,</P>
<P STYLE="margin-bottom: 0cm">growth factor receptor-bound protein 2
(Grb2) and son of sevenless (SOS). EGFR</P>
<P STYLE="margin-bottom: 0cm">also induced the activation of the Ras
signaling pathway through Raf, MEK and</P>
<P STYLE="margin-bottom: 0cm">extracellular signal-regulated kinase
(ERK) phosphorylation. In addition, cell</P>
<P STYLE="margin-bottom: 0cm">cycle analysis revealed the expression
of cell cycle-related proteins. The</P>
<P STYLE="margin-bottom: 0cm">results demonstrated an increased
number of cells in the G1 phase and an enhanced</P>
<P STYLE="margin-bottom: 0cm">cell proliferation. In addition, the
upregulation of cyclin D, cyclin E, Cdk2,</P>
<P STYLE="margin-bottom: 0cm">Cdk4 and Cdk6 was observed accompanied
by a decreased in p21 and p27 expression. 
</P>
<P STYLE="margin-bottom: 0cm">These findings suggest that PYP1 (1-20)
stimulates the proliferation of rat IEC-6</P>
<P STYLE="margin-bottom: 0cm">cells by activating the EGFR signaling
pathway. Therefore, PYP1 (1-20) may be a</P>
<P STYLE="margin-bottom: 0cm">potential source for the development of
bio-functional foods which promotes the</P>
<P STYLE="margin-bottom: 0cm">proliferation of intestinal epithelial
cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4356455</P>
<P STYLE="margin-bottom: 0cm">PMID: 25716690 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">4. Cancer Res. 2014 Oct
15;74(20):5866-77. doi: 10.1158/0008-5472.CAN-14-0806. Epub 
</P>
<P STYLE="margin-bottom: 0cm">2014 Aug 28.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Dsh homolog DVL3 mediates resistance to
IGFIR inhibition by regulating IGF-RAS</P>
<P STYLE="margin-bottom: 0cm">signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gao S(1), Bajrami I(2), Verrill C(3),
Kigozi A(2), Ouaret D(1), Aleksic T(1),</P>
<P STYLE="margin-bottom: 0cm">Asher R(3), Han C(1), Allen P(4),
Bailey D(4), Feller S(1), Kashima T(1),</P>
<P STYLE="margin-bottom: 0cm">Athanasou N(5), Blay JY(6), Schmitz
S(7), Machiels JP(7), Upile N(8), Jones</P>
<P STYLE="margin-bottom: 0cm">TM(8), Thalmann G(9), Ashraf SQ(1),
Wilding JL(1), Bodmer WF(1), Middleton</P>
<P STYLE="margin-bottom: 0cm">MR(10), Ashworth A(2), Lord CJ(2),
Macaulay VM(11).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Oncology, Weatherall
Institute of Molecular Medicine, John</P>
<P STYLE="margin-bottom: 0cm">Radcliffe Hospital, University of
Oxford, Oxford, United Kingdom. (2)Breakthrough</P>
<P STYLE="margin-bottom: 0cm">Breast Cancer Research Centre, The
Institute of Cancer Research, London, United</P>
<P STYLE="margin-bottom: 0cm">Kingdom. (3)Department of Cellular
Pathology and NIHR Oxford Biomedical Research 
</P>
<P STYLE="margin-bottom: 0cm">Centre, Oxford University Hospitals NHS
Trust, John Radcliffe Hospital, Oxford,</P>
<P STYLE="margin-bottom: 0cm">United Kingdom. (4)Department of
Cellular Pathology, Oxford University Hospitals 
</P>
<P STYLE="margin-bottom: 0cm">NHS Trust, John Radcliffe Hospital,
Oxford, United Kingdom. (5)Nuffield</P>
<P STYLE="margin-bottom: 0cm">Department of Orthopaedics,
Rheumatology and Musculoskeletal Science, Department 
</P>
<P STYLE="margin-bottom: 0cm">of Pathology, Nuffield Orthopaedic
Centre, Oxford, United Kingdom. (6)University 
</P>
<P STYLE="margin-bottom: 0cm">Claude Bernard Lyon I, Centre Léon
Bérard, Department of Medicine, Lyon, France. 
</P>
<P STYLE="margin-bottom: 0cm">(7)Service d'oncologie médicale,
Cliniques universitaires Saint-Luc, Université</P>
<P STYLE="margin-bottom: 0cm">catholique de Louvain, Brussels,
Belgium. (8)Liverpool CR-UK Centre, Department</P>
<P STYLE="margin-bottom: 0cm">of Molecular and Clinical Cancer
Medicine, Royal Liverpool University Hospital,</P>
<P STYLE="margin-bottom: 0cm">Liverpool, United Kingdom.
(9)Department of Urology, Inselspital, Bern, Bern,</P>
<P STYLE="margin-bottom: 0cm">Switzerland. (10)Oxford Cancer and
Haematology Centre, Oxford University</P>
<P STYLE="margin-bottom: 0cm">Hospitals NHS Trust, Churchill
Hospital, Oxford, Liverpool, United Kingdom.</P>
<P STYLE="margin-bottom: 0cm">(11)Department of Oncology, Weatherall
Institute of Molecular Medicine, John</P>
<P STYLE="margin-bottom: 0cm">Radcliffe Hospital, University of
Oxford, Oxford, United Kingdom. Oxford Cancer</P>
<P STYLE="margin-bottom: 0cm">and Haematology Centre, Oxford
University Hospitals NHS Trust, Churchill</P>
<P STYLE="margin-bottom: 0cm">Hospital, Oxford, Liverpool, United
Kingdom.</P>
<P STYLE="margin-bottom: 0cm">valentine.macaulay@oncology.ox.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Drugs that inhibit insulin-like growth
factor 1 (IGFI) receptor IGFIR were</P>
<P STYLE="margin-bottom: 0cm">encouraging in early trials, but
predictive biomarkers were lacking and the drugs</P>
<P STYLE="margin-bottom: 0cm">provided insufficient benefit in
unselected patients. In this study, we used</P>
<P STYLE="margin-bottom: 0cm">genetic screening and downstream
validation to identify the WNT pathway element</P>
<P STYLE="margin-bottom: 0cm">DVL3 as a mediator of resistance to
IGFIR inhibition. Sensitivity to IGFIR</P>
<P STYLE="margin-bottom: 0cm">inhibition was enhanced specifically in
vitro and in vivo by genetic or</P>
<P STYLE="margin-bottom: 0cm">pharmacologic blockade of DVL3. In
breast and prostate cancer cells,</P>
<P STYLE="margin-bottom: 0cm">sensitization tracked with enhanced
MEK-ERK activation and relied upon MEK</P>
<P STYLE="margin-bottom: 0cm">activity and DVL3 expression.
Mechanistic investigations showed that DVL3 is</P>
<P STYLE="margin-bottom: 0cm">present in an adaptor complex that
links IGFIR to RAS, which includes Shc, growth</P>
<P STYLE="margin-bottom: 0cm">factor receptor-bound-2 (Grb2),
son-of-sevenless (SOS), and the tumor suppressor 
</P>
<P STYLE="margin-bottom: 0cm">DAB2. Dual DVL and DAB2 blockade
synergized in activating ERKs and sensitizing</P>
<P STYLE="margin-bottom: 0cm">cells to IGFIR inhibition, suggesting a
nonredundant role for DVL3 in the</P>
<P STYLE="margin-bottom: 0cm">Shc-Grb2-SOS complex. Clinically,
tumors that responded to IGFIR inhibition</P>
<P STYLE="margin-bottom: 0cm">contained relatively lower levels of
DVL3 protein than resistant tumors, and DVL3</P>
<P STYLE="margin-bottom: 0cm">levels in tumors correlated inversely
with progression-free survival in patients 
</P>
<P STYLE="margin-bottom: 0cm">treated with IGFIR antibodies. Because
IGFIR does not contain activating</P>
<P STYLE="margin-bottom: 0cm">mutations analogous to EGFR variants
associated with response to EGFR inhibitors,</P>
<P STYLE="margin-bottom: 0cm">we suggest that IGF signaling achieves
an equivalent integration at the</P>
<P STYLE="margin-bottom: 0cm">postreceptor level through adaptor
protein complexes, influencing cellular</P>
<P STYLE="margin-bottom: 0cm">dependence on the IGF axis and
identifying a patient population with potential to</P>
<P STYLE="margin-bottom: 0cm">benefit from IGFIR inhibition.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">©2014 American Association for Cancer
Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25168481 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">5. Proc Natl Acad Sci U S A. 2014 Aug
26;111(34):12544-9. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1073/pnas.1403450111. Epub 2014 Aug
6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">DRK/DOS/SOS converge with
Crk/Mbc/dCed-12 to activate Rac1 during glial</P>
<P STYLE="margin-bottom: 0cm">engulfment of axonal debris.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lu TY(1), Doherty J(1), Freeman MR(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Neurobiology and
Howard Hughes Medical Institute, University of 
</P>
<P STYLE="margin-bottom: 0cm">Massachusetts Medical School,
Worcester, MA 01605. (2)Department of Neurobiology 
</P>
<P STYLE="margin-bottom: 0cm">and Howard Hughes Medical Institute,
University of Massachusetts Medical School, 
</P>
<P STYLE="margin-bottom: 0cm">Worcester, MA 01605
marc.freeman@umassmed.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nervous system injury or disease leads
to activation of glia, which govern</P>
<P STYLE="margin-bottom: 0cm">postinjury responses in the nervous
system. Axonal injury in Drosophila results</P>
<P STYLE="margin-bottom: 0cm">in transcriptional up-regulation of the
glial engulfment receptor Draper; there</P>
<P STYLE="margin-bottom: 0cm">is extension of glial membranes to the
injury site (termed activation), and then 
</P>
<P STYLE="margin-bottom: 0cm">axonal debris is internalized and
degraded. Loss of the small GTPase Rac1 from</P>
<P STYLE="margin-bottom: 0cm">glia completely suppresses glial
responses to injury, but upstream activators</P>
<P STYLE="margin-bottom: 0cm">remain poorly defined. Loss of the Rac
guanine nucleotide exchange factor (GEF)</P>
<P STYLE="margin-bottom: 0cm">Crk/myoblast city (Mbc)/dCed-12 has no
effect on glial activation, but blocks</P>
<P STYLE="margin-bottom: 0cm">internalization and degradation of
debris. Here we show that the signaling</P>
<P STYLE="margin-bottom: 0cm">molecules downstream of receptor kinase
(DRK) and daughter of sevenless (DOS)</P>
<P STYLE="margin-bottom: 0cm">(mammalian homologs, Grb2 and Gab2,
respectively) and the GEF son of sevenless</P>
<P STYLE="margin-bottom: 0cm">(SOS) (mammalian homolog, mSOS) are
required for efficient activation of glia</P>
<P STYLE="margin-bottom: 0cm">after axotomy and
internalization/degradation of axonal debris. At the earliest</P>
<P STYLE="margin-bottom: 0cm">steps of glial activation, DRK/DOS/SOS
function in a partially redundant manner</P>
<P STYLE="margin-bottom: 0cm">with Crk/Mbc/dCed-12, with blockade of
both complexes strongly suppressing all</P>
<P STYLE="margin-bottom: 0cm">glial responses, similar to loss of
Rac1. This work identifies DRK/DOS/SOS as the</P>
<P STYLE="margin-bottom: 0cm">upstream Rac GEF complex required for
glial responses to axonal injury, and</P>
<P STYLE="margin-bottom: 0cm">demonstrates a critical requirement for
multiple GEFs in efficient glial</P>
<P STYLE="margin-bottom: 0cm">activation after injury and
internalization/degradation of axonal debris.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4151738</P>
<P STYLE="margin-bottom: 0cm">PMID: 25099352 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">6. Oncogene. 2015 Mar
26;34(13):1729-35. doi: 10.1038/onc.2014.110. Epub 2014 May</P>
<P STYLE="margin-bottom: 0cm">19.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The ShcA adaptor activates AKT
signaling to potentiate breast tumor angiogenesis 
</P>
<P STYLE="margin-bottom: 0cm">by stimulating VEGF mRNA translation in
a 4E-BP-dependent manner.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Im YK(1), La Selva R(1), Gandin V(1),
Ha JR(1), Sabourin V(1), Sonenberg N(2),</P>
<P STYLE="margin-bottom: 0cm">Pawson T(3), Topisirovic I(1),
Ursini-Siegel J(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Oncology, Lady Davis
Institute for Medical Research, McGill</P>
<P STYLE="margin-bottom: 0cm">University, Montreal, Quebec, Canada.
(2)Goodman Cancer Research Centre,</P>
<P STYLE="margin-bottom: 0cm">Montreal, Quebec, Canada. (3)Samuel
Lunenfeld Research Institute, Mount Sinai</P>
<P STYLE="margin-bottom: 0cm">Hospital, University of Toronto,
Toronto, Ontario, Canada.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The ShcA adaptor protein is engaged by
numerous receptor tyrosine kinases (RTKs) 
</P>
<P STYLE="margin-bottom: 0cm">in breast cancer cells. Once activated,
RTKs phosphorylate three key tyrosine</P>
<P STYLE="margin-bottom: 0cm">phosphorylation sites (Y239, Y240 and
Y317) within ShcA that creates a docking</P>
<P STYLE="margin-bottom: 0cm">site for Grb2/SOS and
Grb2/Gab-containing complexes to activate the MAPK and AKT 
</P>
<P STYLE="margin-bottom: 0cm">signaling pathways, respectively. We
previously demonstrated that a tyrosine to</P>
<P STYLE="margin-bottom: 0cm">phenylalanine substitution of the ShcA
tyrosine phosphorylation sites</P>
<P STYLE="margin-bottom: 0cm">(Shc3F-Y239/240/313F) significantly
impairs breast tumor growth and angiogenesis 
</P>
<P STYLE="margin-bottom: 0cm">in transgenic mouse models, in part,
through the regulation of vascular</P>
<P STYLE="margin-bottom: 0cm">endothelial growth factor (VEGF)
production. Despite this fact, the underlying</P>
<P STYLE="margin-bottom: 0cm">molecular mechanisms by which ShcA
transduces pro-tumorigenic signals in breast</P>
<P STYLE="margin-bottom: 0cm">cancer cells remain poorly defined. In
this study, we demonstrate that</P>
<P STYLE="margin-bottom: 0cm">ShcA-dependent activation of AKT, but
not the RAS/MAPK pathway, induces VEGF</P>
<P STYLE="margin-bottom: 0cm">production by bolstering VEGF mRNA
translation. Accordingly, ShcA drives breast</P>
<P STYLE="margin-bottom: 0cm">tumor growth and angiogenesis in vivo
in a 4E-BP-dependent manner. These findings</P>
<P STYLE="margin-bottom: 0cm">establish ShcA as a biological bridge
that links AKT activation downstream of</P>
<P STYLE="margin-bottom: 0cm">RTKs to cap-dependent VEGF mRNA
translation in order to promote mammary</P>
<P STYLE="margin-bottom: 0cm">tumorigenesis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24837366 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">7. Oncogene. 2015 Jan 22;34(4):474-84.
doi: 10.1038/onc.2013.564. Epub 2014 Jan 27.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Casein kinase 1 regulates Sprouty2 in
FGF-ERK signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Yim DG(1), Ghosh S(2), Guy GR(3),
Virshup DM(4).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)1] Program in Cancer and Stem Cell
Biology, Duke-NUS Graduate Medical School, 
</P>
<P STYLE="margin-bottom: 0cm">Singapore, Singapore [2] Signal
Transduction Laboratory, Institute for Molecular 
</P>
<P STYLE="margin-bottom: 0cm">and Cellular Biology, Biopolis,
Singapore [3] Genome Institute of Singapore,</P>
<P STYLE="margin-bottom: 0cm">Biopolis, Singapore. (2)Center for
Computational Biology, Duke-NUS Graduate</P>
<P STYLE="margin-bottom: 0cm">Medical School, Singapore, Singapore.
(3)Signal Transduction Laboratory,</P>
<P STYLE="margin-bottom: 0cm">Institute for Molecular and Cellular
Biology, Biopolis, Singapore. (4)1] Program 
</P>
<P STYLE="margin-bottom: 0cm">in Cancer and Stem Cell Biology,
Duke-NUS Graduate Medical School, Singapore,</P>
<P STYLE="margin-bottom: 0cm">Singapore [2] Department of
Biochemistry, YYL School of Medicine, National</P>
<P STYLE="margin-bottom: 0cm">University of Singapore, Singapore,
Singapore.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sprouty2 (SPRY2) is a potent negative
regulator of receptor tyrosine kinase</P>
<P STYLE="margin-bottom: 0cm">signaling, and is implicated as a tumor
suppressor. SPRY2 inhibits FGF-RAS-ERK</P>
<P STYLE="margin-bottom: 0cm">signaling by binding to growth factor
receptor bound protein 2 (GRB2) during</P>
<P STYLE="margin-bottom: 0cm">fibroblast growth factor receptor
(FGFR) activation, disrupting the GRB2-SOS (son</P>
<P STYLE="margin-bottom: 0cm">of sevenless) complex that transduces
signals from FGFR to RAS. SPRY2 binding to 
</P>
<P STYLE="margin-bottom: 0cm">GRB2 is modulated by phosphorylation
but the key regulatory kinase(s) are not</P>
<P STYLE="margin-bottom: 0cm">known. Prior studies identified the
frequent presence of CK1 phosphorylation</P>
<P STYLE="margin-bottom: 0cm">motifs on SPRY2. We therefore tested if
CK1 has a role in SPRY2 phosphorylation</P>
<P STYLE="margin-bottom: 0cm">and function. Loss of CK1 binding and
inhibition of CK1 activity by two</P>
<P STYLE="margin-bottom: 0cm">structurally distinct small molecules
abrogated SPRY2 inhibition of FGF-ERK</P>
<P STYLE="margin-bottom: 0cm">signaling, leading to decreased SPRY2
interaction with GRB2. Moreover, CK1</P>
<P STYLE="margin-bottom: 0cm">activity and binding are necessary for
SPRY2 inhibition of FGF-stimulated neurite</P>
<P STYLE="margin-bottom: 0cm">outgrowth in PC12 cells. Consistent
with its proposed role as an inhibitor of FGF</P>
<P STYLE="margin-bottom: 0cm">signaling, we find that CSNK1E
transcript abundance negatively correlates with</P>
<P STYLE="margin-bottom: 0cm">FGF1/FGF7 message in human gastric
cancer samples. Modulation of CK1 activity may</P>
<P STYLE="margin-bottom: 0cm">be therapeutically useful in the
treatment of FGF/SPRY2-related diseases.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24469046 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">8. CPT Pharmacometrics Syst Pharmacol.
2014 Jan 15;3:e92. doi: 10.1038/psp.2013.65.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A General Network Pharmacodynamic
Model-Based Design Pipeline for Customized</P>
<P STYLE="margin-bottom: 0cm">Cancer Therapy Applied to the VEGFR
Pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zhang XY(1), Birtwistle MR(1), Gallo
JM(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Pharmacology and
Systems Therapeutics, Icahn School of Medicine 
</P>
<P STYLE="margin-bottom: 0cm">at Mount Sinai, New York, New York,
USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A unified approach to optimize
multidrug chemotherapy using a pharmacokinetic</P>
<P STYLE="margin-bottom: 0cm">(PK)/enhanced pharmacodynamic model was
developed using the vascular endothelial 
</P>
<P STYLE="margin-bottom: 0cm">growth factor receptor (VEGFR)
signaling system. The base VEGFR network model,</P>
<P STYLE="margin-bottom: 0cm">characterized by ligand-receptor
interactions, enzyme recruitment (Grb2-Sos,</P>
<P STYLE="margin-bottom: 0cm">phospholipase C γ (PLCγ), and
phosphoinositide-3 kinase (PI3K)), and downstream</P>
<P STYLE="margin-bottom: 0cm">mitogen-activated protein kinase and
Akt cascade activation, was linked to a</P>
<P STYLE="margin-bottom: 0cm">sunitinib (VEGFR inhibitor) PK model
and underwent Sobol sensitivity analysis</P>
<P STYLE="margin-bottom: 0cm">that revealed potential
sunitinib-enhancing mechanisms. Drugs targeting these</P>
<P STYLE="margin-bottom: 0cm">mechanisms (a VEGF inhibitor, a PI3K
inhibitor, a PLCγ inhibitor, and a</P>
<P STYLE="margin-bottom: 0cm">mitogen-activated protein kinase
inhibitor) and sunitinib were input to</P>
<P STYLE="margin-bottom: 0cm">optimization-based control analyses to
design multidrug regimens that maintained 
</P>
<P STYLE="margin-bottom: 0cm">80% pERK and pAkt inhibition for 28
days while minimizing drug dose. The</P>
<P STYLE="margin-bottom: 0cm">resultant combination regimens
contained both continuous and discontinuous</P>
<P STYLE="margin-bottom: 0cm">schedules, mostly at low doses, and
were altered by oncogenic mutations. This</P>
<P STYLE="margin-bottom: 0cm">pipeline of computational analyses
demonstrates how model-based methods can</P>
<P STYLE="margin-bottom: 0cm">capture the complexities of drug
action, tailor cancer chemotherapy, and empower 
</P>
<P STYLE="margin-bottom: 0cm">personalized medicine.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3910016</P>
<P STYLE="margin-bottom: 0cm">PMID: 24429593 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">9. Sci Rep. 2013 Oct 9;3:2913. doi:
10.1038/srep02913.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Conformational change of Sos-derived
proline-rich peptide upon binding Grb2</P>
<P STYLE="margin-bottom: 0cm">N-terminal SH3 domain probed by NMR.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ogura K(1), Okamura H.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Structural Biology,
Faculty of Advanced Life Science, Hokkaido</P>
<P STYLE="margin-bottom: 0cm">University, Kita 21 Nishi 11, Kita-ku,
Sapporo 001-0021, Japan.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Growth factor receptor-bound protein 2
(Grb2) is a small adapter protein composed</P>
<P STYLE="margin-bottom: 0cm">of a single SH2 domain flanked by two
SH3 domains. The N-terminal SH3 (nSH3)</P>
<P STYLE="margin-bottom: 0cm">domain of Grb2 binds a proline-rich
region present in the guanine nucleotide</P>
<P STYLE="margin-bottom: 0cm">releasing factor, son of sevenless
(Sos). Using NMR relaxation dispersion and</P>
<P STYLE="margin-bottom: 0cm">chemical shift analysis methods, we
investigated the conformational change of the</P>
<P STYLE="margin-bottom: 0cm">Sos-derived proline-rich peptide during
the transition between the free and Grb2 
</P>
<P STYLE="margin-bottom: 0cm">nSH3-bound states. The chemical shift
analysis revealed that the peptide does not</P>
<P STYLE="margin-bottom: 0cm">present a fully random conformation but
has a relatively rigid structure. The</P>
<P STYLE="margin-bottom: 0cm">relaxation dispersion analysis detected
conformational exchange of several</P>
<P STYLE="margin-bottom: 0cm">residues of the peptide upon binding to
Grb2 nSH3.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24105423 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">10. Cell Physiol Biochem.
2013;31(6):905-13. doi: 10.1159/000350108. Epub 2013 Jun</P>
<P STYLE="margin-bottom: 0cm">17.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Crosstalk between PI3
kinase/PDK1/Akt/Rac1 and Ras/Raf/MEK/ERK pathways</P>
<P STYLE="margin-bottom: 0cm">downstream PDGF receptor.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Niba ET(1), Nagaya H, Kanno T, Tsuchiya
A, Gotoh A, Tabata C, Kuribayashi K,</P>
<P STYLE="margin-bottom: 0cm">Nakano T, Nishizaki T.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Division of Bioinformation,
Department of Physiology, Hyogo College of</P>
<P STYLE="margin-bottom: 0cm">Medicine, Nishinomiya, Japan.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND/AIMS: Our earlier studies
suggested crosstalk between IRS/PI3</P>
<P STYLE="margin-bottom: 0cm">kinase/PDK1/Akt/Rac1/ROCK and
(Shc2/Grb2/SOS)/Ras/Raf/MEK/ERK pathways downstream</P>
<P STYLE="margin-bottom: 0cm">PDGF-ββ receptor responsible for
chemotaxis and proliferation of malignant</P>
<P STYLE="margin-bottom: 0cm">mesothelioma cells. The present study
was conducted to obtain evidence for this.</P>
<P STYLE="margin-bottom: 0cm">METHODS: To assess activation of Akt,
MEK, and ERK, Western blotting was carried 
</P>
<P STYLE="margin-bottom: 0cm">out on MSTO-211H malignant mesothelioma
cells using antibodies against</P>
<P STYLE="margin-bottom: 0cm">phospho-Thr308-Akt, phopho-Ser473-Akt,
Akt, phospho-MEK, MEK, phopho-ERK1/2, and 
</P>
<P STYLE="margin-bottom: 0cm">ERK1/2. To knock-down Akt, PI3 kinase,
PDK1, and Rac1, siRNAs silencing</P>
<P STYLE="margin-bottom: 0cm">each-targeted gene were constructed and
transfected into cells. To monitor Rac1</P>
<P STYLE="margin-bottom: 0cm">activity, FRET monitoring was carried
out on living and fixed cells.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: ERK was activated under the
basal conditions in MSTO-211H cells, and the</P>
<P STYLE="margin-bottom: 0cm">activation was prevented by inhibitors
for PI3 kinase, PDK1, Akt, and Rac1 or by 
</P>
<P STYLE="margin-bottom: 0cm">knocking-down PI3 kinase, PDK1, Akt,
and Rac1. Akt was also activated under the</P>
<P STYLE="margin-bottom: 0cm">basal conditions, and the activation
was suppressed by a MEK inhibitor and an</P>
<P STYLE="margin-bottom: 0cm">ERK1/2 inhibitor. In the FRET analysis,
Rac1 was activated under the basal</P>
<P STYLE="margin-bottom: 0cm">conditions, and the activation was
inhibited by a MEK inhibitor and an ERK1/2</P>
<P STYLE="margin-bottom: 0cm">inhibitor.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: The results of the present
study show that ERK could be activated by 
</P>
<P STYLE="margin-bottom: 0cm">PI3 kinase, PDK1, Akt, and Rac1 and
that alternatively, Akt and Rac1 could be</P>
<P STYLE="margin-bottom: 0cm">activated by MEK and ERK in MSTO-211H
cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2013 S. Karger AG, Basel.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 23817184 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">11. Int J Biomed Sci. 2012
Dec;8(4):219-32.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Multiple Sites of Type II Site Ligand
(Luteolin and BMHPC) Regulation of Gene</P>
<P STYLE="margin-bottom: 0cm">Expression in PC-3 Cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Markaverich BM(1), Vijjeswarapu M.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Molecular and Cellular
Biology, Baylor College of Medicine, One 
</P>
<P STYLE="margin-bottom: 0cm">Baylor Plaza, Houston, Texas 77030,
USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Type II [(3)H]estradiol binding site
ligands including luteolin (a naturally</P>
<P STYLE="margin-bottom: 0cm">occurring bioflavonoid) and synthetic
compounds such as</P>
<P STYLE="margin-bottom: 0cm">2,6-bis((3-methoxy-4-hydroxyphenyl)methylene)cyclohexanone
(BMHPC) inhibit normal</P>
<P STYLE="margin-bottom: 0cm">and malignant prostate cell (PC-3,
LNCaP, DU-145) proliferation in vitro and in</P>
<P STYLE="margin-bottom: 0cm">vivo. Type II sites represent a binding
domain on histone H4 possibly involved in</P>
<P STYLE="margin-bottom: 0cm">an epigenetic mechanism for controlling
gene transcription. Treatment of PC-3</P>
<P STYLE="margin-bottom: 0cm">human prostate cancer cells with
luteolin or BMHPC modulated the expression of a 
</P>
<P STYLE="margin-bottom: 0cm">number of genes in the epidermal growth
factor receptor signaling pathway</P>
<P STYLE="margin-bottom: 0cm">(EGFRSP) and cell cycle pathway (CCP).
Pronounced stimulation (400-2000% of</P>
<P STYLE="margin-bottom: 0cm">control) of c-FOS and p21 RNA
expression was observed, suggesting that these were</P>
<P STYLE="margin-bottom: 0cm">primary sites of action. Both compounds
also caused irreversible G2/M arrest</P>
<P STYLE="margin-bottom: 0cm">(p&lt;0.001). siRNA's for c-FOS or p21
reduced the RNA expression of their</P>
<P STYLE="margin-bottom: 0cm">respective targets by 85-95%, with
minimal effects on cell proliferation.</P>
<P STYLE="margin-bottom: 0cm">Furthermore, neither siRNA alone
(single knockdown), or in combination (double</P>
<P STYLE="margin-bottom: 0cm">knockdown), blocked luteolin or BMHPC
inhibition of PC-3 cell proliferation.</P>
<P STYLE="margin-bottom: 0cm">Thus, although c-FOS and p21 are known
to modulate the expression of genes in the</P>
<P STYLE="margin-bottom: 0cm">ESGRSP (EGFR, SOS, GRB2, JNK1, MKK4,
RasGAP) and CCP (CCNA2, CCNE2, CDC25A,</P>
<P STYLE="margin-bottom: 0cm">CDKN1A, CDKN1B, p27, PLK1) involved in
the regulation of cell proliferation by</P>
<P STYLE="margin-bottom: 0cm">luteolin and BMHPC, the c-FOS and p21
siRNA knockdown studies reported here</P>
<P STYLE="margin-bottom: 0cm">suggest that c-FOS and p21 may be
secondary bystanders in the overall response to</P>
<P STYLE="margin-bottom: 0cm">these ligands in the regulation of PC-3
cell proliferation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3615297</P>
<P STYLE="margin-bottom: 0cm">PMID: 23675277 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">12. Leuk Res. 2013 May;37(5):520-30.
doi: 10.1016/j.leukres.2013.01.014. Epub 2013</P>
<P STYLE="margin-bottom: 0cm">Feb 12.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Aberrant activation of ROS1 represents
a new molecular defect in chronic</P>
<P STYLE="margin-bottom: 0cm">myelomonocytic leukemia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cilloni D(1), Carturan S, Bracco E,
Campia V, Rosso V, Torti D, Calabrese C,</P>
<P STYLE="margin-bottom: 0cm">Gaidano V, Niparuck P, Favole A,
Signorino E, Iacobucci I, Morano A, De Luca L,</P>
<P STYLE="margin-bottom: 0cm">Musto P, Frassoni F, Saglio G.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Division of Hematology and Internal
Medicine, Department of Clinical and</P>
<P STYLE="margin-bottom: 0cm">Biological Sciences, University of
Turin, Turin, Italy. daniela.cilloni@unito.it</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Chronic myelomonocytic leukemia (CMML)
is a clonal disorder sharing features of</P>
<P STYLE="margin-bottom: 0cm">myelodysplastic syndromes and chronic
myeloproliferative neoplasms. Although rare</P>
<P STYLE="margin-bottom: 0cm">chromosomal aberrations and point
mutations are reported in CMML, the molecular</P>
<P STYLE="margin-bottom: 0cm">defects underlying CMML are largely
unknown. ROS1 encodes a tyrosine kinase that 
</P>
<P STYLE="margin-bottom: 0cm">is abnormally expressed and
translocated in brain and lung cancers. In this study</P>
<P STYLE="margin-bottom: 0cm">we show that ROS1 is abnormally
activated in the CD34+ compartment of</P>
<P STYLE="margin-bottom: 0cm">approximately 70% of CMML patients
resulting in the activation of the Erk/Akt</P>
<P STYLE="margin-bottom: 0cm">pathways through the Grb2/SOS complex
thus revealing a central oncogenic role for</P>
<P STYLE="margin-bottom: 0cm">ROS1 in CMML which might represent a
molecular target.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2013 Elsevier Ltd. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 23415111 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">13. Int J Cancer. 2013
Jul;133(1):43-57. doi: 10.1002/ijc.28001. Epub 2013 Feb 12.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Caveolin-1 is a novel regulator of
K-RAS-dependent migration in colon</P>
<P STYLE="margin-bottom: 0cm">carcinogenesis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Basu Roy UK(1), Henkhaus RS, Loupakis
F, Cremolini C, Gerner EW, Ignatenko NA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biochemistry and
Molecular Biophysics, Biochemistry and</P>
<P STYLE="margin-bottom: 0cm">Molecular and Cellular Biology Graduate
Program, University of Arizona, Tucson,</P>
<P STYLE="margin-bottom: 0cm">AZ, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Caveolin-1 is an essential component of
membrane caveolae. It is an important</P>
<P STYLE="margin-bottom: 0cm">regulator of cellular processes such as
signal transduction and endocytosis. We</P>
<P STYLE="margin-bottom: 0cm">report here, for the first time, that
caveolin-1 is a target of the K-RAS</P>
<P STYLE="margin-bottom: 0cm">oncogene in colon carcinogenesis.
Caveolin-1 is induced in colon cancer cells and</P>
<P STYLE="margin-bottom: 0cm">in human colon tumor samples, in
response to K-RAS activating mutations. An</P>
<P STYLE="margin-bottom: 0cm">activated K-RAS oncogene
transcriptionally induces caveolin-1 expression in human</P>
<P STYLE="margin-bottom: 0cm">colon cancer cells and this effect is
not restricted to the type of activating</P>
<P STYLE="margin-bottom: 0cm">K-RAS mutation. Inhibition of the P-I3
Kinase-AKT pathway, but not the ERK MAPK</P>
<P STYLE="margin-bottom: 0cm">pathway, both important K-RAS
effectors, leads to a decrease in caveolin-1</P>
<P STYLE="margin-bottom: 0cm">expression indicating that the AKT
pathway is involved in caveolin-1 expression</P>
<P STYLE="margin-bottom: 0cm">in response to an activated K-RAS.
Increased AKT signaling induces caveolin-1</P>
<P STYLE="margin-bottom: 0cm">expression by increasing the activity
of the transcription factor, Sp1.</P>
<P STYLE="margin-bottom: 0cm">Interestingly; caveolin-1 depletion
alters K-RAS-dependent signaling by</P>
<P STYLE="margin-bottom: 0cm">decreasing Grb2-SOS activity.
Consistent with these finding, caveolin-1-depleted 
</P>
<P STYLE="margin-bottom: 0cm">cells shows decreased migration in
vitro. However, caveolin-1 overexpression by</P>
<P STYLE="margin-bottom: 0cm">itself does not increase migration
whereas an activated Src can increase</P>
<P STYLE="margin-bottom: 0cm">migration in a caveolin-1-dependent
manner. This increased migration is highly</P>
<P STYLE="margin-bottom: 0cm">dependent on the RhoA GTPase,
indicating that an activated K-RAS modulates</P>
<P STYLE="margin-bottom: 0cm">migration in part via caveolin-1
induction, and increasing RhoA activity via</P>
<P STYLE="margin-bottom: 0cm">phospho-caveolin-1. Our findings
indicate that K-RAS regulates both caveolin-1</P>
<P STYLE="margin-bottom: 0cm">expression and other factors affecting
caveolin-1 functions in colon</P>
<P STYLE="margin-bottom: 0cm">cancer-derived cell migration.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2012 UICC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3633716</P>
<P STYLE="margin-bottom: 0cm">PMID: 23280667 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">14. Biochim Biophys Acta. 2013
Feb;1834(2):524-35. doi: 10.1016/j.bbapap.2012.11.001.</P>
<P STYLE="margin-bottom: 0cm">Epub 2012 Nov 15.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Unusual binding of Grb2 protein to a
bivalent polyproline-ligand immobilized on a</P>
<P STYLE="margin-bottom: 0cm">SPR sensor: intermolecular bivalent
binding.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">de Mol NJ(1), Kruijtzer JA, Moret EE,
Broutin I, Liskamp RM.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Medicinal Chemistry &amp;
Chemical Biology, Utrecht Institute of</P>
<P STYLE="margin-bottom: 0cm">Pharmaceutical Sciences,
Universiteitsweg 99, 3484 CG Utrecht, The Netherlands.</P>
<P STYLE="margin-bottom: 0cm">N.J.deMol@uu.nl</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The Grb2 adapter protein is involved in
the activation of the Ras signaling</P>
<P STYLE="margin-bottom: 0cm">pathway. It recruits the Sos protein by
binding of its two SH3 domains to Sos</P>
<P STYLE="margin-bottom: 0cm">polyproline sequences. We observed that
the binding of Grb2 to a bivalent ligand,</P>
<P STYLE="margin-bottom: 0cm">containing two Sos-derived
polyproline-sequences immobilized on a SPR sensor,</P>
<P STYLE="margin-bottom: 0cm">shows unusual kinetic behavior.
SPR-kinetic analysis and supporting data from</P>
<P STYLE="margin-bottom: 0cm">other techniques show major
contributions of an intermolecular bivalent binding</P>
<P STYLE="margin-bottom: 0cm">mode. Each of the two Grb2 SH3 domains
binds to one polyproline-sequence of two</P>
<P STYLE="margin-bottom: 0cm">different ligand molecules,
facilitating binding of a second Grb2 molecule to the</P>
<P STYLE="margin-bottom: 0cm">two remaining free polyproline binding
sites. A molecular model based on the</P>
<P STYLE="margin-bottom: 0cm">X-ray structure of the Grb2 dimer shows
that Grb2 is flexible enough to allow</P>
<P STYLE="margin-bottom: 0cm">this binding mode. The results fit with
a role of Grb2 in protein aggregation,</P>
<P STYLE="margin-bottom: 0cm">achieving specificity by multivalent
interactions, despite the relatively low</P>
<P STYLE="margin-bottom: 0cm">affinity of single SH3 interactions.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2012 Elsevier B.V. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 23159538 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">15. J Vis Exp. 2012 Oct 30;(68). pii:
4382. doi: 10.3791/4382.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A high-content imaging workflow to
study Grb2 signaling complexes by expression</P>
<P STYLE="margin-bottom: 0cm">cloning.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Freeman J(1), Kriston-Vizi J, Seed B,
Ketteler R.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)MRC LMCB, University College London.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Signal transduction by growth factor
receptors is essential for cells to maintain</P>
<P STYLE="margin-bottom: 0cm">proliferation and differentiation and
requires tight control. Signal transduction</P>
<P STYLE="margin-bottom: 0cm">is initiated by binding of an external
ligand to a transmembrane receptor and</P>
<P STYLE="margin-bottom: 0cm">activation of downstream signaling
cascades. A key regulator of mitogenic</P>
<P STYLE="margin-bottom: 0cm">signaling is Grb2, a modular protein
composed of an internal SH2 (Src Homology 2)</P>
<P STYLE="margin-bottom: 0cm">domain flanked by two SH3 domains that
lacks enzymatic activity. Grb2 is</P>
<P STYLE="margin-bottom: 0cm">constitutively associated with the
GTPase Son-Of-Sevenless (SOS) via its</P>
<P STYLE="margin-bottom: 0cm">N-terminal SH3 domain. The SH2 domain
of Grb2 binds to growth factor receptors at</P>
<P STYLE="margin-bottom: 0cm">phosphorylated tyrosine residues thus
coupling receptor activation to the</P>
<P STYLE="margin-bottom: 0cm">SOS-Ras-MAP kinase signaling cascade.
In addition, other roles for Grb2 as a</P>
<P STYLE="margin-bottom: 0cm">positive or negative regulator of
signaling and receptor endocytosis have been</P>
<P STYLE="margin-bottom: 0cm">described. The modular composition of
Grb2 suggests that it can dock to a variety</P>
<P STYLE="margin-bottom: 0cm">of receptors and transduce signals
along a multitude of different pathways(1-3). 
</P>
<P STYLE="margin-bottom: 0cm">Described here is a simple microscopy
assay that monitors recruitment of Grb2 to 
</P>
<P STYLE="margin-bottom: 0cm">the plasma membrane. It is adapted from
an assay that measures changes in</P>
<P STYLE="margin-bottom: 0cm">sub-cellular localization of
green-fluorescent protein (GFP)-tagged Grb2 in</P>
<P STYLE="margin-bottom: 0cm">response to a stimulus(4-6). Plasma
membrane receptors that bind Grb2 such as</P>
<P STYLE="margin-bottom: 0cm">activated Epidermal Growth Factor
Receptor (EGFR) recruit GFP-Grb2 to the plasma 
</P>
<P STYLE="margin-bottom: 0cm">membrane upon cDNA expression and
subsequently relocate to endosomal compartments</P>
<P STYLE="margin-bottom: 0cm">in the cell. In order to identify in
vivo protein complexes of Grb2, this</P>
<P STYLE="margin-bottom: 0cm">technique can be used to perform a
genome-wide high-content screen based on</P>
<P STYLE="margin-bottom: 0cm">changes in Grb2 sub-cellular
localization. The preparation of cDNA expression</P>
<P STYLE="margin-bottom: 0cm">clones, transfection and image
acquisition are described in detail below.</P>
<P STYLE="margin-bottom: 0cm">Compared to other genomic methods used
to identify protein interaction partners, 
</P>
<P STYLE="margin-bottom: 0cm">such as yeast-two-hybrid, this
technique allows the visualization of protein</P>
<P STYLE="margin-bottom: 0cm">complexes in mammalian cells at the
sub-cellular site of interaction by a simple 
</P>
<P STYLE="margin-bottom: 0cm">microscopy-based assay. Hence both
qualitative features, such as patterns of</P>
<P STYLE="margin-bottom: 0cm">localization can be assessed, as well
as the quantitative strength of the</P>
<P STYLE="margin-bottom: 0cm">interaction.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3499067</P>
<P STYLE="margin-bottom: 0cm">PMID: 23150065 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">16. J Pharmacol Sci. 2012;119(2):150-9.
Epub 2012 May 26.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Activated O2(•−) and H2O2 mediated
cell survival in SU11274-treated</P>
<P STYLE="margin-bottom: 0cm">non-small-cell lung cancer A549 cells
via c-Met-PI3K-Akt and</P>
<P STYLE="margin-bottom: 0cm">c-Met-Grb2/SOS-Ras-p38 pathways.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Liu Y(1), Shi QF, Ye YC, Tashiro S,
Onodera S, Ikejima T.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)China-Japan Research Institute of
Medical and Pharmaceutical Sciences,</P>
<P STYLE="margin-bottom: 0cm">Shenyang Pharmaceutical University,
Shenyang, Liaoning, PR China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The pharmacological activity of SU11274
is primarily due to its inhibition of</P>
<P STYLE="margin-bottom: 0cm">hepotocyte growth factor receptor
(c-Met) kinase overexpression. In this study,</P>
<P STYLE="margin-bottom: 0cm">we demonstrated that the pathway
involved in SU11274-induced autophagy was</P>
<P STYLE="margin-bottom: 0cm">presumably through inhibition of c-Met
and its down-stream pathways, including</P>
<P STYLE="margin-bottom: 0cm">phosphatidylinositol 3-kinases – Akt
(PI3K–Akt) and the growth factor receptor</P>
<P STYLE="margin-bottom: 0cm">bound protein-2 / son of sevenless –
Ras – p38 MAPK (Grb2/SOS–Ras–p38) pathway.</P>
<P STYLE="margin-bottom: 0cm">SU11274 time-dependently induced the
generation of superoxide anion (O2(•−)) and 
</P>
<P STYLE="margin-bottom: 0cm">hydrogen peroxide (H2O2). There is a
negative feedback loop between reactive</P>
<P STYLE="margin-bottom: 0cm">oxygen species (ROS) induction and
SU11274. Then, we investigated the role of ROS</P>
<P STYLE="margin-bottom: 0cm">in protecting cells against
SU11274-induced autophagic cell death in A549 cells. 
</P>
<P STYLE="margin-bottom: 0cm">O2(•−) and H2O2 generation
activated c-Met–PI3K–Akt and c-Met–Grb2/SOS–Ras–p38</P>
<P STYLE="margin-bottom: 0cm">signaling pathways, which were
suppressed by O2(•−) scavenger superoxide</P>
<P STYLE="margin-bottom: 0cm">dismutase (SOD) and H2O2 scavenger
catalase. In conclusion, O2(•−) and H2O2</P>
<P STYLE="margin-bottom: 0cm">evoked cell resistance to SU11274 via
activating c-Met–PI3K–Akt and</P>
<P STYLE="margin-bottom: 0cm">c-Met–Grb2/SOS–Ras–p38 pathways
in A549 cells. SU11274 also induced ROS</P>
<P STYLE="margin-bottom: 0cm">generation in Caenorhabditis elegans.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 22673163 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">17. EMBO Rep. 2012 Apr;13(4):386-91.
doi: 10.1038/embor.2012.17.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">TCR-mediated Erk activation does not
depend on Sos and Grb2 in peripheral human T</P>
<P STYLE="margin-bottom: 0cm">cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Warnecke N(1), Poltorak M, Kowtharapu
BS, Arndt B, Stone JC, Schraven B, Simeoni 
</P>
<P STYLE="margin-bottom: 0cm">L.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Institute of Molecular and Clinical
Immunology, Otto-von-Guericke University, 
</P>
<P STYLE="margin-bottom: 0cm">Leipziger Strasse 44, Magdeburg 39120,
Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sos proteins are ubiquitously expressed
activators of Ras. Lymphoid cells also</P>
<P STYLE="margin-bottom: 0cm">express RasGRP1, another Ras activator.
Sos and RasGRP1 are thought to</P>
<P STYLE="margin-bottom: 0cm">cooperatively control full Ras
activation upon T-cell receptor triggering. Using 
</P>
<P STYLE="margin-bottom: 0cm">RNA interference, we evaluated whether
this mechanism operates in primary human T</P>
<P STYLE="margin-bottom: 0cm">cells. We found that T-cell antigen
receptor (TCR)-mediated Erk activation</P>
<P STYLE="margin-bottom: 0cm">requires RasGRP1, but not Grb2/Sos.
Conversely, Grb2/Sos—but not RasGRP1—are</P>
<P STYLE="margin-bottom: 0cm">required for IL2-mediated Erk
activation. Thus, RasGRP1 and Grb2/Sos are</P>
<P STYLE="margin-bottom: 0cm">insulators of signals that lead to Ras
activation induced by different stimuli,</P>
<P STYLE="margin-bottom: 0cm">rather than cooperating downstream of
the TCR.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3321150</P>
<P STYLE="margin-bottom: 0cm">PMID: 22344067 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">18. J Genet. 2011 Dec;90(3):435-42.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Eight paths of ERK1/2 signalling
pathway regulating hepatocyte proliferation in</P>
<P STYLE="margin-bottom: 0cm">rat liver regeneration.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Li JW(1), Wang GP, Fan JY, Chang CF, Xu
CS.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)College of Life Sciences, Henan
Normal University, Xinxiang 453007, Henan</P>
<P STYLE="margin-bottom: 0cm">Province, People's Republic of China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Although it is known that hormones,
growth factors and integrin promote</P>
<P STYLE="margin-bottom: 0cm">hepatocyte proliferation in liver
regeneration (LR) through ERK1/2 signalling</P>
<P STYLE="margin-bottom: 0cm">pathway, reports about regulating
processes of its intracellular paths in</P>
<P STYLE="margin-bottom: 0cm">hepatocytes of LR are limited. This
study aims at exploring which paths of ERK1/2</P>
<P STYLE="margin-bottom: 0cm">signalling pathway participate in the
regulation of rat LR, especially in</P>
<P STYLE="margin-bottom: 0cm">hepatocyte proliferation, and how they
do so. In all, 14 paths and 165 genes are 
</P>
<P STYLE="margin-bottom: 0cm">known to be involved in ERK1/2
signalling pathway. Of them, 161 genes are</P>
<P STYLE="margin-bottom: 0cm">included in Rat Genome 230 2.0 Array.
This array was used to detect expression</P>
<P STYLE="margin-bottom: 0cm">changes of genes related to ERK1/2
signalling pathway in isolated hepatocytes of 
</P>
<P STYLE="margin-bottom: 0cm">rat LR, showing that 60 genes were
related to hepatocytes of LR. In addition,</P>
<P STYLE="margin-bottom: 0cm">bioinformatics and systems biology
methods were used to analyse the roles of 14</P>
<P STYLE="margin-bottom: 0cm">above paths in regenerating
hepatocytes. We found that three paths,</P>
<P STYLE="margin-bottom: 0cm">RTK→SHC→GRB2/SOS→RAS→RAF,
IntegrinΒ→FAK→RAC→PAK→RAF and GΒγ→PI3KΒγ→RAC→PAK→RAF,</P>
<P STYLE="margin-bottom: 0cm">promoted the G1 phase progression of
hepatocytes by activating ERK1/2. A further 
</P>
<P STYLE="margin-bottom: 0cm">four paths,
Gq→PLCΒ→PKC→SRC/PYK2→GRB2/SOS→RAS→RAF,</P>
<P STYLE="margin-bottom: 0cm">RTK→PLCγ→PKC→SRC/PYK2→GRB2/SOS→RAS→RAF,
IntegrinΒ→FAK/SRC→GRB2/SOS→RAS→RAF and</P>
<P STYLE="margin-bottom: 0cm">IntegrinΒ→FAK→RAC→PAK→RAF,
advanced the cell progression of S phase and G(2)/M</P>
<P STYLE="margin-bottom: 0cm">checkpoint by activating ERK1/2, and so
did PP1/2→Mek1/2 by decreasing the</P>
<P STYLE="margin-bottom: 0cm">negative influence on ERK1/2. At the
late phase of LR, Gαs→AC→EPAC→Rap1→Raf</P>
<P STYLE="margin-bottom: 0cm">blocked hepatocyte proliferation by
decreasing the activity of ERK1/2 and so did 
</P>
<P STYLE="margin-bottom: 0cm">PP1/2→Mek1/2. In summary, 60 genes
and 8 paths of ERK1/2 signalling pathway</P>
<P STYLE="margin-bottom: 0cm">regulated hepatocyte proliferation in
rat LR.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 22227930 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">19. PLoS One. 2011;6(11):e27511. doi:
10.1371/journal.pone.0027511. Epub 2011 Nov 21.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Activation of Ras requires the
ERM-dependent link of actin to the plasma</P>
<P STYLE="margin-bottom: 0cm">membrane.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sperka T(1), Geissler KJ, Merkel U,
Scholl I, Rubio I, Herrlich P, Morrison HL.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Morrison Laboratory, Leibniz
Institute for Age Research-Fritz Lipmann</P>
<P STYLE="margin-bottom: 0cm">Institute, Jena, Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Receptor tyrosine kinases
(RTKs) participate in a multitude of</P>
<P STYLE="margin-bottom: 0cm">signaling pathways, some of them via
the small G-protein Ras. An important</P>
<P STYLE="margin-bottom: 0cm">component in the activation of Ras is
Son of sevenless (SOS), which catalyzes the</P>
<P STYLE="margin-bottom: 0cm">nucleotide exchange on Ras.</P>
<P STYLE="margin-bottom: 0cm">PRINCIPAL FINDINGS: We can now
demonstrate that the activation of Ras requires,</P>
<P STYLE="margin-bottom: 0cm">in addition, the essential
participation of ezrin, radixin and/or moesin (ERM), a</P>
<P STYLE="margin-bottom: 0cm">family of actin-binding proteins, and
of actin. Disrupting either the interaction</P>
<P STYLE="margin-bottom: 0cm">of the ERM proteins with co-receptors,
down-regulation of ERM proteins by siRNA, 
</P>
<P STYLE="margin-bottom: 0cm">expression of dominant-negative mutants
of the ERM proteins or disruption of</P>
<P STYLE="margin-bottom: 0cm">F-actin, abolishes growth
factor-induced Ras activation. Ezrin/actin catalyzes</P>
<P STYLE="margin-bottom: 0cm">the formation of a multiprotein complex
consisting of RTK, co-receptor, Grb2, SOS</P>
<P STYLE="margin-bottom: 0cm">and Ras. We also identify binding sites
for both Ras and SOS on ezrin; mutations 
</P>
<P STYLE="margin-bottom: 0cm">of these binding sites destroy the
interactions and inhibit Ras activation.</P>
<P STYLE="margin-bottom: 0cm">Finally, we show that the formation of
the ezrin-dependent complex is necessary</P>
<P STYLE="margin-bottom: 0cm">to enhance the catalytic activity of
SOS and thereby Ras activation.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Taking these findings
together, we propose that the ERM proteins are</P>
<P STYLE="margin-bottom: 0cm">novel scaffolds at the level of SOS
activity control, which is relevant for both 
</P>
<P STYLE="margin-bottom: 0cm">normal Ras function and dysfunction
known to occur in several human cancers.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3221661</P>
<P STYLE="margin-bottom: 0cm">PMID: 22132106 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">20. Cell Signal. 2011
Dec;23(12):1885-95. doi: 10.1016/j.cellsig.2011.06.017. Epub</P>
<P STYLE="margin-bottom: 0cm">2011 Jun 29.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The exquisite regulation of PLD2 by a
wealth of interacting proteins: S6K, Grb2, 
</P>
<P STYLE="margin-bottom: 0cm">Sos, WASp and Rac2 (and a surprise
discovery: PLD2 is a GEF).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gomez-Cambronero J(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biochemistry and
Molecular Biology, Wright State University</P>
<P STYLE="margin-bottom: 0cm">School of Medicine, Dayton, OH 45435,
USA. julian.cambronero@wright.edu</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Phospholipase D (PLD) catalyzes the
conversion of the membrane phospholipid</P>
<P STYLE="margin-bottom: 0cm">phosphatidylcholine to choline and
phosphatidic acid (PA). PLD's mission in the</P>
<P STYLE="margin-bottom: 0cm">cell is two-fold: phospholipid turnover
with maintenance of the structural</P>
<P STYLE="margin-bottom: 0cm">integrity of cellular/intracellular
membranes and cell signaling through PA and</P>
<P STYLE="margin-bottom: 0cm">its metabolites. Precisely, through its
product of the reaction, PA, PLD has been</P>
<P STYLE="margin-bottom: 0cm">implicated in a variety of
physiological cellular functions, such as</P>
<P STYLE="margin-bottom: 0cm">intracellular protein trafficking,
cytoskeletal dynamics, chemotaxis of</P>
<P STYLE="margin-bottom: 0cm">leukocytes and cell proliferation. The
catalytic (HKD) and regulatory (PH and PX)</P>
<P STYLE="margin-bottom: 0cm">domains were studied in detail in the
PLD1 isoform, but PLD2 was traditionally</P>
<P STYLE="margin-bottom: 0cm">studied in lesser detail and much less
was known about its regulation. Our</P>
<P STYLE="margin-bottom: 0cm">laboratory has been focusing on the
study of PLD2 regulation in mammalian cells. 
</P>
<P STYLE="margin-bottom: 0cm">Over the past few years, we have
reported, in regards to the catalytic action of 
</P>
<P STYLE="margin-bottom: 0cm">PLD, that PA is a chemoattractant agent
that binds to and signals inside the cell</P>
<P STYLE="margin-bottom: 0cm">through the ribosomal S6 kinases (S6K).
Regarding the regulatory domains of PLD2,</P>
<P STYLE="margin-bottom: 0cm">we have reported the discovery of the
PLD2 interaction with Grb2 via Y169 in the 
</P>
<P STYLE="margin-bottom: 0cm">PX domain, and further association to
Sos, which results in an increase of de</P>
<P STYLE="margin-bottom: 0cm">novo DNA synthesis and an interaction
(also with Grb2) via the adjacent residue</P>
<P STYLE="margin-bottom: 0cm">Y179, leading to the regulation of cell
ruffling, chemotaxis and phagocytosis of 
</P>
<P STYLE="margin-bottom: 0cm">leukocytes. We also present the complex
regulation by tyrosine phosphorylation by</P>
<P STYLE="margin-bottom: 0cm">epidermal growth factor receptor
(EGF-R), Janus Kinase 3 (JAK3) and Src and the</P>
<P STYLE="margin-bottom: 0cm">role of phosphatases. Recently, there
is evidence supporting a new level of</P>
<P STYLE="margin-bottom: 0cm">regulation of PLD2 at the PH domain, by
the discovery of CRIB domains and a</P>
<P STYLE="margin-bottom: 0cm">Rac2-PLD2 interaction that leads to a
dual (positive and negative) effect on its 
</P>
<P STYLE="margin-bottom: 0cm">enzymatic activity. Lastly, we review
the surprising finding of PLD2 acting as a 
</P>
<P STYLE="margin-bottom: 0cm">GEF. A phospholipase such as PLD that
exists already in the cell membrane that</P>
<P STYLE="margin-bottom: 0cm">acts directly on Rac allows a quick
response of the cell without intermediary</P>
<P STYLE="margin-bottom: 0cm">signaling molecules. This provides only
the latest level of PLD2 regulation in a 
</P>
<P STYLE="margin-bottom: 0cm">field that promises newer and exciting
advances in the next few years.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2011 Elsevier Inc. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3204931</P>
<P STYLE="margin-bottom: 0cm">PMID: 21740967 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Autophagy. 2015 Jun 10:0. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Upregulation of ATG3 contributes to
autophagy induced by the detachment of</P>
<P STYLE="margin-bottom: 0cm">intestinal epithelial cells from the
extracellular matrix, but promotes</P>
<P STYLE="margin-bottom: 0cm">autophagy-independent apoptosis of the
attached cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Yoo BH(1), Zagryazhskaya A, Li Y,
Koomson A, Khan IA, Sasazuki T, Shirasawa S,</P>
<P STYLE="margin-bottom: 0cm">Rosen K.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)a Departments of Pediatrics &amp;
Biochemistry and Molecular Biology , Dalhousie</P>
<P STYLE="margin-bottom: 0cm">University , Halifax , NS Canada.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Detachment of non-malignant intestinal
epithelial cells from the extracellular</P>
<P STYLE="margin-bottom: 0cm">matrix (ECM) triggers their growth
arrest and, ultimately, apoptosis. In</P>
<P STYLE="margin-bottom: 0cm">contrast, colorectal cancer cells can
grow without attachment to the ECM. This</P>
<P STYLE="margin-bottom: 0cm">ability is critical for their malignant
potential. We found previously that</P>
<P STYLE="margin-bottom: 0cm">detachment-induced growth arrest of
non-malignant intestinal epithelial cells is 
</P>
<P STYLE="margin-bottom: 0cm">driven by their detachment-triggered
autophagy, and that RRAS, a major oncogene, 
</P>
<P STYLE="margin-bottom: 0cm">promotes growth of detached cells by
blocking such autophagy. In an effort to</P>
<P STYLE="margin-bottom: 0cm">identify the mechanisms of
detachment-induced autophagy and growth arrest of</P>
<P STYLE="margin-bottom: 0cm">non-malignant cells we found here that
detachment of these cells causes</P>
<P STYLE="margin-bottom: 0cm">upregulation of ATG3 and that ATG3
upregulation contributes to autophagy and</P>
<P STYLE="margin-bottom: 0cm">growth arrest of detached cells. We
also observed that when ATG3 expression is</P>
<P STYLE="margin-bottom: 0cm">artificially increased in the attached
cells, ATG3 promotes neither autophagy nor</P>
<P STYLE="margin-bottom: 0cm">growth arrest but triggers their
apoptosis. ATG3 upregulation likely promotes</P>
<P STYLE="margin-bottom: 0cm">autophagy of the detached but not that
of the attached cells because</P>
<P STYLE="margin-bottom: 0cm">detachment-dependent autophagy requires
other detachment-induced events, such as 
</P>
<P STYLE="margin-bottom: 0cm">the upregulation of ATG7. We further
observed that those few adherent cells that 
</P>
<P STYLE="margin-bottom: 0cm">do not die by apoptosis induced by ATG3
become resistant to apoptosis caused by</P>
<P STYLE="margin-bottom: 0cm">cell detachment, a property that is
critical for the ability of normal epithelial</P>
<P STYLE="margin-bottom: 0cm">cells to become malignant. We conclude
that cell-ECM adhesion can switch ATG3</P>
<P STYLE="margin-bottom: 0cm">functions: when upregulated in detached
cells in the context of other</P>
<P STYLE="margin-bottom: 0cm">autophagy-promoting events, ATG3
contributes to autophagy. However, when</P>
<P STYLE="margin-bottom: 0cm">overexpressed in the adherent cells, in
the circumstances not favoring autophagy,</P>
<P STYLE="margin-bottom: 0cm">ATG3 triggers apoptosis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26061804 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. BMC Cancer. 2015 May 28;15:436. doi:
10.1186/s12885-015-1415-6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Compounds identified by virtual docking
to a tetrameric EGFR extracellular domain</P>
<P STYLE="margin-bottom: 0cm">can modulate Grb2 internalization.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ramirez UD(1), Nikonova AS(2), Liu
H(3), Pecherskaya A(4), Lawrence SH(5),</P>
<P STYLE="margin-bottom: 0cm">Serebriiskii IG(6,)(7), Zhou Y(8),
Robinson MK(9), Einarson MB(10), Golemis</P>
<P STYLE="margin-bottom: 0cm">EA(11), Jaffe EK(12).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Molecular Therapeutics Program, Fox
Chase Cancer Center, 333 Cottman Ave,</P>
<P STYLE="margin-bottom: 0cm">Philadelphia, PA, 19111, USA.
Ursula.Ramirez@fccc.edu. (2)Molecular Therapeutics 
</P>
<P STYLE="margin-bottom: 0cm">Program, Fox Chase Cancer Center, 333
Cottman Ave, Philadelphia, PA, 19111, USA. 
</P>
<P STYLE="margin-bottom: 0cm">Anna.Nikonova@fccc.edu. (3)Molecular
Therapeutics Program, Fox Chase Cancer</P>
<P STYLE="margin-bottom: 0cm">Center, 333 Cottman Ave, Philadelphia,
PA, 19111, USA. hanqing@ujs.edu.cn.</P>
<P STYLE="margin-bottom: 0cm">(4)Translational Facility, Fox Chase
Cancer Center, 333 Cottman Ave,</P>
<P STYLE="margin-bottom: 0cm">Philadelphia, PA, 19111, USA.
anna_pech@yahoo.com. (5)Molecular Therapeutics</P>
<P STYLE="margin-bottom: 0cm">Program, Fox Chase Cancer Center, 333
Cottman Ave, Philadelphia, PA, 19111, USA. 
</P>
<P STYLE="margin-bottom: 0cm">Sarah.Lawrence@fccc.edu. (6)Molecular
Therapeutics Program, Fox Chase Cancer</P>
<P STYLE="margin-bottom: 0cm">Center, 333 Cottman Ave, Philadelphia,
PA, 19111, USA.</P>
<P STYLE="margin-bottom: 0cm">Ilya.Serebriiskii@fccc.edu. (7)Kazan
Federal University, Kazan, Russia.</P>
<P STYLE="margin-bottom: 0cm">Ilya.Serebriiskii@fccc.edu.
(8)Biostatistics and Bioinformatics Facility, Fox</P>
<P STYLE="margin-bottom: 0cm">Chase Cancer Center, 333 Cottman Ave,
Philadelphia, PA, 19111, USA.</P>
<P STYLE="margin-bottom: 0cm">Yan.Zhou@fccc.edu. (9)Molecular
Therapeutics Program, Fox Chase Cancer Center,</P>
<P STYLE="margin-bottom: 0cm">333 Cottman Ave, Philadelphia, PA,
19111, USA. Matthew.Robinson@fccc.edu.</P>
<P STYLE="margin-bottom: 0cm">(10)Translational Facility, Fox Chase
Cancer Center, 333 Cottman Ave,</P>
<P STYLE="margin-bottom: 0cm">Philadelphia, PA, 19111, USA.
Margret.Einarson@fccc.edu. (11)Molecular</P>
<P STYLE="margin-bottom: 0cm">Therapeutics Program, Fox Chase Cancer
Center, 333 Cottman Ave, Philadelphia, PA,</P>
<P STYLE="margin-bottom: 0cm">19111, USA. Erica.Golemis@fccc.edu.
(12)Molecular Therapeutics Program, Fox Chase</P>
<P STYLE="margin-bottom: 0cm">Cancer Center, 333 Cottman Ave,
Philadelphia, PA, 19111, USA.</P>
<P STYLE="margin-bottom: 0cm">Eileen.Jaffe@fccc.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Overexpression or mutation
of the epidermal growth factor receptor</P>
<P STYLE="margin-bottom: 0cm">(EGFR) potently enhances the growth of
many solid tumors. Tumor cells frequently 
</P>
<P STYLE="margin-bottom: 0cm">display resistance to
mechanistically-distinct EGFR-directed therapeutic agents, 
</P>
<P STYLE="margin-bottom: 0cm">making it valuable to develop
therapeutics that work by additional mechanisms.</P>
<P STYLE="margin-bottom: 0cm">Current EGFR-targeting therapeutics
include antibodies targeting the</P>
<P STYLE="margin-bottom: 0cm">extracellular domains, and small
molecules inhibiting the intracellular kinase</P>
<P STYLE="margin-bottom: 0cm">domain. Recent studies have identified
a novel prone extracellular tetrameric</P>
<P STYLE="margin-bottom: 0cm">EGFR configuration, which we identify
as a potential target for drug discovery.</P>
<P STYLE="margin-bottom: 0cm">METHODS: Our focus is on the prone EGFR
tetramer, which contains a novel</P>
<P STYLE="margin-bottom: 0cm">protein-protein interface involving
extracellular domain III. This EGFR tetramer 
</P>
<P STYLE="margin-bottom: 0cm">is computationally targeted for
stabilization by small molecule ligand binding.</P>
<P STYLE="margin-bottom: 0cm">This study performed virtual screening
of a Life Chemicals, Inc. small molecule</P>
<P STYLE="margin-bottom: 0cm">library of 345,232 drug-like compounds
against a molecular dynamics simulation of</P>
<P STYLE="margin-bottom: 0cm">protein-protein interfaces distinct to
the novel tetramer. One hundred nine</P>
<P STYLE="margin-bottom: 0cm">chemically diverse candidate molecules
were selected and evaluated using a</P>
<P STYLE="margin-bottom: 0cm">cell-based high-content imaging screen
that directly assessed induced</P>
<P STYLE="margin-bottom: 0cm">internalization of the EGFR effector
protein Grb2. Positive hits were further</P>
<P STYLE="margin-bottom: 0cm">evaluated for influence on
phosphorylation of EGFR and its effector ERK1/2.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: Fourteen hit compounds
affected internalization of Grb2, an adaptor</P>
<P STYLE="margin-bottom: 0cm">responsive to EGFR activation. Most
hits had limited effect on cell viability,</P>
<P STYLE="margin-bottom: 0cm">and minimally influenced EGFR and
ERK1/2 phosphorylation. Docked hit compound</P>
<P STYLE="margin-bottom: 0cm">poses generally include Arg270 or
neighboring residues, which are also involved</P>
<P STYLE="margin-bottom: 0cm">in binding the effective therapeutic
cetuximab, guiding further chemical</P>
<P STYLE="margin-bottom: 0cm">optimization.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: These data suggest that
the EGFR tetrameric configuration offers a</P>
<P STYLE="margin-bottom: 0cm">novel cancer drug target.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4451962</P>
<P STYLE="margin-bottom: 0cm">PMID: 26016476 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. Sci Signal. 2015 May 12;8(376):ra46.
doi: 10.1126/scisignal.2005697.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">EGFR-activated Src family kinases
maintain GAB1-SHP2 complexes distal from EGFR.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Furcht CM(1), Buonato JM(1), Lazzara
MJ(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Chemical and
Biomolecular Engineering, University of</P>
<P STYLE="margin-bottom: 0cm">Pennsylvania, Philadelphia, PA 19104,
USA. (2)Department of Chemical and</P>
<P STYLE="margin-bottom: 0cm">Biomolecular Engineering, University of
Pennsylvania, Philadelphia, PA 19104,</P>
<P STYLE="margin-bottom: 0cm">USA. Department of Bioengineering,
University of Pennsylvania, Philadelphia, PA</P>
<P STYLE="margin-bottom: 0cm">19104, USA. mlazzara@seas.upenn.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Complexes of signaling proteins that
are nucleated upon activation of receptor</P>
<P STYLE="margin-bottom: 0cm">tyrosine kinases are dynamic
macromolecular assemblies held together by</P>
<P STYLE="margin-bottom: 0cm">interactions, such as the recognition
of phosphotyrosines by Src homology 2 (SH2)</P>
<P STYLE="margin-bottom: 0cm">domains. We predicted that reversible
binding and phosphatase activity enable</P>
<P STYLE="margin-bottom: 0cm">dynamic regulation of these protein
complexes, which could affect signal</P>
<P STYLE="margin-bottom: 0cm">transduction. We explored how dynamics
in the interactions among the epidermal</P>
<P STYLE="margin-bottom: 0cm">growth factor (EGF) receptor (EGFR),
GRB2-associated binder protein 1 (GAB1), and</P>
<P STYLE="margin-bottom: 0cm">SH2 domain-containing phosphatase 2
(SHP2) affected EGFR signaling output,</P>
<P STYLE="margin-bottom: 0cm">specifically SHP2 binding to
tyrosine-phosphorylated GAB1, which relieves the</P>
<P STYLE="margin-bottom: 0cm">autoinhibition of SHP2. Among the
effects of activated SHP2 is increased</P>
<P STYLE="margin-bottom: 0cm">extracellular signal-regulated kinase
(ERK) activity. We found that in H1666 lung</P>
<P STYLE="margin-bottom: 0cm">adenocarcinoma cells, EGFR-activated
Src family kinases (SFKs) counteracted</P>
<P STYLE="margin-bottom: 0cm">repeated GAB1 dephosphorylation events
and maintained the association of SHP2</P>
<P STYLE="margin-bottom: 0cm">with phosphorylated GAB1 at a cytosolic
site distal from EGFR. A computational</P>
<P STYLE="margin-bottom: 0cm">model predicted that an experimentally
verified delay in SFK inactivation after</P>
<P STYLE="margin-bottom: 0cm">EGFR inactivation, combined with an
amplification of GAB1 phosphorylation in</P>
<P STYLE="margin-bottom: 0cm">cells with proteins in a specific range
of concentrations, enabled GAB1</P>
<P STYLE="margin-bottom: 0cm">phosphorylation and GAB1-SHP2 complexes
to persist longer than EGFR</P>
<P STYLE="margin-bottom: 0cm">phosphorylation persisted in response
to EGF. This SFK-dependent mechanism was</P>
<P STYLE="margin-bottom: 0cm">specific to EGFR and did not occur in
response to activation of the receptor</P>
<P STYLE="margin-bottom: 0cm">tyrosine kinase c-MET. Thus, our
results quantitatively describe a regulatory</P>
<P STYLE="margin-bottom: 0cm">mechanism used by some receptor
tyrosine kinases to remotely control the duration</P>
<P STYLE="margin-bottom: 0cm">of a signal by regulating the
persistence of a signaling protein complex.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Association
for the Advancement of Science.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25969544 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">4. PLoS One. 2015 Apr
27;10(4):e0125793. doi: 10.1371/journal.pone.0125793.</P>
<P STYLE="margin-bottom: 0cm">eCollection 2015.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lipopolysaccharide (LPS)-Induced
Biliary Epithelial Cell NRas Activation Requires</P>
<P STYLE="margin-bottom: 0cm">Epidermal Growth Factor Receptor
(EGFR).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Trussoni CE(1), Tabibian JH(1),
Splinter PL(1), O'Hara SP(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Division of Gastroenterology and
Hepatology, and the Mayo Clinic Center for</P>
<P STYLE="margin-bottom: 0cm">Cell Signaling in Gastroenterology,
Mayo Clinic, Rochester, Minnesota, 55905,</P>
<P STYLE="margin-bottom: 0cm">United States of America.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cholangiocytes (biliary epithelial
cells) actively participate in microbe-induced</P>
<P STYLE="margin-bottom: 0cm">proinflammatory responses in the liver
and contribute to inflammatory and</P>
<P STYLE="margin-bottom: 0cm">infectious cholangiopathies. We
previously demonstrated that cholangiocyte</P>
<P STYLE="margin-bottom: 0cm">TLR-dependent NRas activation
contributes to proinflammatory/ proliferative</P>
<P STYLE="margin-bottom: 0cm">responses. We test the hypothesis that
LPS-induced activation of NRas requires</P>
<P STYLE="margin-bottom: 0cm">the EGFR. SV40-transformed human
cholangiocytes (H69 cells), or low passage</P>
<P STYLE="margin-bottom: 0cm">normal human cholangiocytes (NHC), were
treated with LPS in the presence or</P>
<P STYLE="margin-bottom: 0cm">absence of EGFR or ADAM
metallopeptidase domain 17 (TACE) inhibitors. Ras</P>
<P STYLE="margin-bottom: 0cm">activation assays, quantitative RT-PCR,
and proliferation assays were performed</P>
<P STYLE="margin-bottom: 0cm">in cells cultured with or without
inhibitors or an siRNA to Grb2.</P>
<P STYLE="margin-bottom: 0cm">Immunofluorescence for phospho-EGFR was
performed on LPS-treated mouse samples</P>
<P STYLE="margin-bottom: 0cm">and specimens from patients with
primary sclerosing cholangitis, primary biliary 
</P>
<P STYLE="margin-bottom: 0cm">cirrhosis, hepatitis C, and normal
livers. LPS-treatment induced an association</P>
<P STYLE="margin-bottom: 0cm">between the TLR/MyD88 and EGFR/Grb2
signaling apparatus, NRas activation, and</P>
<P STYLE="margin-bottom: 0cm">EGFR phosphorylation. NRas activation
was sensitive to EGFR and TACE inhibitors</P>
<P STYLE="margin-bottom: 0cm">and correlated with EGFR
phosphorylation. The TACE inhibitor and Grb2 depletion</P>
<P STYLE="margin-bottom: 0cm">prevented LPS-induced IL6 expression
(p&lt;0.05) and proliferation (p&lt;0.01).</P>
<P STYLE="margin-bottom: 0cm">Additionally, cholangiocytes from
LPS-treated mouse livers and human primary</P>
<P STYLE="margin-bottom: 0cm">sclerosing cholangitis (PSC) livers
exhibited increased phospho-EGFR (p&lt;0.01).</P>
<P STYLE="margin-bottom: 0cm">Moreover, LPS-induced mouse
cholangiocyte proliferation was inhibited by</P>
<P STYLE="margin-bottom: 0cm">concurrent treatment with the EGFR
inhibitor, Erlotinib. Our results suggest that</P>
<P STYLE="margin-bottom: 0cm">EGFR is essential for LPS-induced,
TLR4/MyD88-mediated NRas activation and</P>
<P STYLE="margin-bottom: 0cm">induction of a robust proinflammatory
cholangiocyte response. These findings have</P>
<P STYLE="margin-bottom: 0cm">implications not only for revealing the
signaling potential of TLRs, but also</P>
<P STYLE="margin-bottom: 0cm">implicate EGFR as an integral component
of cholangiocyte TLR-induced</P>
<P STYLE="margin-bottom: 0cm">proinflammatory processes.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4411066</P>
<P STYLE="margin-bottom: 0cm">PMID: 25915403 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">5. Biophys J. 2015 Apr
7;108(7):1819-29. doi: 10.1016/j.bpj.2015.02.030.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Use of mechanistic models to integrate
and analyze multiple proteomic datasets.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Stites EC(1), Aziz M(2), Creamer MS(3),
Von Hoff DD(2), Posner RG(4), Hlavacek</P>
<P STYLE="margin-bottom: 0cm">WS(5).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Clinical Translational Research
Division, Translational Genomics Research</P>
<P STYLE="margin-bottom: 0cm">Institute, Phoenix, Arizona; Department
of Pathology &amp; Immunology, Washington</P>
<P STYLE="margin-bottom: 0cm">University School of Medicine, St.
Louis, Missouri. Electronic address:</P>
<P STYLE="margin-bottom: 0cm">estites@path.wustl.edu. (2)Clinical
Translational Research Division,</P>
<P STYLE="margin-bottom: 0cm">Translational Genomics Research
Institute, Phoenix, Arizona. (3)Clinical</P>
<P STYLE="margin-bottom: 0cm">Translational Research Division,
Translational Genomics Research Institute,</P>
<P STYLE="margin-bottom: 0cm">Phoenix, Arizona; Department of
Molecular, Cellular, and Developmental Biology,</P>
<P STYLE="margin-bottom: 0cm">Yale University, New Haven,
Connecticut. (4)Clinical Translational Research</P>
<P STYLE="margin-bottom: 0cm">Division, Translational Genomics
Research Institute, Phoenix, Arizona; Department</P>
<P STYLE="margin-bottom: 0cm">of Biological Sciences, Northern
Arizona University, Flagstaff, Arizona.</P>
<P STYLE="margin-bottom: 0cm">Electronic address: rposner@tgen.org.
(5)Clinical Translational Research</P>
<P STYLE="margin-bottom: 0cm">Division, Translational Genomics
Research Institute, Phoenix, Arizona;</P>
<P STYLE="margin-bottom: 0cm">Theoretical Biology and Biophysics
Group, Theoretical Division, Los Alamos</P>
<P STYLE="margin-bottom: 0cm">National Laboratory, Los Alamos, New
Mexico. Electronic address: wish@lanl.gov.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Proteins in cell signaling networks
tend to interact promiscuously through</P>
<P STYLE="margin-bottom: 0cm">low-affinity interactions.
Consequently, evaluating the physiological importance 
</P>
<P STYLE="margin-bottom: 0cm">of mapped interactions can be
difficult. Attempts to do so have tended to focus</P>
<P STYLE="margin-bottom: 0cm">on single, measurable physicochemical
factors, such as affinity or abundance. For</P>
<P STYLE="margin-bottom: 0cm">example, interaction importance has
been assessed on the basis of the relative</P>
<P STYLE="margin-bottom: 0cm">affinities of binding partners for a
protein of interest, such as a receptor.</P>
<P STYLE="margin-bottom: 0cm">However, multiple factors can be
expected to simultaneously influence the</P>
<P STYLE="margin-bottom: 0cm">recruitment of proteins to a receptor
(and the potential of these proteins to</P>
<P STYLE="margin-bottom: 0cm">contribute to receptor signaling),
including affinity, abundance, and</P>
<P STYLE="margin-bottom: 0cm">competition, which is a network
property. Here, we demonstrate that measurements 
</P>
<P STYLE="margin-bottom: 0cm">of protein copy numbers and binding
affinities can be integrated within the</P>
<P STYLE="margin-bottom: 0cm">framework of a mechanistic,
computational model that accounts for mass action and</P>
<P STYLE="margin-bottom: 0cm">competition. We use cell line-specific
models to rank the relative importance of 
</P>
<P STYLE="margin-bottom: 0cm">protein-protein interactions in the
epidermal growth factor receptor (EGFR)</P>
<P STYLE="margin-bottom: 0cm">signaling network for 11 different cell
lines. Each model accounts for</P>
<P STYLE="margin-bottom: 0cm">experimentally characterized
interactions of six autophosphorylation sites in</P>
<P STYLE="margin-bottom: 0cm">EGFR with proteins containing a Src
homology 2 and/or phosphotyrosine-binding</P>
<P STYLE="margin-bottom: 0cm">domain. We measure importance as the
predicted maximal extent of recruitment of a</P>
<P STYLE="margin-bottom: 0cm">protein to EGFR following
ligand-stimulated activation of EGFR signaling. We find</P>
<P STYLE="margin-bottom: 0cm">that interactions ranked highly by this
metric include experimentally detected</P>
<P STYLE="margin-bottom: 0cm">interactions. Proteins with high
importance rank in multiple cell lines include</P>
<P STYLE="margin-bottom: 0cm">proteins with recognized,
well-characterized roles in EGFR signaling, such as</P>
<P STYLE="margin-bottom: 0cm">GRB2 and SHC1, as well as a protein
with a less well-defined role, YES1. Our</P>
<P STYLE="margin-bottom: 0cm">results reveal potential cell
line-specific differences in recruitment.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015 Biophysical Society.
Published by Elsevier Inc. All rights</P>
<P STYLE="margin-bottom: 0cm">reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4390817 [Available on
2016-04-07]</P>
<P STYLE="margin-bottom: 0cm">PMID: 25863072 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">6. Biomed Opt Express. 2015 Jan
6;6(2):277-96. doi: 10.1364/BOE.6.000277.</P>
<P STYLE="margin-bottom: 0cm">eCollection 2015.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A high speed multifocal multiphoton
fluorescence lifetime imaging microscope for 
</P>
<P STYLE="margin-bottom: 0cm">live-cell FRET imaging.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Poland SP(1), Krstajić N(2), Monypenny
J(1), Coelho S(1), Tyndall D(2), Walker</P>
<P STYLE="margin-bottom: 0cm">RJ(3), Devauges V(1), Richardson J(3),
Dutton N(2), Barber P(4), Li DD(5),</P>
<P STYLE="margin-bottom: 0cm">Suhling K(6), Ng T(7), Henderson RK(2),
Ameer-Beg SM(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Division of Cancer Studies, Guy's
Campus, Kings College, London, UK ; Randall 
</P>
<P STYLE="margin-bottom: 0cm">Division of Cell and Molecular
Biophysics, Guy's Campus, Kings College, London,</P>
<P STYLE="margin-bottom: 0cm">UK. (2)Institute for Integrated Micro
and Nano Systems, School of Engineering,</P>
<P STYLE="margin-bottom: 0cm">University of Edinburgh, Edinburgh, UK.
(3)Institute for Integrated Micro and</P>
<P STYLE="margin-bottom: 0cm">Nano Systems, School of Engineering,
University of Edinburgh, Edinburgh, UK ;</P>
<P STYLE="margin-bottom: 0cm">Photon-Force Ltd., Edinburgh, UK.
(4)Gray Institute for Radiation Oncology &amp;</P>
<P STYLE="margin-bottom: 0cm">Biology, University of Oxford, Old Road
Campus Research Building, Roosevelt</P>
<P STYLE="margin-bottom: 0cm">Drive, Oxford OX3 7DQ UK.
(5)Strathclyde Institute of Pharmacy and Biomedical</P>
<P STYLE="margin-bottom: 0cm">Sciences, 161 Cathedral Street,
Glasgow, G4 0RE, UK. (6)Department of Physics,</P>
<P STYLE="margin-bottom: 0cm">King's College London, Strand, London,
UK. (7)Division of Cancer Studies, Guy's</P>
<P STYLE="margin-bottom: 0cm">Campus, Kings College, London, UK ;
Randall Division of Cell and Molecular</P>
<P STYLE="margin-bottom: 0cm">Biophysics, Guy's Campus, Kings
College, London, UK ; UCL Cancer Institute, Paul 
</P>
<P STYLE="margin-bottom: 0cm">O'Gorman Building, University College
London, London WC1E 6DD, UK.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">We demonstrate diffraction limited
multiphoton imaging in a massively parallel,</P>
<P STYLE="margin-bottom: 0cm">fully addressable time-resolved
multi-beam multiphoton microscope capable of</P>
<P STYLE="margin-bottom: 0cm">producing fluorescence lifetime images
with sub-50ps temporal resolution. This</P>
<P STYLE="margin-bottom: 0cm">imaging platform offers a significant
improvement in acquisition speed over</P>
<P STYLE="margin-bottom: 0cm">single-beam laser scanning FLIM by a
factor of 64 without compromising in either 
</P>
<P STYLE="margin-bottom: 0cm">the temporal or spatial resolutions of
the system. We demonstrate FLIM</P>
<P STYLE="margin-bottom: 0cm">acquisition at 500 ms with live cells
expressing green fluorescent protein. The</P>
<P STYLE="margin-bottom: 0cm">applicability of the technique to
imaging protein-protein interactions in live</P>
<P STYLE="margin-bottom: 0cm">cells is exemplified by observation of
time-dependent FRET between the epidermal 
</P>
<P STYLE="margin-bottom: 0cm">growth factor receptor (EGFR) and the
adapter protein Grb2 following stimulation 
</P>
<P STYLE="margin-bottom: 0cm">with the receptor ligand. Furthermore,
ligand-dependent association of HER2-HER3 
</P>
<P STYLE="margin-bottom: 0cm">receptor tyrosine kinases was observed
on a similar timescale and involved the</P>
<P STYLE="margin-bottom: 0cm">internalisation and accumulation or
receptor heterodimers within endosomes. These</P>
<P STYLE="margin-bottom: 0cm">data demonstrate the broad
applicability of this novel FLIM technique to the</P>
<P STYLE="margin-bottom: 0cm">spatio-temporal dynamics of
protein-protein interaction.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4354599</P>
<P STYLE="margin-bottom: 0cm">PMID: 25780724 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">7. Int J Mol Med. 2015
Apr;35(4):909-14. doi: 10.3892/ijmm.2015.2111. Epub 2015 Feb 
</P>
<P STYLE="margin-bottom: 0cm">26.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The proliferative effects of Pyropia
yezoensis peptide on IEC-6 cells are</P>
<P STYLE="margin-bottom: 0cm">mediated through the epidermal growth
factor receptor signaling pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lee MK(1), Kim IH(2), Choi YH(2), Choi
JW(1), Kim YM(2), Nam TJ(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Food Science and
Nutrition, Pukyong National University, Busan</P>
<P STYLE="margin-bottom: 0cm">608-737, Republic of Korea.
(2)Institute of Fisheries Science, Pukyong National</P>
<P STYLE="margin-bottom: 0cm">University, Busan 619-911, Republic of
Korea.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">For a number of years, seaweed has been
used as a functional food in Asian</P>
<P STYLE="margin-bottom: 0cm">countries, particularly in Korea, Japan
and China. Pyropia yezoensis is a marine 
</P>
<P STYLE="margin-bottom: 0cm">red alga that has potentially
beneficial biological activities. In this study, we</P>
<P STYLE="margin-bottom: 0cm">examined the mechanisms through which a
Pyropia yezoensis peptide [PYP1 (1-20)]</P>
<P STYLE="margin-bottom: 0cm">induces the proliferation of IEC-6
cells, a rat intestinal epithelial cell line, 
</P>
<P STYLE="margin-bottom: 0cm">and the involvement of the epidermal
growth factor receptor (EGFR) signaling</P>
<P STYLE="margin-bottom: 0cm">pathway. First, cell viability assay
revealed that PYP1 (1-20) induced cell</P>
<P STYLE="margin-bottom: 0cm">proliferation in a
concentration-dependent manner. Subsequently, we examined the 
</P>
<P STYLE="margin-bottom: 0cm">mechanisms responsible for this
induction of proliferation induced by PYP1</P>
<P STYLE="margin-bottom: 0cm">(1-20). EGFR is widely expressed in
mammalian epithelial tissues, and the binding</P>
<P STYLE="margin-bottom: 0cm">of this ligand affects a variety of
cell physiological parameters, such as cell</P>
<P STYLE="margin-bottom: 0cm">growth and proliferation. PYP1 (1-20)
increased the expression of EGFR, Shc,</P>
<P STYLE="margin-bottom: 0cm">growth factor receptor-bound protein 2
(Grb2) and son of sevenless (SOS). EGFR</P>
<P STYLE="margin-bottom: 0cm">also induced the activation of the Ras
signaling pathway through Raf, MEK and</P>
<P STYLE="margin-bottom: 0cm">extracellular signal-regulated kinase
(ERK) phosphorylation. In addition, cell</P>
<P STYLE="margin-bottom: 0cm">cycle analysis revealed the expression
of cell cycle-related proteins. The</P>
<P STYLE="margin-bottom: 0cm">results demonstrated an increased
number of cells in the G1 phase and an enhanced</P>
<P STYLE="margin-bottom: 0cm">cell proliferation. In addition, the
upregulation of cyclin D, cyclin E, Cdk2,</P>
<P STYLE="margin-bottom: 0cm">Cdk4 and Cdk6 was observed accompanied
by a decreased in p21 and p27 expression. 
</P>
<P STYLE="margin-bottom: 0cm">These findings suggest that PYP1 (1-20)
stimulates the proliferation of rat IEC-6</P>
<P STYLE="margin-bottom: 0cm">cells by activating the EGFR signaling
pathway. Therefore, PYP1 (1-20) may be a</P>
<P STYLE="margin-bottom: 0cm">potential source for the development of
bio-functional foods which promotes the</P>
<P STYLE="margin-bottom: 0cm">proliferation of intestinal epithelial
cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4356455</P>
<P STYLE="margin-bottom: 0cm">PMID: 25716690 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">8. BMC Genet. 2015 Feb 5;16:9. doi:
10.1186/s12863-015-0170-7.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Identification of kinases and
regulatory proteins required for cell migration</P>
<P STYLE="margin-bottom: 0cm">using a transfected cell-microarray
system.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Onuki-Nagasaki R(1,)(2), Nagasaki A(3),
Hakamada K(4,)(5,)(6), Uyeda TQ(7),</P>
<P STYLE="margin-bottom: 0cm">Miyake M(8), Miyake J(9,)(10), Fujita
S(11).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Biomedical Research Institute,
National Institute of Advanced Industrial</P>
<P STYLE="margin-bottom: 0cm">Science and Technology (AIST), 1-1-1
Higashi, Tsukuba, Ibaraki, 305-8566, Japan. 
</P>
<P STYLE="margin-bottom: 0cm">r-nagasaki@aist.go.jp. (2)Research
Fellow of Japan Society for the Promotion of</P>
<P STYLE="margin-bottom: 0cm">Science, 5-3-1 Kojimachi, Chiyoda-ku,
Tokyo, 102-0083, Japan.</P>
<P STYLE="margin-bottom: 0cm">r-nagasaki@aist.go.jp. (3)Biomedical
Research Institute, National Institute of</P>
<P STYLE="margin-bottom: 0cm">Advanced Industrial Science and
Technology (AIST), 1-1-1 Higashi, Tsukuba,</P>
<P STYLE="margin-bottom: 0cm">Ibaraki, 305-8566, Japan.
a-nagasaki@aist.go.jp. (4)Biomedical Research</P>
<P STYLE="margin-bottom: 0cm">Institute, National Institute of
Advanced Industrial Science and Technology</P>
<P STYLE="margin-bottom: 0cm">(AIST), 1-1-1 Higashi, Tsukuba,
Ibaraki, 305-8566, Japan.</P>
<P STYLE="margin-bottom: 0cm">Hakamada.Kazumi@sysmex.co.jp.
(5)Department of Mechanical Science and</P>
<P STYLE="margin-bottom: 0cm">Bioengineering, Graduate School of
Engineering Science, Osaka University, 1-3</P>
<P STYLE="margin-bottom: 0cm">Machikaneyama-cho, Toyonaka, Osaka,
560-8531, Japan.</P>
<P STYLE="margin-bottom: 0cm">Hakamada.Kazumi@sysmex.co.jp.
(6)Current address: Central Research Laboratories</P>
<P STYLE="margin-bottom: 0cm">Sysmex Corporation, 4-4-4 Takatsukadai,
Nishi-ku, Kobe, 657-2271, Japan.</P>
<P STYLE="margin-bottom: 0cm">Hakamada.Kazumi@sysmex.co.jp.
(7)Biomedical Research Institute, National</P>
<P STYLE="margin-bottom: 0cm">Institute of Advanced Industrial
Science and Technology (AIST), 1-1-1 Higashi,</P>
<P STYLE="margin-bottom: 0cm">Tsukuba, Ibaraki, 305-8566, Japan.
t-uyeda@aist.go.jp. (8)Biomedical Research</P>
<P STYLE="margin-bottom: 0cm">Institute, National Institute of
Advanced Industrial Science and Technology</P>
<P STYLE="margin-bottom: 0cm">(AIST), 1-1-1 Higashi, Tsukuba,
Ibaraki, 305-8566, Japan.</P>
<P STYLE="margin-bottom: 0cm">masato-miyake@aist.go.jp. (9)Biomedical
Research Institute, National Institute of</P>
<P STYLE="margin-bottom: 0cm">Advanced Industrial Science and
Technology (AIST), 1-1-1 Higashi, Tsukuba,</P>
<P STYLE="margin-bottom: 0cm">Ibaraki, 305-8566, Japan.
jun_miyake@bpe.es.osaka-u.ac.jp. (10)Department of</P>
<P STYLE="margin-bottom: 0cm">Mechanical Science and Bioengineering,
Graduate School of Engineering Science,</P>
<P STYLE="margin-bottom: 0cm">Osaka University, 1-3
Machikaneyama-cho, Toyonaka, Osaka, 560-8531, Japan.</P>
<P STYLE="margin-bottom: 0cm">jun_miyake@bpe.es.osaka-u.ac.jp.
(11)Biomedical Research Institute, National</P>
<P STYLE="margin-bottom: 0cm">Institute of Advanced Industrial
Science and Technology (AIST), 1-1-1 Higashi,</P>
<P STYLE="margin-bottom: 0cm">Tsukuba, Ibaraki, 305-8566, Japan.
s-fujita@aist.go.jp.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Cell migration plays a
major role in a variety of normal biological</P>
<P STYLE="margin-bottom: 0cm">processes, and a detailed understanding
of the associated mechanisms should lead 
</P>
<P STYLE="margin-bottom: 0cm">to advances in the medical sciences in
areas such as cancer therapy. Previously, 
</P>
<P STYLE="margin-bottom: 0cm">we developed a simple chip, based on
transfected-cell microarray (TCM)</P>
<P STYLE="margin-bottom: 0cm">technology, for the identification of
genes related to cell migration. In the</P>
<P STYLE="margin-bottom: 0cm">present study, we used the TCM chip for
high-throughput screening (HTS) of a</P>
<P STYLE="margin-bottom: 0cm">kinome siRNA library to identify genes
involved in the motility of highly</P>
<P STYLE="margin-bottom: 0cm">invasive NBT-L2b cells.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: We performed HTS using TCM
coupled with a programmed image tracer to</P>
<P STYLE="margin-bottom: 0cm">capture time-lapse fluorescence images
of siRNA-transfected cells and calculated 
</P>
<P STYLE="margin-bottom: 0cm">speeds of cell movement. This first
screening allowed us to identify 52 genes.</P>
<P STYLE="margin-bottom: 0cm">After quantitative PCR (qPCR) and a
second screening by a conventional</P>
<P STYLE="margin-bottom: 0cm">transfection method, we confirmed that
32 of these genes were associated with the</P>
<P STYLE="margin-bottom: 0cm">migration of NBT-L2b cells. We
investigated the subcellular localization of</P>
<P STYLE="margin-bottom: 0cm">proteins and levels of expression of
these 32 genes, and then we used our results</P>
<P STYLE="margin-bottom: 0cm">and databases of protein-protein
interactions (PPIs) to construct a hypothetic</P>
<P STYLE="margin-bottom: 0cm">but comprehensive signal network for
cell migration.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: The genes that we
identified belonged to several functional</P>
<P STYLE="margin-bottom: 0cm">categories, and our pathway analysis
suggested that some of the encoded proteins 
</P>
<P STYLE="margin-bottom: 0cm">functioned as the hubs of networks
required for cell migration. Our signal</P>
<P STYLE="margin-bottom: 0cm">pathways suggest that epidermal growth
factor receptor (EGFR) is an upstream</P>
<P STYLE="margin-bottom: 0cm">regulator in the network, while Src and
GRB2 seem to represent nodes for control 
</P>
<P STYLE="margin-bottom: 0cm">of respective the downstream proteins
that are required to coordinate the many</P>
<P STYLE="margin-bottom: 0cm">cellular events that are involved in
migration. Our microarray appears to be a</P>
<P STYLE="margin-bottom: 0cm">useful tool for the analysis of protein
networks and signal pathways related to</P>
<P STYLE="margin-bottom: 0cm">cancer metastasis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4365556</P>
<P STYLE="margin-bottom: 0cm">PMID: 25652422 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">9. Sci Signal. 2015 Jan 13;8(359):ra4.
doi: 10.1126/scisignal.2005906.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Annotation of human cancers with EGFR
signaling-associated protein complexes</P>
<P STYLE="margin-bottom: 0cm">using proximity ligation assays.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Smith MA(1), Hall R(2), Fisher K(3),
Haake SM(2), Khalil F(4), Schabath MB(5),</P>
<P STYLE="margin-bottom: 0cm">Vuaroqueaux V(6), Fiebig HH(6), Altiok
S(4), Chen YA(3), Haura EB(7).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Thoracic Oncology, H.
Lee Moffitt Cancer Center &amp; Research</P>
<P STYLE="margin-bottom: 0cm">Institute, Tampa, FL 33612, USA.
(2)Graduate Medical Education, H. Lee Moffitt</P>
<P STYLE="margin-bottom: 0cm">Cancer Center &amp; Research Institute,
Tampa, FL 33612, USA. (3)Department of</P>
<P STYLE="margin-bottom: 0cm">Biostatistics, H. Lee Moffitt Cancer
Center &amp; Research Institute, Tampa, FL</P>
<P STYLE="margin-bottom: 0cm">33612, USA. (4)Department of Pathology,
H. Lee Moffitt Cancer Center &amp; Research</P>
<P STYLE="margin-bottom: 0cm">Institute, Tampa, FL 33612, USA.
(5)Department of Cancer Epidemiology, H. Lee</P>
<P STYLE="margin-bottom: 0cm">Moffitt Cancer Center &amp; Research
Institute, Tampa, FL 33612, USA. (6)Oncotest</P>
<P STYLE="margin-bottom: 0cm">GmbH, Am Flughafen 12-14, 79108
Freiburg, Germany. (7)Department of Thoracic</P>
<P STYLE="margin-bottom: 0cm">Oncology, H. Lee Moffitt Cancer Center
&amp; Research Institute, Tampa, FL 33612,</P>
<P STYLE="margin-bottom: 0cm">USA. eric.haura@moffitt.org.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Strategies to measure functional
signaling-associated protein complexes have the 
</P>
<P STYLE="margin-bottom: 0cm">potential to augment current molecular
biomarker assays, such as genotyping and</P>
<P STYLE="margin-bottom: 0cm">expression profiling, used to annotate
diseases. Aberrant activation of epidermal</P>
<P STYLE="margin-bottom: 0cm">growth factor receptor (EGFR) signaling
contributes to diverse cancers. We used a</P>
<P STYLE="margin-bottom: 0cm">proximity ligation assay (PLA) to
detect EGFR in a complex with growth factor</P>
<P STYLE="margin-bottom: 0cm">receptor-bound protein 2 (GRB2), the
major signaling adaptor for EGFR. We used</P>
<P STYLE="margin-bottom: 0cm">multiple lung cancer cell lines to
develop and characterize EGFR:GRB2 PLA and</P>
<P STYLE="margin-bottom: 0cm">correlated this assay with established
biochemical measures of EGFR signaling. In</P>
<P STYLE="margin-bottom: 0cm">a panel of patient-derived xenografts
in mice, the intensity of EGFR:GRB2 PLA</P>
<P STYLE="margin-bottom: 0cm">correlated with the reduction in tumor
size in response to the EGFR inhibitor</P>
<P STYLE="margin-bottom: 0cm">cetuximab. In tumor biopsies from three
cohorts of lung cancer patients, positive</P>
<P STYLE="margin-bottom: 0cm">EGFR:GRB2 PLA was observed in patients
with and without EGFR mutations, and the</P>
<P STYLE="margin-bottom: 0cm">intensity of EGFR:GRB2 PLA was
predictive of overall survival in an EGFR</P>
<P STYLE="margin-bottom: 0cm">inhibitor-treated cohort. Thus, we
established the feasibility of using PLA to</P>
<P STYLE="margin-bottom: 0cm">measure EGFR signaling-associated
protein complexes in patient-based materials,</P>
<P STYLE="margin-bottom: 0cm">suggesting the potential for similar
assays for a broader array of receptor</P>
<P STYLE="margin-bottom: 0cm">tyrosine kinases and other key
signaling molecules.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Association
for the Advancement of Science.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4440040 [Available on
2016-01-13]</P>
<P STYLE="margin-bottom: 0cm">PMID: 25587191 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">10. Chin J Physiol. 2014 Dec
31;57(6):350-7. doi: 10.4077/CJP.2014.BAD281.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Effects of RING-SH2Grb², a chimeric
protein containing the E3 ligase domain of</P>
<P STYLE="margin-bottom: 0cm">Cbl, on the EGFR pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lee WH(1), Wang PY, Lin YH, Chou HY,
Lee YH, Lee CK, Pai LM.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Graduate Institute of Biomedical
Science, College of Medicine, Taiwan,</P>
<P STYLE="margin-bottom: 0cm">Republic of China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The E3 ubiquitin-protein ligase Casitas
B-lineage lymphoma protein (Cbl)</P>
<P STYLE="margin-bottom: 0cm">negatively regulates epidermal growth
factor receptor (EGFR) signaling pathway in</P>
<P STYLE="margin-bottom: 0cm">many organisms, and has crucial roles
in cell growth, development and human</P>
<P STYLE="margin-bottom: 0cm">pathologies, including lung cancers.
RING-SH2Grb² a chimeric protein of 215 amino</P>
<P STYLE="margin-bottom: 0cm">acids containing the RING domain of Cbl
that provides E3 ligase activity, and the</P>
<P STYLE="margin-bottom: 0cm">SH2 domain of Grb2 that serves as an
adaptor for EGFR. In this study, we</P>
<P STYLE="margin-bottom: 0cm">demonstrated that RING-SH2Grb² could
promote the ubiquitinylation and degradation</P>
<P STYLE="margin-bottom: 0cm">of EGFR in a human non-small cell lung
carcinoma cell line H1299. Moreover, we</P>
<P STYLE="margin-bottom: 0cm">discovered that the RING-SH2Grb²
chimera promoted the internalization of</P>
<P STYLE="margin-bottom: 0cm">ligand-bound EGFR, inhibited the growth
of H1299 cells, and significantly</P>
<P STYLE="margin-bottom: 0cm">suppressed tumor growth in a xenograft
mouse model. In summary, our results</P>
<P STYLE="margin-bottom: 0cm">revealed a potential new cancer
therapeutic approach for non-small cell lung</P>
<P STYLE="margin-bottom: 0cm">cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25575524 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">11. Cancer Lett. 2015 Apr
1;359(1):57-64. doi: 10.1016/j.canlet.2014.12.043. Epub</P>
<P STYLE="margin-bottom: 0cm">2015 Jan 5.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Chimeric ubiquitin ligases inhibit
non-small cell lung cancer via negative</P>
<P STYLE="margin-bottom: 0cm">modulation of EGFR signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zhong D(1), Ru Y(2), Wang Q(2), Zhang
J(3), Zhang J(2), Wei J(4), Wu J(5), Yao</P>
<P STYLE="margin-bottom: 0cm">L(2), Li X(6), Li X(7).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)State Key Laboratory of Cancer
Biology, Department of Biochemistry and</P>
<P STYLE="margin-bottom: 0cm">Molecular Biology, the Fourth Military
Medical University, Xi'an, Shaanxi 710032,</P>
<P STYLE="margin-bottom: 0cm">China; Department of Thoracic Surgery,
Tangdu Hospital, the Fourth Military</P>
<P STYLE="margin-bottom: 0cm">Medical University, Xi'an, Shaanxi
710038, China. (2)State Key Laboratory of</P>
<P STYLE="margin-bottom: 0cm">Cancer Biology, Department of
Biochemistry and Molecular Biology, the Fourth</P>
<P STYLE="margin-bottom: 0cm">Military Medical University, Xi'an,
Shaanxi 710032, China. (3)Experiment Teaching</P>
<P STYLE="margin-bottom: 0cm">Center, the Fourth Military Medical
University, Xi'an, Shaanxi 710032, China.</P>
<P STYLE="margin-bottom: 0cm">(4)Department of Clinical Laboratory
and Research Center, Tangdu Hospital, the</P>
<P STYLE="margin-bottom: 0cm">Fourth Military Medical University,
Xi'an, Shaanxi 710038, China. (5)Department</P>
<P STYLE="margin-bottom: 0cm">of Orthopaedics, the Affiliated
Southeast Hospital of Xiamen University,</P>
<P STYLE="margin-bottom: 0cm">Zhangzhou, Fujian 363000, China.
(6)Department of Thoracic Surgery, Tangdu</P>
<P STYLE="margin-bottom: 0cm">Hospital, the Fourth Military Medical
University, Xi'an, Shaanxi 710038, China.</P>
<P STYLE="margin-bottom: 0cm">Electronic address:
lxfchest@fmmu.edu.cn. (7)State Key Laboratory of Cancer</P>
<P STYLE="margin-bottom: 0cm">Biology, Department of Biochemistry and
Molecular Biology, the Fourth Military</P>
<P STYLE="margin-bottom: 0cm">Medical University, Xi'an, Shaanxi
710032, China. Electronic address:</P>
<P STYLE="margin-bottom: 0cm">lixia@fmmu.edu.cn.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Targeting epidermal growth factor
receptor (EGFR) represents a promising</P>
<P STYLE="margin-bottom: 0cm">therapeutic strategy for non-small cell
lung cancers (NSCLC). The</P>
<P STYLE="margin-bottom: 0cm">ubiquitin-proteasome system (UPS) is a
major pathway that mediates protein</P>
<P STYLE="margin-bottom: 0cm">degradation. To target the degradation
of EGFR, we generated two artificial</P>
<P STYLE="margin-bottom: 0cm">ubiquitin ligases, which are composed
of an EGFR-binding domain, i.e., the SH2</P>
<P STYLE="margin-bottom: 0cm">domain from growth factor receptor
binding protein 2 (Grb2), and an ubiquitin</P>
<P STYLE="margin-bottom: 0cm">ligase catalytic domain, i.e., the RING
domain from Cbl or the U-box domain from 
</P>
<P STYLE="margin-bottom: 0cm">CHIP. When the chimeric ubiquitin
ligases were introduced into lung cancer SPC-A1</P>
<P STYLE="margin-bottom: 0cm">cells, they effectively associated with
EGFR, promoted its ubiquitination and</P>
<P STYLE="margin-bottom: 0cm">degradation, and as a result, blocked
the downstream PI3K-Akt signal pathway.</P>
<P STYLE="margin-bottom: 0cm">Moreover, cell proliferation and
invasion were inhibited, the sensitivity to</P>
<P STYLE="margin-bottom: 0cm">docetaxel-induced apoptosis was
enhanced and the tumorigenicity was suppressed.</P>
<P STYLE="margin-bottom: 0cm">In conclusion, negative modulation of
EGFR signaling by the chimeric ubiquitin</P>
<P STYLE="margin-bottom: 0cm">ligases can inhibit malignancy of
SPC-A1 cells and sensitize these cells to</P>
<P STYLE="margin-bottom: 0cm">chemotherapy, thus it may be applied to
targeted therapy for NSCLC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2014 Elsevier Ireland Ltd.
All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25573345 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">12. J R Soc Interface. 2015 Feb
6;12(103). pii: 20141215. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1098/rsif.2014.1215.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Analytical reduction of combinatorial
complexity arising from multiple protein</P>
<P STYLE="margin-bottom: 0cm">modification sites.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Birtwistle MR(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Pharmacology and
Systems Therapeutics, Icahn School of Medicine 
</P>
<P STYLE="margin-bottom: 0cm">at Mount Sinai, One Gustave L. Levy
Place, New York, NY 10029, USA</P>
<P STYLE="margin-bottom: 0cm">marc.birtwistle@mssm.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Combinatorial complexity is a major
obstacle to ordinary differential equation</P>
<P STYLE="margin-bottom: 0cm">(ODE) modelling of biochemical
networks. For example, a protein with 10 sites</P>
<P STYLE="margin-bottom: 0cm">that can each be unphosphorylated,
phosphorylated or bound to adaptor protein</P>
<P STYLE="margin-bottom: 0cm">requires 3(10) ODEs. This problem is
often dealt with by making ad hoc</P>
<P STYLE="margin-bottom: 0cm">assumptions which have unclear validity
and disallow modelling of site-specific</P>
<P STYLE="margin-bottom: 0cm">dynamics. Such site-specific dynamics,
however, are important in many biological 
</P>
<P STYLE="margin-bottom: 0cm">systems. We show here that for a common
biological situation where adaptors bind 
</P>
<P STYLE="margin-bottom: 0cm">modified sites, binding is slow
relative to modification/demodification, and</P>
<P STYLE="margin-bottom: 0cm">binding to one modified site hinders
binding to other sites, for a protein with n</P>
<P STYLE="margin-bottom: 0cm">modification sites and m adaptor
proteins the number of ODEs needed to simulate</P>
<P STYLE="margin-bottom: 0cm">the site-specific dynamics of
biologically relevant, lumped bound adaptor states 
</P>
<P STYLE="margin-bottom: 0cm">is independent of the number of
modification sites and equal to m + 1, giving a</P>
<P STYLE="margin-bottom: 0cm">significant reduction in system size.
These considerations can be relaxed</P>
<P STYLE="margin-bottom: 0cm">considerably while retaining reasonably
accurate descriptions of the true system 
</P>
<P STYLE="margin-bottom: 0cm">dynamics. We apply the theory to model,
using only 11 ODEs, the dynamics of</P>
<P STYLE="margin-bottom: 0cm">ligand-induced phosphorylation of nine
tyrosines on epidermal growth factor</P>
<P STYLE="margin-bottom: 0cm">receptor (EGFR) and primary recruitment
of six signalling proteins (Grb2, PI3K,</P>
<P STYLE="margin-bottom: 0cm">PLCγ1, SHP2, RasA1 and Shc1). The
model quantitatively accounts for</P>
<P STYLE="margin-bottom: 0cm">experimentally determined site-specific
phosphorylation and dephosphorylation</P>
<P STYLE="margin-bottom: 0cm">rates, differential affinities of
binding proteins for the phosphorylated sites</P>
<P STYLE="margin-bottom: 0cm">and binding protein expression levels.
Analysis suggests that local concentration</P>
<P STYLE="margin-bottom: 0cm">of site-specific phosphatases such as
SHP2 in membrane subdomains by a factor of 
</P>
<P STYLE="margin-bottom: 0cm">approximately 10(7) is critical for
effective site-specific regulation. We</P>
<P STYLE="margin-bottom: 0cm">further show how our framework can be
extended with minimal effort to consider</P>
<P STYLE="margin-bottom: 0cm">binding cooperativity between Grb2 and
c-Cbl, which is important for receptor</P>
<P STYLE="margin-bottom: 0cm">trafficking. Our theory has potentially
broad application to reduce combinatorial</P>
<P STYLE="margin-bottom: 0cm">complexity and allow practical
simulation of a variety ODE models relevant to</P>
<P STYLE="margin-bottom: 0cm">systems biology and pharmacology
applications to allow exploration of key aspects</P>
<P STYLE="margin-bottom: 0cm">of complexity that control signal flux.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2014 The Author(s) Published by the
Royal Society. All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4305424 [Available on
2016-02-06]</P>
<P STYLE="margin-bottom: 0cm">PMID: 25519995 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">13. Genetica. 2014 Dec;142(6):517-23.
doi: 10.1007/s10709-014-9798-x. Epub 2014 Nov</P>
<P STYLE="margin-bottom: 0cm">7.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sequence analysis of the Ras-MAPK
pathway genes SOS1, EGFR &amp; GRB2 in silver foxes</P>
<P STYLE="margin-bottom: 0cm">(Vulpes vulpes): candidate genes for
hereditary hyperplastic gingivitis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Clark JA(1), Tully SJ, Dawn Marshall H.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biology, Memorial
University of Newfoundland, St. John's NL, A1B</P>
<P STYLE="margin-bottom: 0cm">3X9, Canada, j.clark@mun.ca.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hereditary hyperplastic gingivitis
(HHG) is an autosomal recessive disease that</P>
<P STYLE="margin-bottom: 0cm">presents with progressive gingival
proliferation in farmed silver foxes.</P>
<P STYLE="margin-bottom: 0cm">Hereditary gingival fibromatosis (HGF)
is an analogous condition in humans that</P>
<P STYLE="margin-bottom: 0cm">is genetically heterogeneous with
several known autosomal dominant loci. For one 
</P>
<P STYLE="margin-bottom: 0cm">locus the causative mutation is in the
Son of sevenless homologue 1 (SOS1) gene. 
</P>
<P STYLE="margin-bottom: 0cm">For the remaining loci, the molecular
mechanisms are unknown but Ras pathway</P>
<P STYLE="margin-bottom: 0cm">involvement is suspected. Here we
compare sequences for the SOS1 gene, and two</P>
<P STYLE="margin-bottom: 0cm">adjacent genes in the Ras pathway,
growth receptor bound protein 2 (GRB2) and</P>
<P STYLE="margin-bottom: 0cm">epidermal growth factor receptor
(EGFR), between HHG-affected and unaffected</P>
<P STYLE="margin-bottom: 0cm">foxes. We conclude that the known HGF
causative mutation does not cause HHG in</P>
<P STYLE="margin-bottom: 0cm">foxes, nor do the coding regions or
intron-exon boundaries of these three genes</P>
<P STYLE="margin-bottom: 0cm">contain any candidate mutations for fox
gum disease. Patterns of molecular</P>
<P STYLE="margin-bottom: 0cm">evolution among foxes and other mammals
reflect high conservation and strong</P>
<P STYLE="margin-bottom: 0cm">functional constraints for SOS1 and
GRB2 but reveal a lineage-specific pattern of</P>
<P STYLE="margin-bottom: 0cm">variability in EGFR consistent with
mutational rate differences, relaxed</P>
<P STYLE="margin-bottom: 0cm">functional constraints, and possibly
positive selection.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25377643 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">14. Tumour Biol. 2014
Dec;35(12):12497-508. doi: 10.1007/s13277-014-2568-7. Epub 2014</P>
<P STYLE="margin-bottom: 0cm">Sep 14.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Essential role of polymorphism of Gab1,
EGFR, and EGF for the susceptibility of</P>
<P STYLE="margin-bottom: 0cm">biliary tract cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Meng LQ(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of General Surgery,
Shengjing Hospital of China Medical University,</P>
<P STYLE="margin-bottom: 0cm">No. 36 Sanhao Street, Heping District,
Shenyang, Liaoning, 110004, China,</P>
<P STYLE="margin-bottom: 0cm">lingqinm425@163.com.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cholangiocarcinoma is a malignant
neoplasm arising from the epithelial cells</P>
<P STYLE="margin-bottom: 0cm">lining the biliary ducts and its
occurrence can be anatomically classified as</P>
<P STYLE="margin-bottom: 0cm">within the liver (intrahepatic) or
outside the liver (extrahepatic). Extrahepatic</P>
<P STYLE="margin-bottom: 0cm">cholangiocarcinoma, which can be called
as biliary tract cancer (BTC), is the</P>
<P STYLE="margin-bottom: 0cm">most common form of this malignancy,
and its etiology is still unclear. In this</P>
<P STYLE="margin-bottom: 0cm">study, we tried to elucidate the
complicated association between receptor</P>
<P STYLE="margin-bottom: 0cm">tyrosine kinase (RTK) gene
polymorphisms and susceptibility of BTC by analyzing</P>
<P STYLE="margin-bottom: 0cm">frequency distribution of genotypes and
alleles of GRB2-associated-binding</P>
<P STYLE="margin-bottom: 0cm">protein 1 (Gab1), endothelial growth
factor receptor (EGFR), and endothelial</P>
<P STYLE="margin-bottom: 0cm">growth factor (EGF) and identified
potential risk of BTC for people carrying</P>
<P STYLE="margin-bottom: 0cm">specific genotype of Gab1 and EGFR. Two
hundred twenty-five and 300 patients with</P>
<P STYLE="margin-bottom: 0cm">BTC and cholelithiasis (gallstone
(GS)), respectively, and 300 controls matched</P>
<P STYLE="margin-bottom: 0cm">by age, sex, and ethnicity with
patients were recruited from Shengjing Hospital</P>
<P STYLE="margin-bottom: 0cm">of China Medical University from
January 2008 to July 2011 with informed</P>
<P STYLE="margin-bottom: 0cm">consents. Genomic DNA of BTC group was
extracted and purified from</P>
<P STYLE="margin-bottom: 0cm">formalin-fixed, paraffin-embedded tumor
tissue sections using QiAamp DNA FFPE</P>
<P STYLE="margin-bottom: 0cm">Tissue kit. For GS group and controls,
DNA was extracted from peripheral blood</P>
<P STYLE="margin-bottom: 0cm">leukocytes using genomic DNA extraction
kit from Aid Lab. Target genes of RTK</P>
<P STYLE="margin-bottom: 0cm">family were identified from National
Center of Biotechnology Information (NCBI)</P>
<P STYLE="margin-bottom: 0cm">SNP database and Japanese Single
Nucleotide Polymorphisms (JSNP) database.</P>
<P STYLE="margin-bottom: 0cm">Frequency distribution of genotypes and
alleles was analyzed using HapMap Project</P>
<P STYLE="margin-bottom: 0cm">database. All of the statistical
analysis was conducted with SPSS 13.0 software. 
</P>
<P STYLE="margin-bottom: 0cm">Eight loci were identified for Gab1
(4), EGFR (3), and EGF (1) as the target</P>
<P STYLE="margin-bottom: 0cm">single-nucleotide polymorphisms (SNPs)
for the association of gene polymorphisms 
</P>
<P STYLE="margin-bottom: 0cm">and BTC. A/A genotype and A allele of
rs3805246 in Gab1 and G/G genotype and G</P>
<P STYLE="margin-bottom: 0cm">allele of rs2017000 in EGFR were
significantly higher in BTC group than in GS</P>
<P STYLE="margin-bottom: 0cm">group or controls. After controlling
for BMI, age, gender, and smoking habit,</P>
<P STYLE="margin-bottom: 0cm">patients with &quot;A/A + G/A&quot; had
2.154 times odds to have BTC; as for patients with 
</P>
<P STYLE="margin-bottom: 0cm">&quot;A/A&quot; only, they still had
1.976 times odds to have BTC. In the rs2017000 of</P>
<P STYLE="margin-bottom: 0cm">EGFR, patients with &quot;G/G + G/A&quot;
had 1.772 times odds to have BTC, and patients</P>
<P STYLE="margin-bottom: 0cm">with &quot;G/G&quot; only had 1.530
times odds to have BTC. Furthermore, patients with A/A 
</P>
<P STYLE="margin-bottom: 0cm">in rs3805246 and G/G in rs2017000
simultaneously had 1.620 times chance to have</P>
<P STYLE="margin-bottom: 0cm">BTC than people with other genotypes.
This study explored the independent</P>
<P STYLE="margin-bottom: 0cm">potential effect of EGFR signaling
transduction pathway and its downstream</P>
<P STYLE="margin-bottom: 0cm">element Gab1 and the gene-gene
interaction on the disease mechanism of BTC in the</P>
<P STYLE="margin-bottom: 0cm">perspective of genetics and molecular
epidemiology.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25217982 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">15. BMB Rep. 2014 Oct;47(10):581-6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">YAC tripeptide of epidermal growth
factor promotes the proliferation of HaCaT</P>
<P STYLE="margin-bottom: 0cm">keratinocytes through activation of
EGFR.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Yoo YH(1), Kim YR(1), Kim MS(1), Lee
KJ(1), Park KH(1), Hahn JH(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Anatomy and Cell
Biology, School of Medicine, Kangwon National</P>
<P STYLE="margin-bottom: 0cm">University, Chuncheon 200-701, Korea.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Epidermal growth factor (EGF) is known
to play key roles in skin regeneration and</P>
<P STYLE="margin-bottom: 0cm">wound-healing. Here, we demonstrate
that Pep2-YAC, a tripeptide covering residues</P>
<P STYLE="margin-bottom: 0cm">29-31 in the B loop of EGF, promotes
the proliferation of HaCaT keratinocytes</P>
<P STYLE="margin-bottom: 0cm">with activity comparable to EGF. The
treatment of HaCaT cells with Pep2-YAC</P>
<P STYLE="margin-bottom: 0cm">induced phosphorylation,
internalization, and degradation of EGFR and</P>
<P STYLE="margin-bottom: 0cm">organization of signaling complexes,
which consist of Grb2, Gab1, SHP2, and PI3K.</P>
<P STYLE="margin-bottom: 0cm">In addition, it stimulated the
phosphorylation of ERK1/2 at Thr 202/Tyr 204 and</P>
<P STYLE="margin-bottom: 0cm">of Akt1 at Ser 473 and the nuclear
translocation of EGFR, STAT3, c-Jun, and</P>
<P STYLE="margin-bottom: 0cm">c-Fos. These results suggest that
Pep2-YAC may be useful as a therapeutic agent</P>
<P STYLE="margin-bottom: 0cm">for skin regeneration and wound-healing
as an EGFR agonist.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4261517</P>
<P STYLE="margin-bottom: 0cm">PMID: 25179402 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">16. Cancer Res. 2014 Oct
15;74(20):5866-77. doi: 10.1158/0008-5472.CAN-14-0806. Epub 
</P>
<P STYLE="margin-bottom: 0cm">2014 Aug 28.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Dsh homolog DVL3 mediates resistance to
IGFIR inhibition by regulating IGF-RAS</P>
<P STYLE="margin-bottom: 0cm">signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gao S(1), Bajrami I(2), Verrill C(3),
Kigozi A(2), Ouaret D(1), Aleksic T(1),</P>
<P STYLE="margin-bottom: 0cm">Asher R(3), Han C(1), Allen P(4),
Bailey D(4), Feller S(1), Kashima T(1),</P>
<P STYLE="margin-bottom: 0cm">Athanasou N(5), Blay JY(6), Schmitz
S(7), Machiels JP(7), Upile N(8), Jones</P>
<P STYLE="margin-bottom: 0cm">TM(8), Thalmann G(9), Ashraf SQ(1),
Wilding JL(1), Bodmer WF(1), Middleton</P>
<P STYLE="margin-bottom: 0cm">MR(10), Ashworth A(2), Lord CJ(2),
Macaulay VM(11).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Oncology, Weatherall
Institute of Molecular Medicine, John</P>
<P STYLE="margin-bottom: 0cm">Radcliffe Hospital, University of
Oxford, Oxford, United Kingdom. (2)Breakthrough</P>
<P STYLE="margin-bottom: 0cm">Breast Cancer Research Centre, The
Institute of Cancer Research, London, United</P>
<P STYLE="margin-bottom: 0cm">Kingdom. (3)Department of Cellular
Pathology and NIHR Oxford Biomedical Research 
</P>
<P STYLE="margin-bottom: 0cm">Centre, Oxford University Hospitals NHS
Trust, John Radcliffe Hospital, Oxford,</P>
<P STYLE="margin-bottom: 0cm">United Kingdom. (4)Department of
Cellular Pathology, Oxford University Hospitals 
</P>
<P STYLE="margin-bottom: 0cm">NHS Trust, John Radcliffe Hospital,
Oxford, United Kingdom. (5)Nuffield</P>
<P STYLE="margin-bottom: 0cm">Department of Orthopaedics,
Rheumatology and Musculoskeletal Science, Department 
</P>
<P STYLE="margin-bottom: 0cm">of Pathology, Nuffield Orthopaedic
Centre, Oxford, United Kingdom. (6)University 
</P>
<P STYLE="margin-bottom: 0cm">Claude Bernard Lyon I, Centre Léon
Bérard, Department of Medicine, Lyon, France. 
</P>
<P STYLE="margin-bottom: 0cm">(7)Service d'oncologie médicale,
Cliniques universitaires Saint-Luc, Université</P>
<P STYLE="margin-bottom: 0cm">catholique de Louvain, Brussels,
Belgium. (8)Liverpool CR-UK Centre, Department</P>
<P STYLE="margin-bottom: 0cm">of Molecular and Clinical Cancer
Medicine, Royal Liverpool University Hospital,</P>
<P STYLE="margin-bottom: 0cm">Liverpool, United Kingdom.
(9)Department of Urology, Inselspital, Bern, Bern,</P>
<P STYLE="margin-bottom: 0cm">Switzerland. (10)Oxford Cancer and
Haematology Centre, Oxford University</P>
<P STYLE="margin-bottom: 0cm">Hospitals NHS Trust, Churchill
Hospital, Oxford, Liverpool, United Kingdom.</P>
<P STYLE="margin-bottom: 0cm">(11)Department of Oncology, Weatherall
Institute of Molecular Medicine, John</P>
<P STYLE="margin-bottom: 0cm">Radcliffe Hospital, University of
Oxford, Oxford, United Kingdom. Oxford Cancer</P>
<P STYLE="margin-bottom: 0cm">and Haematology Centre, Oxford
University Hospitals NHS Trust, Churchill</P>
<P STYLE="margin-bottom: 0cm">Hospital, Oxford, Liverpool, United
Kingdom.</P>
<P STYLE="margin-bottom: 0cm">valentine.macaulay@oncology.ox.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Drugs that inhibit insulin-like growth
factor 1 (IGFI) receptor IGFIR were</P>
<P STYLE="margin-bottom: 0cm">encouraging in early trials, but
predictive biomarkers were lacking and the drugs</P>
<P STYLE="margin-bottom: 0cm">provided insufficient benefit in
unselected patients. In this study, we used</P>
<P STYLE="margin-bottom: 0cm">genetic screening and downstream
validation to identify the WNT pathway element</P>
<P STYLE="margin-bottom: 0cm">DVL3 as a mediator of resistance to
IGFIR inhibition. Sensitivity to IGFIR</P>
<P STYLE="margin-bottom: 0cm">inhibition was enhanced specifically in
vitro and in vivo by genetic or</P>
<P STYLE="margin-bottom: 0cm">pharmacologic blockade of DVL3. In
breast and prostate cancer cells,</P>
<P STYLE="margin-bottom: 0cm">sensitization tracked with enhanced
MEK-ERK activation and relied upon MEK</P>
<P STYLE="margin-bottom: 0cm">activity and DVL3 expression.
Mechanistic investigations showed that DVL3 is</P>
<P STYLE="margin-bottom: 0cm">present in an adaptor complex that
links IGFIR to RAS, which includes Shc, growth</P>
<P STYLE="margin-bottom: 0cm">factor receptor-bound-2 (Grb2),
son-of-sevenless (SOS), and the tumor suppressor 
</P>
<P STYLE="margin-bottom: 0cm">DAB2. Dual DVL and DAB2 blockade
synergized in activating ERKs and sensitizing</P>
<P STYLE="margin-bottom: 0cm">cells to IGFIR inhibition, suggesting a
nonredundant role for DVL3 in the</P>
<P STYLE="margin-bottom: 0cm">Shc-Grb2-SOS complex. Clinically,
tumors that responded to IGFIR inhibition</P>
<P STYLE="margin-bottom: 0cm">contained relatively lower levels of
DVL3 protein than resistant tumors, and DVL3</P>
<P STYLE="margin-bottom: 0cm">levels in tumors correlated inversely
with progression-free survival in patients 
</P>
<P STYLE="margin-bottom: 0cm">treated with IGFIR antibodies. Because
IGFIR does not contain activating</P>
<P STYLE="margin-bottom: 0cm">mutations analogous to EGFR variants
associated with response to EGFR inhibitors,</P>
<P STYLE="margin-bottom: 0cm">we suggest that IGF signaling achieves
an equivalent integration at the</P>
<P STYLE="margin-bottom: 0cm">postreceptor level through adaptor
protein complexes, influencing cellular</P>
<P STYLE="margin-bottom: 0cm">dependence on the IGF axis and
identifying a patient population with potential to</P>
<P STYLE="margin-bottom: 0cm">benefit from IGFIR inhibition.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">©2014 American Association for Cancer
Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25168481 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">17. Sci Signal. 2014 Aug
19;7(339):ra78. doi: 10.1126/scisignal.2005157.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The ErbB4 CYT2 variant protects EGFR
from ligand-induced degradation to enhance</P>
<P STYLE="margin-bottom: 0cm">cancer cell motility.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Kiuchi T(1), Ortiz-Zapater E(2),
Monypenny J(1), Matthews DR(3), Nguyen LK(4),</P>
<P STYLE="margin-bottom: 0cm">Barbeau J(3), Coban O(3), Lawler K(3),
Burford B(5), Rolfe DJ(6), de Rinaldis</P>
<P STYLE="margin-bottom: 0cm">E(5), Dafou D(7), Simpson MA(7),
Woodman N(8), Pinder S(8), Gillett CE(8),</P>
<P STYLE="margin-bottom: 0cm">Devauges V(3), Poland SP(3), Fruhwirth
G(3), Marra P(5), Boersma YL(9), Plückthun</P>
<P STYLE="margin-bottom: 0cm">A(9), Gullick WJ(10), Yarden Y(11),
Santis G(2), Winn M(12), Kholodenko BN(4),</P>
<P STYLE="margin-bottom: 0cm">Martin-Fernandez ML(6), Parker P(13),
Tutt A(5), Ameer-Beg SM(14), Ng T(15).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Richard Dimbleby Department of
Cancer Research, Randall Division of Cell and</P>
<P STYLE="margin-bottom: 0cm">Molecular Biophysics, King's College
London, Guy's Medical School Campus, London 
</P>
<P STYLE="margin-bottom: 0cm">SE1 1UL, UK. Division of Cancer
Studies, King's College London, London SE1 1UL,</P>
<P STYLE="margin-bottom: 0cm">UK. Breakthrough Breast Cancer Research
Unit, Research Oncology, King's College</P>
<P STYLE="margin-bottom: 0cm">London, Guy's Hospital, London SE1 9RT,
UK. (2)Department of Asthma, Allergy and 
</P>
<P STYLE="margin-bottom: 0cm">Respiratory Science, King's College
London, Guy's Hospital, London SE1 9RT, UK.</P>
<P STYLE="margin-bottom: 0cm">(3)Richard Dimbleby Department of
Cancer Research, Randall Division of Cell and</P>
<P STYLE="margin-bottom: 0cm">Molecular Biophysics, King's College
London, Guy's Medical School Campus, London 
</P>
<P STYLE="margin-bottom: 0cm">SE1 1UL, UK. Division of Cancer
Studies, King's College London, London SE1 1UL,</P>
<P STYLE="margin-bottom: 0cm">UK. (4)Systems Biology Ireland,
University College Dublin, Belfield, Dublin 4,</P>
<P STYLE="margin-bottom: 0cm">Ireland. (5)Breakthrough Breast Cancer
Research Unit, Research Oncology, King's</P>
<P STYLE="margin-bottom: 0cm">College London, Guy's Hospital, London
SE1 9RT, UK. (6)Central Laser Facility,</P>
<P STYLE="margin-bottom: 0cm">Rutherford Appleton Laboratory, Science
and Technology Facilities Council,</P>
<P STYLE="margin-bottom: 0cm">Research Complex at Harwell, Didcot
OX11 0QX, UK. (7)Genetics and Molecular</P>
<P STYLE="margin-bottom: 0cm">Medicine, King's College London, Guy's
Hospital, London SE1 9RT, UK. (8)Guy's and</P>
<P STYLE="margin-bottom: 0cm">St Thomas' Breast Tissue and Data Bank,
King's College London, Guy's Hospital,</P>
<P STYLE="margin-bottom: 0cm">London SE1 9RT, UK. Research Oncology,
Division of Cancer Studies, King's College</P>
<P STYLE="margin-bottom: 0cm">London, Guy's Hospital, London SE1 9RT,
UK. (9)Department of Biochemistry,</P>
<P STYLE="margin-bottom: 0cm">University of Zurich, 190, 8057 Zurich,
Switzerland. (10)Department of</P>
<P STYLE="margin-bottom: 0cm">Biosciences, University of Kent,
Canterbury, Kent CT2 7NJ, UK. (11)Department of 
</P>
<P STYLE="margin-bottom: 0cm">Biological Regulation, The Weizmann
Institute of Science, Rehovot 76100, Israel. 
</P>
<P STYLE="margin-bottom: 0cm">(12)Computational Science and
Engineering Department, Daresbury Laboratory,</P>
<P STYLE="margin-bottom: 0cm">Science and Technology Facilities
Council, Research Complex at Warrington,</P>
<P STYLE="margin-bottom: 0cm">Warrington WA4 4AD, UK. (13)Division of
Cancer Studies, King's College London,</P>
<P STYLE="margin-bottom: 0cm">London SE1 1UL, UK. Protein
Phosphorylation Laboratory, Cancer Research UK,</P>
<P STYLE="margin-bottom: 0cm">London Research Institute, Lincoln's
Inn Fields, London WC2A 3PX, UK. (14)Richard</P>
<P STYLE="margin-bottom: 0cm">Dimbleby Department of Cancer Research,
Randall Division of Cell and Molecular</P>
<P STYLE="margin-bottom: 0cm">Biophysics, King's College London,
Guy's Medical School Campus, London SE1 1UL,</P>
<P STYLE="margin-bottom: 0cm">UK. Division of Cancer Studies, King's
College London, London SE1 1UL, UK.</P>
<P STYLE="margin-bottom: 0cm">simon.ameer-beg@kcl.ac.uk
tony.ng@kcl.ac.uk. (15)Richard Dimbleby Department of</P>
<P STYLE="margin-bottom: 0cm">Cancer Research, Randall Division of
Cell and Molecular Biophysics, King's</P>
<P STYLE="margin-bottom: 0cm">College London, Guy's Medical School
Campus, London SE1 1UL, UK. Division of</P>
<P STYLE="margin-bottom: 0cm">Cancer Studies, King's College London,
London SE1 1UL, UK. Breakthrough Breast</P>
<P STYLE="margin-bottom: 0cm">Cancer Research Unit, Research
Oncology, King's College London, Guy's Hospital,</P>
<P STYLE="margin-bottom: 0cm">London SE1 9RT, UK. UCL Cancer
Institute, Paul O'Gorman Building, University</P>
<P STYLE="margin-bottom: 0cm">College London, London WC1E 6BT, UK.
simon.ameer-beg@kcl.ac.uk tony.ng@kcl.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The epidermal growth factor receptor
(EGFR) is a member of the ErbB family that</P>
<P STYLE="margin-bottom: 0cm">can promote the migration and
proliferation of breast cancer cells. Therapies</P>
<P STYLE="margin-bottom: 0cm">that target EGFR can promote the
dimerization of EGFR with other ErbB receptors, 
</P>
<P STYLE="margin-bottom: 0cm">which is associated with the
development of drug resistance. Understanding how</P>
<P STYLE="margin-bottom: 0cm">interactions among ErbB receptors alter
EGFR biology could provide avenues for</P>
<P STYLE="margin-bottom: 0cm">improving cancer therapy. We found that
EGFR interacted directly with the CYT1</P>
<P STYLE="margin-bottom: 0cm">and CYT2 variants of ErbB4 and the
membrane-anchored intracellular domain (mICD).</P>
<P STYLE="margin-bottom: 0cm">The CYT2 variant, but not the CYT1
variant, protected EGFR from ligand-induced</P>
<P STYLE="margin-bottom: 0cm">degradation by competing with EGFR for
binding to a complex containing the E3</P>
<P STYLE="margin-bottom: 0cm">ubiquitin ligase c-Cbl and the adaptor
Grb2. Cultured breast cancer cells</P>
<P STYLE="margin-bottom: 0cm">overexpressing both EGFR and ErbB4 CYT2
mICD exhibited increased migration. With 
</P>
<P STYLE="margin-bottom: 0cm">molecular modeling, we identified
residues involved in stabilizing the EGFR</P>
<P STYLE="margin-bottom: 0cm">dimer. Mutation of these residues in
the dimer interface destabilized the complex</P>
<P STYLE="margin-bottom: 0cm">in cells and abrogated growth
factor-stimulated cell migration. An exon array</P>
<P STYLE="margin-bottom: 0cm">analysis of 155 breast tumors revealed
that the relative mRNA abundance of the</P>
<P STYLE="margin-bottom: 0cm">ErbB4 CYT2 variant was increased in ER+
HER2- breast cancer patients, suggesting 
</P>
<P STYLE="margin-bottom: 0cm">that our findings could be clinically
relevant. We propose a mechanism whereby</P>
<P STYLE="margin-bottom: 0cm">competition for binding to c-Cbl in an
ErbB signaling heterodimer promotes</P>
<P STYLE="margin-bottom: 0cm">migration in response to a growth
factor gradient.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2014, American Association
for the Advancement of Science.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25140053 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">18. Zhonghua Bing Li Xue Za Zhi. 2014
May;43(5):313-7.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">[Expression profiling of
metastasis-related microRNAs in early esophageal</P>
<P STYLE="margin-bottom: 0cm">squamous cell carcinoma].</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">[Article in Chinese]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lu J(1), Xue L, Jin M, Lyu N(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Beijing Chaoyang Hospital, Capital
Medical University, Beijing 100020, China. 
</P>
<P STYLE="margin-bottom: 0cm">(2)Cancer Institute and Hospital,
Chinese Academy of Medical Sciences, Beijing</P>
<P STYLE="margin-bottom: 0cm">100021, China. E-mail:nlu03@126.com.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">OBJECTIVE: To study the difference of
microRNA (miRNA) expression between two</P>
<P STYLE="margin-bottom: 0cm">groups of early stage (pT1N0)
esophageal squamous cell carcinoma (ESCC) patients 
</P>
<P STYLE="margin-bottom: 0cm">who had different outcome and the
prognostic significance of different miRNA in</P>
<P STYLE="margin-bottom: 0cm">metastatic of early ESCC, and to
identify useful prognostic markers in the</P>
<P STYLE="margin-bottom: 0cm">selection of appropriate treatment for
early ESCC patients.</P>
<P STYLE="margin-bottom: 0cm">METHODS: TaqMan human miRNA arrays and
bioinformatics were used to detect and</P>
<P STYLE="margin-bottom: 0cm">analyze the expression profiles of
miRNAs in the two groups, and RT-PCR was used 
</P>
<P STYLE="margin-bottom: 0cm">to verify the differences in miRNA
expression.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: The miRNA arrays revealed a
total of 41 markedly changed miRNAs in the</P>
<P STYLE="margin-bottom: 0cm">survival group compared with the death
group. Bioinformatics analysis, prediction</P>
<P STYLE="margin-bottom: 0cm">and significant function analyses of
targeted genes and pathway analysis</P>
<P STYLE="margin-bottom: 0cm">identified that miR-27a, miR-143 and
miR-886-5p levels were increased or</P>
<P STYLE="margin-bottom: 0cm">decreased by seven-folds or more. The
enriched target genes were GRB2, SOS1,</P>
<P STYLE="margin-bottom: 0cm">MAPK1, EGFR, CBL, SPRY2, RPS6KA5,
IGF1R, NGFR, MAPK14 and CREB1. These genes were</P>
<P STYLE="margin-bottom: 0cm">significantly related to the following
signaling pathways, i.e.Sprouty regulation</P>
<P STYLE="margin-bottom: 0cm">of tyrosine kinase signals pathway,
Erk1/Erk2 Mapk signaling pathway and</P>
<P STYLE="margin-bottom: 0cm">transcription factor CREB and its
extracellular signals.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: miR-27a, miR-886-5p, and
miR-143 may be potential prognostic markers</P>
<P STYLE="margin-bottom: 0cm">of metastasis for early ESCC. The
detection of these miRNAs plays a directive</P>
<P STYLE="margin-bottom: 0cm">role for the treatment options of early
ESCC. The regulation of targeted genes</P>
<P STYLE="margin-bottom: 0cm">and mechanism remain to be further
studied.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25030863 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">19. Ann Surg Oncol. 2014 Dec;21 Suppl
4:S743-9. doi: 10.1245/s10434-014-3889-x. Epub 
</P>
<P STYLE="margin-bottom: 0cm">2014 Jul 17.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Clinical significance of GAB2, a
scaffolding/docking protein acting downstream of</P>
<P STYLE="margin-bottom: 0cm">EGFR in human colorectal cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Matsumura T(1), Sugimachi K, Takahashi
Y, Uchi R, Sawada G, Ueda M, Hirata H,</P>
<P STYLE="margin-bottom: 0cm">Sakimura S, Ueo H, Takano Y, Kurashige
J, Shinden Y, Eguchi H, Sudo T, Yamamoto</P>
<P STYLE="margin-bottom: 0cm">H, Doki Y, Mori M, Mimori K.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Surgery, Kyushu
University Beppu Hospital, Beppu, Oita, Japan,</P>
<P STYLE="margin-bottom: 0cm">tmatsumura@beppu.kyushu-u.ac.jp.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PURPOSE: Recent studies indicated that
the scaffolding adaptor protein GAB2</P>
<P STYLE="margin-bottom: 0cm">(GRB2-associated binding protein 2)
plays a critical role in the proliferation</P>
<P STYLE="margin-bottom: 0cm">and migration of various cancers. This
study aimed to determine the role of</P>
<P STYLE="margin-bottom: 0cm">aberrant GAB2 expression in human
colorectal cancer (CRC).</P>
<P STYLE="margin-bottom: 0cm">METHODS: Quantitative real-time reverse
transcription polymerase chain reaction</P>
<P STYLE="margin-bottom: 0cm">was used to evaluate GAB2 mRNA
expression in 152 CRC tissues samples to determine</P>
<P STYLE="margin-bottom: 0cm">the clinicopathological significance of
GAB2 expression. We also performed in</P>
<P STYLE="margin-bottom: 0cm">vitro proliferation assays using
siGAB2-transfected CRC cells.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: GAB2 expression in tumor
colorectal tissues was significantly higher</P>
<P STYLE="margin-bottom: 0cm">than in normal colorectal tissues (p =
0.0212). High GAB2 expression levels were 
</P>
<P STYLE="margin-bottom: 0cm">associated with malignant
clinicopathologic potential factors, including</P>
<P STYLE="margin-bottom: 0cm">lymphatic invasion (p = 0.0003), venous
invasion (p = 0.0170), and liver</P>
<P STYLE="margin-bottom: 0cm">metastasis (p = 0.0144). The survival
rate of patients with high GAB2 expression 
</P>
<P STYLE="margin-bottom: 0cm">levels was significantly lower than
that of patients with low GAB2 expression (p 
</P>
<P STYLE="margin-bottom: 0cm">= 0.0074). Multivariate analysis
indicated that GAB2 expression was a factor</P>
<P STYLE="margin-bottom: 0cm">affecting lymph node metastasis. Cell
proliferation was significantly suppressed 
</P>
<P STYLE="margin-bottom: 0cm">by siGAB2 expression in CRC cells in
vitro.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: GAB2 expression was
associated with lymph node metastasis and may</P>
<P STYLE="margin-bottom: 0cm">play a role in the growth and
metastasis of CRC. These results suggest that GAB2 
</P>
<P STYLE="margin-bottom: 0cm">is a potential therapeutic target in
CRC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25029990 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">20. ACS Synth Biol. 2015 Apr
17;4(4):421-9. doi: 10.1021/sb500083t. Epub 2014 Jul 9.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Rapid evaluation of tyrosine kinase
activity of membrane-integrated human</P>
<P STYLE="margin-bottom: 0cm">epidermal growth factor receptor using
the yeast Gγ recruitment system.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Fukuda N(1), Honda S(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Biomedical Research Institute,
National Institute of Advanced Industrial</P>
<P STYLE="margin-bottom: 0cm">Science and Technology (AIST), Higashi,
Tsukuba, Ibaraki 305-8566, Japan.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Epidermal growth factor receptor (EGFR)
is a member of the receptor tyrosine</P>
<P STYLE="margin-bottom: 0cm">kinase family and plays key roles in
the regulation of fundamental cellular</P>
<P STYLE="margin-bottom: 0cm">processes, including cell
proliferation, migration, differentiation, and</P>
<P STYLE="margin-bottom: 0cm">survival. Deregulation of EGFR tyrosine
kinase activity is involved in the</P>
<P STYLE="margin-bottom: 0cm">development and progression of human
cancers. In the present study, we attempted 
</P>
<P STYLE="margin-bottom: 0cm">to develop a method to evaluate the
tyrosine kinase activity of human EGFR using 
</P>
<P STYLE="margin-bottom: 0cm">the yeast Gγ recruitment system.
Autophosphorylation of tyrosine residues on the 
</P>
<P STYLE="margin-bottom: 0cm">cytoplasmic tail of EGFR induces
recruitment of Grb2-fused Gγ subunits to the</P>
<P STYLE="margin-bottom: 0cm">inner leaflet of the plasma membrane in
yeast cells, which leads to G-protein</P>
<P STYLE="margin-bottom: 0cm">signal transduction and activation of
downstream signaling events, including</P>
<P STYLE="margin-bottom: 0cm">mating and diploid cell growth. We
demonstrate that our system is applicable for 
</P>
<P STYLE="margin-bottom: 0cm">the evaluation of tyrosine kinase
inhibitors, which are regarded as promising</P>
<P STYLE="margin-bottom: 0cm">drug candidates to prevent the growth
of tumor cells. This approach provides a</P>
<P STYLE="margin-bottom: 0cm">rapid and easy-to-use tool to select
EGFR-targeting tyrosine kinase inhibitors</P>
<P STYLE="margin-bottom: 0cm">that are able to permeate eukaryotic
membranes and function in intracellular</P>
<P STYLE="margin-bottom: 0cm">environments.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25006755 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Pharm Sci Pharmacol. 2014 Jun
1;1(2):160-164.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Modulation of Epidermal Growth Factor
Stimulated ERK Phosphorylation and Cell</P>
<P STYLE="margin-bottom: 0cm">Motility by Inositol Trisphosphate
Kinase.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sekar MC(1), Shahiwala K(1), Leloup
L(2), Wells A(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)College of Pharmacy, University of
Findlay, Findlay, 45840, OH, USA.</P>
<P STYLE="margin-bottom: 0cm">(2)Department of Pathology, University
of Pittsburgh, Pittsburgh, 15261, PA, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Epidermal growth factor [EGF] mediated
stimulation of its receptor in endothelial</P>
<P STYLE="margin-bottom: 0cm">cell [EC] is accompanied by
phosphorylation of the EGF-receptor [EGFR] and</P>
<P STYLE="margin-bottom: 0cm">activation of phospholipase C-γ,
resulting in the breakdown of</P>
<P STYLE="margin-bottom: 0cm">phosphatidylinositol(4,5)-bisphosphate
and generating inositol</P>
<P STYLE="margin-bottom: 0cm">(1,4,5)-trisphosphate [IP3] and
diacylglycerol. IP3 thus formed can be further</P>
<P STYLE="margin-bottom: 0cm">converted to inositol
(1,3,4,5)-tetrakisphosphate [IP4] by an enzyme called</P>
<P STYLE="margin-bottom: 0cm">IP3-kinase [IP3K]. In this study we
have investigated the effect of modulation of</P>
<P STYLE="margin-bottom: 0cm">intracellular IP3K activity by the use
of an inhibitor, 2-trifluoromethyl</P>
<P STYLE="margin-bottom: 0cm">[6-(4-nitrobenzyl)-purine] [IP3KI] and
siRNA against IP3KB on EGF-induced</P>
<P STYLE="margin-bottom: 0cm">ERK-phosphorylation and cell motility.
EGF stimulated ERK-phosphorylation that</P>
<P STYLE="margin-bottom: 0cm">has been implicated in EGF-stimulated
cell migration was inhibited by both IP3KI 
</P>
<P STYLE="margin-bottom: 0cm">and siRNA against IP3KB. Inhibition of
ERK-phosphorylation was accompanied by</P>
<P STYLE="margin-bottom: 0cm">decreased cell migration in the
presence of IP3KI.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4512952</P>
<P STYLE="margin-bottom: 0cm">PMID: 26213696 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. Neurochem Int. 2015 Jul 21. pii:
S0197-0186(15)30009-7. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.neuint.2015.07.007. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Rapidly activated epidermal growth
factor receptor mediates</P>
<P STYLE="margin-bottom: 0cm">lipopolysaccharide-triggered migration
of microglia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Qu WS(1), Liu JL(2), Li CY(1), Li X(1),
Xie MJ(1), Wang W(1), Tian DS(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Neurology, Tongji
Hospital, Tongji Medical College, Huazhong</P>
<P STYLE="margin-bottom: 0cm">University of Science and Technology,
Wuhan, Hubei 430030, P.R. China. (2)Cancer 
</P>
<P STYLE="margin-bottom: 0cm">center, Union Hospital, Tongji Medical
College, Huazhong University of Science</P>
<P STYLE="margin-bottom: 0cm">and Technology, Wuhan 430023, P.R.
China. (3)Department of Neurology, Tongji</P>
<P STYLE="margin-bottom: 0cm">Hospital, Tongji Medical College,
Huazhong University of Science and Technology, 
</P>
<P STYLE="margin-bottom: 0cm">Wuhan, Hubei 430030, P.R. China.
Electronic address: tiands@tjh.tjmu.edu.cn.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Previous reports have suggested that
epidermal growth factor receptor (EGFR) is</P>
<P STYLE="margin-bottom: 0cm">involved in microglia activation
characterized by cell morphology changes,</P>
<P STYLE="margin-bottom: 0cm">cytokine production and cell migration;
and the biochemical regulation of the</P>
<P STYLE="margin-bottom: 0cm">microglia migration is a potential
therapeutic target following CNS inflammatory 
</P>
<P STYLE="margin-bottom: 0cm">damages. However, the role of EGFR in
microglia motility after inflammatory</P>
<P STYLE="margin-bottom: 0cm">stimulation remains unknown. In the
present study, lipopolysaccharide (LPS) was</P>
<P STYLE="margin-bottom: 0cm">found to trigger rapid EGFR
phosphorylation within 10 min, which was sustained</P>
<P STYLE="margin-bottom: 0cm">during long-term stimulation in both
primary microglial cells and the cultured</P>
<P STYLE="margin-bottom: 0cm">BV2 microglial cells, furthermore,
blocking EGFR phosphorylation by AG1478</P>
<P STYLE="margin-bottom: 0cm">significantly attenuated the
LPS-induced chemotactic and chemokinetic migration</P>
<P STYLE="margin-bottom: 0cm">of microglia. In addition, LPS could
initiate calcium oscillation in microglia</P>
<P STYLE="margin-bottom: 0cm">during live-cell recording, however, an
intracellular calcium chelator and a</P>
<P STYLE="margin-bottom: 0cm">selective inhibitor of
calcium/calmodulin-dependent protein kinase II, but not an</P>
<P STYLE="margin-bottom: 0cm">extracellular calcium chelator,
remarkably suppressed the LPS-induced EGFR</P>
<P STYLE="margin-bottom: 0cm">phosphorylation in BV2 microglia cells.
As EGFR is not a traditional receptor for</P>
<P STYLE="margin-bottom: 0cm">LPS, these findings suggest that the
rapid phosphorylation of EGFR is attributed 
</P>
<P STYLE="margin-bottom: 0cm">to the LPS-triggered intracellular
calcium mobilization. By examining the</P>
<P STYLE="margin-bottom: 0cm">downstream signals of EGFR, we further
proved that extracellular signal-regulated</P>
<P STYLE="margin-bottom: 0cm">kinase (ERK) is essential for
EGFR-mediated microglia migration, because ERK</P>
<P STYLE="margin-bottom: 0cm">inhibition attenuated the chemotactic
and chemokinetic migration of microglia</P>
<P STYLE="margin-bottom: 0cm">that had been induced by either LPS or
EGF. Collectively, these results suggest</P>
<P STYLE="margin-bottom: 0cm">that LPS could trigger the rapid
phosphorylation of EGFR and subsequent ERK</P>
<P STYLE="margin-bottom: 0cm">activation through mobilizing calcium
activity, which underlies the microglia</P>
<P STYLE="margin-bottom: 0cm">migration in an inflammatory condition.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015. Published by
Elsevier Ltd.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26209152 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. J Endocrinol Invest. 2015 Jul 25.
[Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Genetics of Cushing's disease: an
update.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Perez-Rivas LG(1), Reincke M.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Medizinische Klinik und Poliklinik
IV, Ludwig-Maximilians-Universität München,</P>
<P STYLE="margin-bottom: 0cm">Ziemssenstrasse 1, 80336, Munich,
Germany, luis.perez@med.lmu.de.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">INTRODUCTION: Cushing's disease (CD)
results from uncontrolled hypercortisolism</P>
<P STYLE="margin-bottom: 0cm">induced by ACTH-secreting corticotroph
adenomas; accordingly, patients diagnosed 
</P>
<P STYLE="margin-bottom: 0cm">with CD usually present several
comorbidities and an increased risk of mortality.</P>
<P STYLE="margin-bottom: 0cm">Hypothesis-driven screenings have led
to identification of rare alterations in a 
</P>
<P STYLE="margin-bottom: 0cm">low number of patients, although the
genetic basis underlying CD has remained</P>
<P STYLE="margin-bottom: 0cm">unclear until recently. Using
whole-exome sequencing, recurrent mutations have</P>
<P STYLE="margin-bottom: 0cm">been reported in the gene coding for
the ubiquitin-specific protease 8 (USP8), a 
</P>
<P STYLE="margin-bottom: 0cm">protein with deubiquitinase (DUB)
activity that modulates the lysosomal turnover 
</P>
<P STYLE="margin-bottom: 0cm">of the EGF receptor (EGFR) and other
membrane proteins.</P>
<P STYLE="margin-bottom: 0cm">METHODS: In this review, we summarize
the recent genetic findings and discuss the</P>
<P STYLE="margin-bottom: 0cm">clinical and pathological implications
of USP8 deregulation in corticotroph</P>
<P STYLE="margin-bottom: 0cm">adenomas.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Mutations in USP8 have
been identified in 35-62 % of functional</P>
<P STYLE="margin-bottom: 0cm">sporadic corticotroph adenomas causing
Cushing's disease, but not in any other</P>
<P STYLE="margin-bottom: 0cm">type of pituitary tumor. These
mutations are found mostly in adult female</P>
<P STYLE="margin-bottom: 0cm">patients and lead to an aberrant DUB
activation by impairing the regulation of</P>
<P STYLE="margin-bottom: 0cm">USP8 by members of the 14-3-3 family of
proteins. The consequence of this</P>
<P STYLE="margin-bottom: 0cm">hyperactivation is a longer retention
of EGFR at the plasma membrane which</P>
<P STYLE="margin-bottom: 0cm">promotes an enhanced production of
ACTH.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26208471 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">4. Neuroscience. 2015 Jul 20. pii:
S0306-4522(15)00635-1. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.neuroscience.2015.07.021.
[Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">EGFR signaling upregulates surface
expression of the GluN2B-containing NMDA</P>
<P STYLE="margin-bottom: 0cm">receptor and contributes to long-term
potentiation in the hippocampus.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Tang Y(1), Ye M(1), Du Y(1), Qiu X(1),
Lv X(1), Yang W(1), Luo J(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Neurobiology, Key
Laboratory of Medical Neurobiology of the</P>
<P STYLE="margin-bottom: 0cm">Ministry of Health of China, Zhejiang
University School of Medicine, Hangzhou,</P>
<P STYLE="margin-bottom: 0cm">Zhejiang 310058, China. (2)Department
of Neurobiology, Key Laboratory of Medical 
</P>
<P STYLE="margin-bottom: 0cm">Neurobiology of the Ministry of Health
of China, Zhejiang University School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, Hangzhou, Zhejiang 310058,
China. Electronic address:</P>
<P STYLE="margin-bottom: 0cm">luojianhong@zju.edu.cn.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">N-methyl-d-aspartate receptors (NMDARs)
have been known to be regulated by</P>
<P STYLE="margin-bottom: 0cm">various receptor tyrosine kinases.
Activation of epidermal growth factor receptor</P>
<P STYLE="margin-bottom: 0cm">(EGFR) specifically increases
NMDAR-mediated currents and enhances long-term</P>
<P STYLE="margin-bottom: 0cm">potentiation (LTP) in the hippocampus.
However, the mechanism through which EGFR 
</P>
<P STYLE="margin-bottom: 0cm">regulates NMDARs remains to be
elucidated. In this study we found that EGFR was</P>
<P STYLE="margin-bottom: 0cm">highly expressed in the hippocampus and
mainly localized in the non-synaptic</P>
<P STYLE="margin-bottom: 0cm">region including the soma and neurites
of cultured hippocampal neurons. EGFR</P>
<P STYLE="margin-bottom: 0cm">activation led to an increase in
ifenprodil-sensitive NMDAR currents. Consistent 
</P>
<P STYLE="margin-bottom: 0cm">with this, we also observed that
surface expression of GluN2B-containing NMDAR</P>
<P STYLE="margin-bottom: 0cm">was upregulated. Our biochemical data
from hippocampal slices and hippocampal</P>
<P STYLE="margin-bottom: 0cm">cultured neurons demonstrated that EGF
treatment in vitro significantly increased</P>
<P STYLE="margin-bottom: 0cm">phosphorylation of the GluN2B subunit
at Y1472 with a coincidental activation of 
</P>
<P STYLE="margin-bottom: 0cm">Src family kinases (SFKs). EGFR
blockade with a specific antagonist BIBX-1382</P>
<P STYLE="margin-bottom: 0cm">attenuated an increase of GluN2B in the
postsynaptic density during</P>
<P STYLE="margin-bottom: 0cm">high-frequency stimulation
(HFS)-induced LTP. Moreover, BIBX blockade</P>
<P STYLE="margin-bottom: 0cm">significantly impaired HFS-induced LTP.
In conclusion, our findings suggest that 
</P>
<P STYLE="margin-bottom: 0cm">EGFR signaling upregulates NMDARs
through modification of the GluN2B subunit, and</P>
<P STYLE="margin-bottom: 0cm">is required for HFS-induced LTP in the
hippocampus.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015 IBRO. Published by
Elsevier Ltd. All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26204818 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">5. BMC Cancer. 2015 Jul 25;15:545. doi:
10.1186/s12885-015-1544-y.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">High basal Wnt signaling is further
induced by PI3K/mTor inhibition but sensitive</P>
<P STYLE="margin-bottom: 0cm">to cSRC inhibition in mammary carcinoma
cell lines with HER2/3 overexpression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Timmermans-Sprang EP(1), Gracanin A(2),
Mol JA(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Clinical Sciences of
Companion Animals, Faculty of Veterinary</P>
<P STYLE="margin-bottom: 0cm">Medicine, Utrecht University, Yalelaan
104, 3584, CM, Utrecht, The Netherlands.</P>
<P STYLE="margin-bottom: 0cm">e.p.m.timmermans@uu.nl. (2)Department
of Clinical Sciences of Companion Animals, 
</P>
<P STYLE="margin-bottom: 0cm">Faculty of Veterinary Medicine, Utrecht
University, Yalelaan 104, 3584, CM,</P>
<P STYLE="margin-bottom: 0cm">Utrecht, The Netherlands.
a.gracanin@uu.nl. (3)Department of Clinical Sciences of</P>
<P STYLE="margin-bottom: 0cm">Companion Animals, Faculty of
Veterinary Medicine, Utrecht University, Yalelaan</P>
<P STYLE="margin-bottom: 0cm">104, 3584, CM, Utrecht, The
Netherlands. j.a.mol@uu.nl.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Elevated basal,
ligand-independent, Wnt signaling in some canine</P>
<P STYLE="margin-bottom: 0cm">breast cancer cells is not caused by
classical mutations in APC, β-Catenin or</P>
<P STYLE="margin-bottom: 0cm">GSK3β but, at least partially, by
enhanced LEF1 expression. We examined the</P>
<P STYLE="margin-bottom: 0cm">expression and function of
EGFR/HER-regulated pathways on the ligand-independent 
</P>
<P STYLE="margin-bottom: 0cm">Wnt signaling.</P>
<P STYLE="margin-bottom: 0cm">METHODS: Twelve canine mammary tumor
cell lines with previously reported</P>
<P STYLE="margin-bottom: 0cm">differential basal Wnt activity were
used. The expression levels of genes related</P>
<P STYLE="margin-bottom: 0cm">to EGF-signaling were analyzed by
cluster analysis. Cell lines with a combined</P>
<P STYLE="margin-bottom: 0cm">overexpression of EGF-related genes and
enhanced basal Wnt activity were treated 
</P>
<P STYLE="margin-bottom: 0cm">with PI3K/mTor or cSRC inhibitors or
transfected with a construct expressing</P>
<P STYLE="margin-bottom: 0cm">wild-type PTEN. Subsequently, effects
were measured on Wnt activity, cell</P>
<P STYLE="margin-bottom: 0cm">proliferation, gene expression and
protein level.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: High basal Wnt/LEF1 activity
was associated with overexpression of</P>
<P STYLE="margin-bottom: 0cm">HER2/3, ID1, ID2, RAC1 and HSP90
together with low to absent cMET and PTEN mRNA</P>
<P STYLE="margin-bottom: 0cm">expression, suggesting a connection
between Wnt- and HER-signaling pathways.</P>
<P STYLE="margin-bottom: 0cm">Inhibition of the HER-regulated
PI3K/mTor pathway using the dual PI3K/mTor</P>
<P STYLE="margin-bottom: 0cm">inhibitor BEZ235 or the mTor inhibitor
Everolimus® resulted in reduced cell</P>
<P STYLE="margin-bottom: 0cm">proliferation. In the cell line with
high basal Wnt activity, however, an</P>
<P STYLE="margin-bottom: 0cm">unexpected further increased Wnt
activity was found that could be greatly reduced</P>
<P STYLE="margin-bottom: 0cm">after inhibition of the HER-regulated
cSRC activity. Inhibition of the PI3K/mTor 
</P>
<P STYLE="margin-bottom: 0cm">pathway was associated with enhanced
expression of β-Catenin, Axin2, MUC1, cMET, 
</P>
<P STYLE="margin-bottom: 0cm">EGFR and HER2 and a somewhat increased
β-Catenin protein content, whereas cSRC</P>
<P STYLE="margin-bottom: 0cm">inhibition was associated with slightly
enhanced HER3 and SLUG mRNA expression. A</P>
<P STYLE="margin-bottom: 0cm">high protein expression of HER3 was
found only in a cell line with high basal Wnt</P>
<P STYLE="margin-bottom: 0cm">activity.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: High basal Wnt activity in
some mammary cancer cell lines is</P>
<P STYLE="margin-bottom: 0cm">associated with overexpression of
HER-receptor related genes and HER3 protein,</P>
<P STYLE="margin-bottom: 0cm">and the absence of PTEN. Inhibition of
the PI3K/mTor pathway further stimulated, 
</P>
<P STYLE="margin-bottom: 0cm">however, canonical Wnt signaling,
whereas the inhibitory effect with the cSRC</P>
<P STYLE="margin-bottom: 0cm">inhibitor Src-I1 on the Wnt activity
further suggested a connection between Wnt</P>
<P STYLE="margin-bottom: 0cm">and HER2/3-signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4513708</P>
<P STYLE="margin-bottom: 0cm">PMID: 26205886 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">6. Biol Reprod. 2015 Jul 22. pii:
biolreprod.115.130971. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">LH-Induced Steroidogenesis in the Mouse
Ovary, but Not Testis, Requires Matrix</P>
<P STYLE="margin-bottom: 0cm">Metalloproteinase 2 and 9-Mediated
Cleavage of Upregulated EGF Receptor Ligands.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Light A, Hammes SR.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Oocyte maturation and cumulus cell
expansion depend on LH-mediated upregulation</P>
<P STYLE="margin-bottom: 0cm">of membrane bound EGF-like ligands,
including amphiregulin, epiregulin, and</P>
<P STYLE="margin-bottom: 0cm">betacellulin. These ligands then
trans-activate the EGF receptor (EGFR) after</P>
<P STYLE="margin-bottom: 0cm">release by matrix metalloproteinases
(MMPs). However, direct measurement of</P>
<P STYLE="margin-bottom: 0cm">released EGF-like ligands or MMPs from
granulosa cells has not been formally</P>
<P STYLE="margin-bottom: 0cm">evaluated, nor has direct
identification of responsible MMPs. Here we address</P>
<P STYLE="margin-bottom: 0cm">these issues by analyzing LH-induced
steroidogenesis, which is also MMP- and</P>
<P STYLE="margin-bottom: 0cm">EGFR-dependent, in freshly isolated
mouse primary granulosa cells. We demonstrate</P>
<P STYLE="margin-bottom: 0cm">a correlation between amphiregulin and
epiregulin mRNA induction and steroid</P>
<P STYLE="margin-bottom: 0cm">production in LH-treated granulosa
cells as well as in ovaries of hCG-treated</P>
<P STYLE="margin-bottom: 0cm">mice. In contrast, LH does not alter
Mmp1, Mmp2, Mmp3, Mmp8, Mmp9, or Adam17 mRNA</P>
<P STYLE="margin-bottom: 0cm">expression. We demonstrate that, in
primary mouse granulosa cells, LH triggers</P>
<P STYLE="margin-bottom: 0cm">release of soluble amphiregulin that
correlates with steroid production, both of 
</P>
<P STYLE="margin-bottom: 0cm">which are blocked by MMP2/9 inhibition,
confirming that MMP2/9 likely regulates</P>
<P STYLE="margin-bottom: 0cm">LH-induced amphiregulin release and
downstream processes. Notably, LH does not</P>
<P STYLE="margin-bottom: 0cm">alter secretion of MMP2/9 from primary
granulosa cells, nor does it modulate MMP 
</P>
<P STYLE="margin-bottom: 0cm">activity. These findings indicate that,
in the ovary, LH dictates EGFR-mediated</P>
<P STYLE="margin-bottom: 0cm">processes not by regulating MMPs, but
instead by increasing EGF-like ligand</P>
<P STYLE="margin-bottom: 0cm">availability. In contrast, LH
stimulation of primary mouse Leydig cells does not 
</P>
<P STYLE="margin-bottom: 0cm">induce EGF-like ligand expression or
require MMP2/9 for steroidogenesis,</P>
<P STYLE="margin-bottom: 0cm">confirming marked differences in LH
receptor-induced processes in the testes. Our</P>
<P STYLE="margin-bottom: 0cm">results suggest that MMP inhibition may
be a means of attenuating excess ovarian 
</P>
<P STYLE="margin-bottom: 0cm">steroid production in diseases like
polycystic ovary syndrome.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright 2015 by The Society for the
Study of Reproduction.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26203177 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">7. Proc Natl Acad Sci U S A. 2015 Jul
20. pii: 201511794. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Erlotinib protects against LPS-induced
Endotoxicity because TLR4 needs EGFR to</P>
<P STYLE="margin-bottom: 0cm">signal.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">De S(1), Zhou H(2), DeSantis D(3),
Croniger CM(3), Li X(2), Stark GR(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Cancer Biology, Lerner
Research Institute, Cleveland Clinic,</P>
<P STYLE="margin-bottom: 0cm">Cleveland, OH 44195; starkg@ccf.org
des@ccf.org. (2)Department of Immunology,</P>
<P STYLE="margin-bottom: 0cm">Lerner Research Institute, Cleveland
Clinic, Cleveland, OH 44195; (3)Department</P>
<P STYLE="margin-bottom: 0cm">of Nutrition, Case Western Reserve
University School of Medicine, Cleveland, OH</P>
<P STYLE="margin-bottom: 0cm">44106.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Several components of the canonical
pathway of response to lipopolysaccharide</P>
<P STYLE="margin-bottom: 0cm">(LPS) are required for the
EGF-dependent activation of NFκB. Conversely, the</P>
<P STYLE="margin-bottom: 0cm">ability of Toll-like Receptor 4 (TLR4)
to activate NFκB in response to LPS is</P>
<P STYLE="margin-bottom: 0cm">impaired by down regulating EGF
receptor (EGFR) expression or by using the EGFR</P>
<P STYLE="margin-bottom: 0cm">inhibitor erlotinib. The LYN
proto-oncogene (LYN) is required for signaling in</P>
<P STYLE="margin-bottom: 0cm">both directions. LYN binds to the EGFR
upon LPS stimulation, and erlotinib</P>
<P STYLE="margin-bottom: 0cm">impairs this association. In mice,
erlotinib blocks the LPS-induced expression of</P>
<P STYLE="margin-bottom: 0cm">tumor necrosis factor α (TNFα) and
interleukin-6 (IL-6) and ameliorates</P>
<P STYLE="margin-bottom: 0cm">LPS-induced endotoxity, revealing that
EGFR is essential for LPS-induced</P>
<P STYLE="margin-bottom: 0cm">signaling in vivo.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26195767 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">8. Microsc Res Tech. 2015 Jul 15. doi:
10.1002/jemt.22544. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Immunohistochemical localization of
epidermal growth factor system in the lung of</P>
<P STYLE="margin-bottom: 0cm">the Japanese quail (Coturnix coturnix
japonica) during the post-hatching period.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Alan E(1), Lİman N(1), Sağsöz H(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Histology and
Embryology, Faculty of Veterinary Medicine,</P>
<P STYLE="margin-bottom: 0cm">University of Erciyes, Kayseri, Turkey.
(2)Department of Histology and</P>
<P STYLE="margin-bottom: 0cm">Embryology, Faculty of Veterinary
Medicine, University of Dicle, Diyarbakır,</P>
<P STYLE="margin-bottom: 0cm">Turkey.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The purpose of this study is to
determine the possible changes in the</P>
<P STYLE="margin-bottom: 0cm">localization of the four Epidermal
Growth Factor Receptors and three ligands in</P>
<P STYLE="margin-bottom: 0cm">quail lungs from the first day of
hatching until the 125th after hatching using</P>
<P STYLE="margin-bottom: 0cm">immunohistochemical methods.
Immunohistochemical results demonstrated that four</P>
<P STYLE="margin-bottom: 0cm">EGFRs and their ligands are chiefly
located in the cytoplasm of cells.</P>
<P STYLE="margin-bottom: 0cm">Additionally, ErbB4, AREG, and NRG1 are
localized to the nucleus and nucleolus,</P>
<P STYLE="margin-bottom: 0cm">but EGF is present in the nucleolus.
ErbB2 was also found in the cell membrane.</P>
<P STYLE="margin-bottom: 0cm">In the epithelium of secondary bronchi,
the goblet cells only exhibited ErbB1 and</P>
<P STYLE="margin-bottom: 0cm">ErbB2, whereas the basal and ciliated
cells exhibited EGFRs and ligands</P>
<P STYLE="margin-bottom: 0cm">immunoreactivity. The atrial granular
cells displayed moderate levels of</P>
<P STYLE="margin-bottom: 0cm">ErbB1-ErbB3 and EGF and strong levels
of ErbB4, AREG, and NRG1 immunoreactivity. 
</P>
<P STYLE="margin-bottom: 0cm">While the squamous atrial cells and
squamous respiratory cells of air capillaries</P>
<P STYLE="margin-bottom: 0cm">and endothelial cells of blood
capillaries exhibited moderate to strong ErbB2,</P>
<P STYLE="margin-bottom: 0cm">ErbB4, AREG, and NRG1 immunoreactivity,
they had negative or weak ErbB1, ErbB3,</P>
<P STYLE="margin-bottom: 0cm">and EGF immunoreactivity. The
expression levels of ErbB2-ErbB4, EGF, AREG, and</P>
<P STYLE="margin-bottom: 0cm">NRG1 were also detected in fibroblasts.
Although ErbB2 was highly expressed in</P>
<P STYLE="margin-bottom: 0cm">the bronchial and vascular smooth
muscle cells, weak expression of ErbB1, ErbB3, 
</P>
<P STYLE="margin-bottom: 0cm">AREG and EGF and moderate expression of
ErbB4 and NRG1 were observed. Macrophages</P>
<P STYLE="margin-bottom: 0cm">were only negative for ErbB1. In
conclusion, these data indicate that the</P>
<P STYLE="margin-bottom: 0cm">EGFR-system is functionally active at
hatching, which supports the hypothesis</P>
<P STYLE="margin-bottom: 0cm">that the members of EGFR-system play
several cell-specific roles in quail lung</P>
<P STYLE="margin-bottom: 0cm">growth after hatching. Microsc. Res.
Tech., 2015. © 2015 Wiley Periodicals, Inc.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2015 Wiley Periodicals, Inc.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26179370 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">9. PLoS One. 2015 Jul
15;10(7):e0132737. doi: 10.1371/journal.pone.0132737.</P>
<P STYLE="margin-bottom: 0cm">eCollection 2015.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">αPIX Is a Trafficking Regulator that
Balances Recycling and Degradation of the</P>
<P STYLE="margin-bottom: 0cm">Epidermal Growth Factor Receptor.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Kortüm F(1), Harms FL(1), Hennighausen
N(1), Rosenberger G(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Institute of Human Genetics,
University Medical Center Hamburg-Eppendorf,</P>
<P STYLE="margin-bottom: 0cm">Hamburg, Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Endosomal sorting is an essential
control mechanism for signaling through the</P>
<P STYLE="margin-bottom: 0cm">epidermal growth factor receptor
(EGFR). We report here that the guanine</P>
<P STYLE="margin-bottom: 0cm">nucleotide exchange factor αPIX, which
modulates the activity of Rho-GTPases, is 
</P>
<P STYLE="margin-bottom: 0cm">a potent bimodal regulator of EGFR
trafficking. αPIX interacts with the E3</P>
<P STYLE="margin-bottom: 0cm">ubiquitin ligase c-Cbl, an enzyme that
attaches ubiquitin to EGFR, thereby</P>
<P STYLE="margin-bottom: 0cm">labelling this tyrosine kinase receptor
for lysosomal degradation. We show that</P>
<P STYLE="margin-bottom: 0cm">EGF stimulation induces αPIX::c-Cbl
complex formation. Simultaneously, αPIX and</P>
<P STYLE="margin-bottom: 0cm">c-Cbl protein levels decrease, which
depends on both αPIX binding to c-Cbl and</P>
<P STYLE="margin-bottom: 0cm">c-Cbl ubiquitin ligase activity.
Through interaction αPIX sequesters c-Cbl from</P>
<P STYLE="margin-bottom: 0cm">EGFR and this results in reduced EGFR
ubiquitination and decreased EGFR</P>
<P STYLE="margin-bottom: 0cm">degradation upon EGF treatment.
However, quantitatively more decisive for</P>
<P STYLE="margin-bottom: 0cm">cellular EGFR distribution than
impaired EGFR degradation is a strong stimulating</P>
<P STYLE="margin-bottom: 0cm">effect of αPIX on EGFR recycling to
the cell surface. This function depends on</P>
<P STYLE="margin-bottom: 0cm">the GIT binding domain of αPIX but not
on interaction with c-Cbl or αPIX exchange</P>
<P STYLE="margin-bottom: 0cm">activity. In summary, our data
demonstrate a previously unappreciated function of</P>
<P STYLE="margin-bottom: 0cm">αPIX as a strong promoter of EGFR
recycling. We suggest that the novel recycling 
</P>
<P STYLE="margin-bottom: 0cm">regulator αPIX and the degradation
factor c-Cbl closely cooperate in the</P>
<P STYLE="margin-bottom: 0cm">regulation of EGFR trafficking:
uncomplexed αPIX and c-Cbl mediate a positive and</P>
<P STYLE="margin-bottom: 0cm">a negative feedback on EGFR signaling,
respectively; αPIX::c-Cbl complex</P>
<P STYLE="margin-bottom: 0cm">formation, however, results in mutual
inhibition, which may reflect a stable</P>
<P STYLE="margin-bottom: 0cm">condition in the homeostasis of
EGF-induced signal flow.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4503440</P>
<P STYLE="margin-bottom: 0cm">PMID: 26177020 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">10. Cancer Biol Ther. 2015 Jul 15:0.
[Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The small GTPase ADP-Ribosylation
Factor 1 mediates the sensitivity of triple</P>
<P STYLE="margin-bottom: 0cm">negative breast cancer cells to EGFR
tyrosine kinase inhibitors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Haines E(1), Schlienger S, Claing A.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)a Department of Pharmacology ,
Faculty of Medicine, Université de Montréal ,</P>
<P STYLE="margin-bottom: 0cm">Montreal, QC , Canada H3C 3J7.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The clinical use of EGFR-targeted
therapy, in triple negative breast cancer</P>
<P STYLE="margin-bottom: 0cm">patients, has been limited by the
development of resistance to these drugs.</P>
<P STYLE="margin-bottom: 0cm">Although activated signaling molecules
contribute to this process, the molecular 
</P>
<P STYLE="margin-bottom: 0cm">mechanisms remain relatively unknown.
We have previously reported that the small 
</P>
<P STYLE="margin-bottom: 0cm">GTPase ADP-Ribosylation Factor 1 (ARF1)
is highly expressed in invasive breast</P>
<P STYLE="margin-bottom: 0cm">cancer cells and acts as a molecular
switch to activate EGF-mediated responses.</P>
<P STYLE="margin-bottom: 0cm">In this study, we aimed at defining
whether the high expression of ARF1 limits</P>
<P STYLE="margin-bottom: 0cm">sensitivity of these tumor cells to
EGFR inhibitors, such as gefitinib. Here, we 
</P>
<P STYLE="margin-bottom: 0cm">show that the knock down of ARF1
expression or activity decreased the dose and</P>
<P STYLE="margin-bottom: 0cm">latency time required by tyrosine
kinase inhibitors to induce cell death. This</P>
<P STYLE="margin-bottom: 0cm">may be explained by the observation
that the depletion of ARF1 suppressed</P>
<P STYLE="margin-bottom: 0cm">gefitinib-mediated activation of key
mediators of survival such as ERK1/2, AKT</P>
<P STYLE="margin-bottom: 0cm">and Src, while enhancing cascades
leading to apoptosis such as the p38MAPK and</P>
<P STYLE="margin-bottom: 0cm">JNK pathways, modifying the Bax/Bcl2
ratio and cytochrome c release. In addition,</P>
<P STYLE="margin-bottom: 0cm">inhibiting ARF1 expression and
activation also results in an increase in</P>
<P STYLE="margin-bottom: 0cm">gefitinib-mediated EGFR internalization
and degradation further limiting the</P>
<P STYLE="margin-bottom: 0cm">ability of this receptor to promote its
effects. Interestingly, we observed that 
</P>
<P STYLE="margin-bottom: 0cm">gefitinib treatment resulted in the
enhanced activation of ARF1 by promoting its 
</P>
<P STYLE="margin-bottom: 0cm">recruitment to the receptor AXL, an
important mediator of EGFR inhibition</P>
<P STYLE="margin-bottom: 0cm">suggesting that ARF1 may promote its
pro-survival effects by coupling to</P>
<P STYLE="margin-bottom: 0cm">alternative mitogenic receptors in
conditions where the EGFR is inhibited.</P>
<P STYLE="margin-bottom: 0cm">Together our results uncover a new role
for ARF1 in mediating the sensitivity to 
</P>
<P STYLE="margin-bottom: 0cm">EGFR inhibition and thus suggest that
limiting the activation of this GTPase</P>
<P STYLE="margin-bottom: 0cm">could improve the therapeutic efficacy
of EGFR inhibitors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26176330 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">11. J Biomed Sci. 2015 Jul 15;22:53.
doi: 10.1186/s12929-015-0165-8.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Tumor necrosis factor-alpha induces
VCAM-1-mediated inflammation via</P>
<P STYLE="margin-bottom: 0cm">c-Src-dependent transactivation of EGF
receptors in human cardiac fibroblasts.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lin CC(1,)(2), Pan CS(3,)(4), Wang
CY(3,)(4), Liu SW(1,)(2), Hsiao LD(1,)(2),</P>
<P STYLE="margin-bottom: 0cm">Yang CM(5,)(6).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Anesthetics, Chang
Gung Memorial Hospital at Linkuo, Kwei-Shan, 
</P>
<P STYLE="margin-bottom: 0cm">Tao-Yuan, Taiwan. (2)College of
Medicine, Chang Gung University, Kwei-Shan,</P>
<P STYLE="margin-bottom: 0cm">Tao-Yuan, Taiwan. (3)Department of
Physiology, College of Medicine, Chang Gung</P>
<P STYLE="margin-bottom: 0cm">University, Kwei-Shan, Tao-Yuan,
Taiwan. (4)Department of Pharmacology and Health</P>
<P STYLE="margin-bottom: 0cm">Aging Research Center, College of
Medicine, Chang Gung University, 259 Wen-Hwa</P>
<P STYLE="margin-bottom: 0cm">1st Road, Kwei-Shan, Tao-Yuan, Taiwan.
(5)Department of Physiology, College of</P>
<P STYLE="margin-bottom: 0cm">Medicine, Chang Gung University,
Kwei-Shan, Tao-Yuan, Taiwan.</P>
<P STYLE="margin-bottom: 0cm">chuenmao@mail.cgu.edu.tw. (6)Department
of Pharmacology and Health Aging Research</P>
<P STYLE="margin-bottom: 0cm">Center, College of Medicine, Chang Gung
University, 259 Wen-Hwa 1st Road,</P>
<P STYLE="margin-bottom: 0cm">Kwei-Shan, Tao-Yuan, Taiwan.
chuenmao@mail.cgu.edu.tw.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Tumor necrosis factor-α
(TNF-α) is a proinflammatory cytokine and</P>
<P STYLE="margin-bottom: 0cm">elevated in the regions of tissue
injury and inflammatory diseases. The</P>
<P STYLE="margin-bottom: 0cm">deleterious effects of TNF-α on
fibroblasts may aggravate heart inflammation</P>
<P STYLE="margin-bottom: 0cm">mediated through the up-regulation of
adhesion molecules such as vascular cell</P>
<P STYLE="margin-bottom: 0cm">adhesion molecule-1 (VCAM-1). However,
the mechanisms underlying TNF-α-induced</P>
<P STYLE="margin-bottom: 0cm">VCAM-1 expression in cardiac
fibroblasts remain unknown. This study aimed to</P>
<P STYLE="margin-bottom: 0cm">investigate the roles of TNF-α in
VCAM-1 expression and its effects on human</P>
<P STYLE="margin-bottom: 0cm">cardiac fibroblasts (HCFs).</P>
<P STYLE="margin-bottom: 0cm">RESULTS: The primary culture HCFs were
used in this study. The results obtained</P>
<P STYLE="margin-bottom: 0cm">with Western blotting, real
time-quantitative PCR, and promoter activity analyses</P>
<P STYLE="margin-bottom: 0cm">showed that TNF-α-induced VCAM-1
expression was mediated through TNF receptor</P>
<P STYLE="margin-bottom: 0cm">(TNFR) 1-dependent gene up-regulation.
Activation of TNFR1 by TNF-α</P>
<P STYLE="margin-bottom: 0cm">transactivated c-Src-dependent EGF
receptor (EGFR) linking to PI3K/Akt cascade,</P>
<P STYLE="margin-bottom: 0cm">and then led to transcriptional
activity of NF-κB. Moreover, the results of</P>
<P STYLE="margin-bottom: 0cm">promoter reporter assay demonstrated
that the phosphorylated p65 NF-κB turned on 
</P>
<P STYLE="margin-bottom: 0cm">VCAM-1 gene expression. Subsequently,
up-regulation of VCAM-1 promoted monocytes 
</P>
<P STYLE="margin-bottom: 0cm">adhesion to HCFs challenged with TNF-α
determined by cell adhesion assay.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Taken together, these
results indicate that in HCFs, activation of</P>
<P STYLE="margin-bottom: 0cm">NF-κB by c-Src-mediated
transactivation of EGFR/PI3K/Akt cascade is required for 
</P>
<P STYLE="margin-bottom: 0cm">TNF-α-induced VCAM-1 expression.
Finally, increased VCAM-1 enhances monocytes</P>
<P STYLE="margin-bottom: 0cm">adhering to HCFs challenged with TNF-α.
Understanding the mechanisms of VCAM-1</P>
<P STYLE="margin-bottom: 0cm">up-regulated by TNF-α on HCFs may
provide rationally therapeutic interventions</P>
<P STYLE="margin-bottom: 0cm">for heart injury or inflammatory
diseases.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4502472</P>
<P STYLE="margin-bottom: 0cm">PMID: 26173590 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">12. Oncol Lett. 2015 Jul;10(1):479-484.
Epub 2015 May 19.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nitric oxide/cyclic guanosine
monophosphate inducers sodium nitroprusside and</P>
<P STYLE="margin-bottom: 0cm">L-arginine inhibit the proliferation of
gastric cancer cells via the activation</P>
<P STYLE="margin-bottom: 0cm">of type II cyclic guanosine
monophosphate-dependent protein kinase.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Yao X(1), Wu Y(1), Zhu M(1), Qian H(1),
Chen Y(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Physiology, School of
Medicine, Jiangsu University, Zhenjiang,</P>
<P STYLE="margin-bottom: 0cm">Jiangsu 212013, P.R. China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nitric oxide (NO) may activate soluble
guanylyl cyclase (sGC), resulting in the</P>
<P STYLE="margin-bottom: 0cm">increase of intracellular cyclic
guanosine monophosphate (cGMP), a key molecule</P>
<P STYLE="margin-bottom: 0cm">in the activation of type II
cGMP-dependent protein kinase (PKG II). In our</P>
<P STYLE="margin-bottom: 0cm">previous study, the membrane-permeable
cGMP analogue 8-pCPT-cGMP was used to</P>
<P STYLE="margin-bottom: 0cm">activate PKG II. The aim of the present
study was to investigate whether</P>
<P STYLE="margin-bottom: 0cm">NO/sGC-induced endogenous cGMP is able
to activate PKG II and induce the</P>
<P STYLE="margin-bottom: 0cm">corresponding effects. In the AGS
gastric cancer cell line, the expression of PKG</P>
<P STYLE="margin-bottom: 0cm">II was increased by infecting the cells
with an adenoviral construct encoding PKG</P>
<P STYLE="margin-bottom: 0cm">II cDNA (Ad-PKG II) and the activation
of PKG II was induced by 8-pCPT-cGMP</P>
<P STYLE="margin-bottom: 0cm">(positive control), the NO donor sodium
nitroprusside (SNP) and the NO precursor 
</P>
<P STYLE="margin-bottom: 0cm">L-arginine. ELISA was performed to
detect the concentration of cGMP in AGS cells 
</P>
<P STYLE="margin-bottom: 0cm">and the Cell Counting Kit-8 was used to
analyze the proliferation of differently 
</P>
<P STYLE="margin-bottom: 0cm">treated cells. Western blot analysis
was used to detect the expression and</P>
<P STYLE="margin-bottom: 0cm">phosphorylation of associated proteins.
The results demonstrated that the level</P>
<P STYLE="margin-bottom: 0cm">of cGMP was increased in cells treated
with the NO donor or precursor. There was 
</P>
<P STYLE="margin-bottom: 0cm">an obvious increase of Ser239
phosphorylation of the vasodilator-stimulated</P>
<P STYLE="margin-bottom: 0cm">phosphoprotein, representing the
increase in the activity of PKG II. The</P>
<P STYLE="margin-bottom: 0cm">epidermal growth factor (EGF)-induced
proliferation of AGS cells was inhibited by</P>
<P STYLE="margin-bottom: 0cm">infection with Ad-PKG II and treatment
with SNP or L-arginine. In addition,</P>
<P STYLE="margin-bottom: 0cm">EGF-induced tyrosine phosphorylation of
the EGF receptor (EGFR) and</P>
<P STYLE="margin-bottom: 0cm">tyrosine/serine phosphorylation of
extracellular signal-regulated kinase (ERK)</P>
<P STYLE="margin-bottom: 0cm">were also inhibited by infection with
Ad-PKG II and treatment with the NO donor</P>
<P STYLE="margin-bottom: 0cm">or precursor. These data indicated that
NO donors and precursors may activate the</P>
<P STYLE="margin-bottom: 0cm">expression of PKG II, thereby blocking
EGF-initiated signaling of the</P>
<P STYLE="margin-bottom: 0cm">mitogen-activated protein kinase/ERK
pathway and inhibiting EGF-induced</P>
<P STYLE="margin-bottom: 0cm">proliferative activity through
preventing the phosphorylation of EGFR at tyr1068.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4487134</P>
<P STYLE="margin-bottom: 0cm">PMID: 26171055 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">13. Free Radic Biol Med. 2015 Jul 10.
pii: S0891-5849(15)00335-4. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.freeradbiomed.2015.07.011.
[Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Mitogen-activated protein
kinase-activated protein kinase 2 mediates resistance</P>
<P STYLE="margin-bottom: 0cm">to Hydrogen peroxide-induced oxidative
stress in Human hepatobiliary Cancer</P>
<P STYLE="margin-bottom: 0cm">cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ho-Bouldoires TH(1), Clapéron A(1),
Mergey M(1), Wendum D(2), Desbois-Mouthon</P>
<P STYLE="margin-bottom: 0cm">C(1), Tahraoui S(1), Fartoux L(3),
Chettouh H(1), Merabtene F(1), Scatton O(4),</P>
<P STYLE="margin-bottom: 0cm">Gaestel M(5), Praz F(1), Housset C(3),
Fouassier L(6).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)INSERM, UMR_S 938, Centre de
Recherche Saint-Antoine, F-75012, Paris, France; 
</P>
<P STYLE="margin-bottom: 0cm">Sorbonne Universités, UPMC Univ Paris
06, UMR_S 938, Centre de Recherche</P>
<P STYLE="margin-bottom: 0cm">Saint-Antoine, F-75012, Paris, France.
(2)INSERM, UMR_S 938, Centre de Recherche 
</P>
<P STYLE="margin-bottom: 0cm">Saint-Antoine, F-75012, Paris, France;
Sorbonne Universités, UPMC Univ Paris 06, 
</P>
<P STYLE="margin-bottom: 0cm">UMR_S 938, Centre de Recherche
Saint-Antoine, F-75012, Paris, France; AP-HP,</P>
<P STYLE="margin-bottom: 0cm">Hôpital Saint-Antoine, Service
d'Anatomie et Cytologie Pathologiques,</P>
<P STYLE="margin-bottom: 0cm">F-75012Paris, France. (3)INSERM, UMR_S
938, Centre de Recherche Saint-Antoine,</P>
<P STYLE="margin-bottom: 0cm">F-75012, Paris, France; Sorbonne
Universités, UPMC Univ Paris 06, UMR_S 938,</P>
<P STYLE="margin-bottom: 0cm">Centre de Recherche Saint-Antoine,
F-75012, Paris, France; AP-HP, Hôpital</P>
<P STYLE="margin-bottom: 0cm">Saint-Antoine, Service d'Hépatologie,
F-75012Paris, France. (4)INSERM, UMR_S 938,</P>
<P STYLE="margin-bottom: 0cm">Centre de Recherche Saint-Antoine,
F-75012, Paris, France; Sorbonne Universités, 
</P>
<P STYLE="margin-bottom: 0cm">UPMC Univ Paris 06, UMR_S 938, Centre
de Recherche Saint-Antoine, F-75012, Paris,</P>
<P STYLE="margin-bottom: 0cm">France; AP-HP, Hôpital Saint-Antoine,
Service de Chirurgie Hépato-Biliaire et</P>
<P STYLE="margin-bottom: 0cm">Transplantation Hépatique, F-75012,
Paris, France. (5)Institute of Physiological 
</P>
<P STYLE="margin-bottom: 0cm">Chemistry, Hannover Medical School,
Carl-Neuberg-Str. 1, d-30625 Hannover,</P>
<P STYLE="margin-bottom: 0cm">Germany. (6)INSERM, UMR_S 938, Centre
de Recherche Saint-Antoine, F-75012, Paris,</P>
<P STYLE="margin-bottom: 0cm">France; Sorbonne Universités, UPMC
Univ Paris 06, UMR_S 938, Centre de Recherche 
</P>
<P STYLE="margin-bottom: 0cm">Saint-Antoine, F-75012, Paris, France.
Electronic address:</P>
<P STYLE="margin-bottom: 0cm">laura.fouassier@inserm.fr.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The development and progression of
liver cancer are characterized by increased</P>
<P STYLE="margin-bottom: 0cm">levels of reactive oxygen species
(ROS). ROS-induced oxidative stress impairs</P>
<P STYLE="margin-bottom: 0cm">cell proliferation and ultimately leads
to cell death. Although liver cancer</P>
<P STYLE="margin-bottom: 0cm">cells are especially resistant to
oxidative stress, mechanisms of such resistance</P>
<P STYLE="margin-bottom: 0cm">remain understudied. We identified the
MAPK-activated protein kinase 2 (MK2)/Heat</P>
<P STYLE="margin-bottom: 0cm">shock protein 27 (Hsp27) signaling
pathway mediating defenses against oxidative</P>
<P STYLE="margin-bottom: 0cm">stress. Besides to MK2 and Hsp27
overexpression in primary liver tumors compared 
</P>
<P STYLE="margin-bottom: 0cm">to adjacent non-tumorous tissues,
MK2/Hsp27 pathway is activated by hydrogen</P>
<P STYLE="margin-bottom: 0cm">peroxide-induced oxidative stress in
hepatobiliary cancer cells. MK2 inactivation</P>
<P STYLE="margin-bottom: 0cm">or inhibition of MK2 or Hsp27
expression increases Caspase-3 and PARP cleavage</P>
<P STYLE="margin-bottom: 0cm">and DNA breaks, and therefore cell
death. Interestingly, MK2/Hsp27 inhibition</P>
<P STYLE="margin-bottom: 0cm">decreases antioxidant defenses such as
heme-oxygenase 1 (HO-1) through</P>
<P STYLE="margin-bottom: 0cm">down-regulation of the transcription
factor nuclear factor-erythroid-derived</P>
<P STYLE="margin-bottom: 0cm">2-like 2 (Nrf2). Moreover, MK2/Hsp27
inhibition decreases both phosphorylation of</P>
<P STYLE="margin-bottom: 0cm">epidermal growth factor receptor (EGFR)
and expression of its ligand,</P>
<P STYLE="margin-bottom: 0cm">heparin-binding EGF-like growth factor
(HB-EGF). A new identified partner of MK2,</P>
<P STYLE="margin-bottom: 0cm">the scaffold PDZ-protein EBP50, could
facilitate these effects through MK2/Hsp27 
</P>
<P STYLE="margin-bottom: 0cm">pathway regulation. These findings
demonstrate that MK2/Hsp27 pathway actively</P>
<P STYLE="margin-bottom: 0cm">participates in resistance to oxidative
stress and may contribute to liver cancer</P>
<P STYLE="margin-bottom: 0cm">progression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015. Published by
Elsevier Inc.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26169728 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">14. Tumour Biol. 2015 Jul 14. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Prognostic significance of the
tumour-adjacent tissue in head and neck cancers.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Raudenska M(1,)(2), Sztalmachova
M(1,)(2), Gumulec J(1,)(2), Fojtu M(1,)(2,)(3), 
</P>
<P STYLE="margin-bottom: 0cm">Polanska H(1,)(2), Balvan J(1,)(2),
Feith M(1), Binkova H(4), Horakova Z(4),</P>
<P STYLE="margin-bottom: 0cm">Kostrica R(4), Kizek R(2,)(5), Masarik
M(6,)(7).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Pathological
Physiology, Faculty of Medicine, Masaryk</P>
<P STYLE="margin-bottom: 0cm">University, Kamenice 5, CZ-625 00,
Brno, Czech Republic. (2)Central European</P>
<P STYLE="margin-bottom: 0cm">Institute of Technology, Brno
University of Technology, Technicka 3058/10, CZ-616</P>
<P STYLE="margin-bottom: 0cm">00, Brno, Czech Republic. (3)Department
of Physiology, Faculty of Medicine,</P>
<P STYLE="margin-bottom: 0cm">Masaryk University, Kamenice 5, CZ-625
00, Brno, Czech Republic. (4)Department of</P>
<P STYLE="margin-bottom: 0cm">Otorhinolaryngology and Head and Neck
Surgery, St. Anne's Faculty Hospital,</P>
<P STYLE="margin-bottom: 0cm">Pekarska 53, CZ-656 91, Brno, Czech
Republic. (5)Department of Chemistry and</P>
<P STYLE="margin-bottom: 0cm">Biochemistry, Mendel University in
Brno, Zemedelska 1, CZ-613 00, Brno, Czech</P>
<P STYLE="margin-bottom: 0cm">Republic. (6)Department of Pathological
Physiology, Faculty of Medicine, Masaryk 
</P>
<P STYLE="margin-bottom: 0cm">University, Kamenice 5, CZ-625 00,
Brno, Czech Republic. masarik@med.muni.cz.</P>
<P STYLE="margin-bottom: 0cm">(7)Central European Institute of
Technology, Brno University of Technology,</P>
<P STYLE="margin-bottom: 0cm">Technicka 3058/10, CZ-616 00, Brno,
Czech Republic. masarik@med.muni.cz.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Even with significant advances in
operative skills and adjuvant therapies, the</P>
<P STYLE="margin-bottom: 0cm">overall survival of patients suffering
with head and neck squamous cancers</P>
<P STYLE="margin-bottom: 0cm">(HNSCC) is unsatisfactory. Accordingly,
no clinically useful prognostic</P>
<P STYLE="margin-bottom: 0cm">biomarkers have been found yet for
HNSCC. Many studies analysed the expression of</P>
<P STYLE="margin-bottom: 0cm">potential markers in tumour tissues
compared to adjacent tissues. Nevertheless,</P>
<P STYLE="margin-bottom: 0cm">due to the sharing of the same
microenvironment, adjacent tissues show molecular 
</P>
<P STYLE="margin-bottom: 0cm">similarity to tumour tissues. Thus,
gene expression patterns of 94 HNSCC tumorous</P>
<P STYLE="margin-bottom: 0cm">tissues were compared with 31 adjacent
tissues and with 10 tonsillectomy</P>
<P STYLE="margin-bottom: 0cm">specimens of non-cancer individuals.
The genes analysed at RNA level using</P>
<P STYLE="margin-bottom: 0cm">quantitative RT-PCR and correlated with
clinico-pathological conditions were as</P>
<P STYLE="margin-bottom: 0cm">follows: EGF, EGFR, MKI67, BCL2, BAX,
FOS, JUN, TP53, VEGF, FLT1, MMP2, MMP9,</P>
<P STYLE="margin-bottom: 0cm">MT1A and MT2A. The elevated MT2A, BAX,
EGF and JUN expression was associated with</P>
<P STYLE="margin-bottom: 0cm">the influence of tumour cells on the
rearrangement of healthy tissues, as well as</P>
<P STYLE="margin-bottom: 0cm">a significant shift in the BAX/BCL2
ratio. Our investigation also indicated that 
</P>
<P STYLE="margin-bottom: 0cm">adjacent tissues play an important role
in cancerogenesis by releasing several</P>
<P STYLE="margin-bottom: 0cm">tumour-supporting factors such as EGF.
A gradual increase in the metallothionein 
</P>
<P STYLE="margin-bottom: 0cm">expression, from the lowest one in
tonsillectomy samples to the highest ones in</P>
<P STYLE="margin-bottom: 0cm">tumour samples, suggests that MT
expression might be tissue reaction to the</P>
<P STYLE="margin-bottom: 0cm">presence of tumour cells. The results
of this study confirmed the significance of</P>
<P STYLE="margin-bottom: 0cm">metallothionein in tumori-genesis and
gave evidences for its use as a potential</P>
<P STYLE="margin-bottom: 0cm">HNSCC biomarker. Furthermore, this
study highlighted the importance of</P>
<P STYLE="margin-bottom: 0cm">histologically normal tumour-adjacent
tissue in prediction of HNSCC progress.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26168959 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">15. Anticancer Res. 2015
Aug;35(8):4433-40.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Validity of HB-EGF as Target for Human
Neuroblastoma Therapy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nam SO(1), Yotsumoto F(2), Miyata K(1),
Souzaki R(3), Taguchi T(3), Kuroki M(4), 
</P>
<P STYLE="margin-bottom: 0cm">Miyamoto S(5).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Obstetrics and
Gynecology, Faculty of Medicine, Fukuoka</P>
<P STYLE="margin-bottom: 0cm">University, Fukuoka, Japan Central
Research Institute for Advanced Molecular</P>
<P STYLE="margin-bottom: 0cm">Medicine, Faculty of Medicine, Fukuoka
University, Fukuoka, Japan. (2)Central</P>
<P STYLE="margin-bottom: 0cm">Research Institute for Advanced
Molecular Medicine, Faculty of Medicine, Fukuoka 
</P>
<P STYLE="margin-bottom: 0cm">University, Fukuoka, Japan Department
of Biochemistry, Faculty of Medicine,</P>
<P STYLE="margin-bottom: 0cm">Fukuoka University, Fukuoka, Japan.
(3)Department of Pediatric Surgery, Faculty</P>
<P STYLE="margin-bottom: 0cm">of Medical Sciences, Kyushu University,
Fukuoka, Japan. (4)Department of</P>
<P STYLE="margin-bottom: 0cm">Biochemistry, Faculty of Medicine,
Fukuoka University, Fukuoka, Japan.</P>
<P STYLE="margin-bottom: 0cm">(5)Department of Obstetrics and
Gynecology, Faculty of Medicine, Fukuoka</P>
<P STYLE="margin-bottom: 0cm">University, Fukuoka, Japan Central
Research Institute for Advanced Molecular</P>
<P STYLE="margin-bottom: 0cm">Medicine, Faculty of Medicine, Fukuoka
University, Fukuoka, Japan</P>
<P STYLE="margin-bottom: 0cm">smiya@cis.fukuoka-u.ac.jp.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND/AIM: Neuroblastoma (NB) is
the most common and lethal extracranial</P>
<P STYLE="margin-bottom: 0cm">solid tumor in children. The present
study aimed to verify that the</P>
<P STYLE="margin-bottom: 0cm">heparin-binding epidermal growth
factor-like growth factor (HB-EGF) is a rational</P>
<P STYLE="margin-bottom: 0cm">target in NB therapy.</P>
<P STYLE="margin-bottom: 0cm">MATERIAL AND METHODS: We examined
expression of EGFR ligands in four NB cell</P>
<P STYLE="margin-bottom: 0cm">lines using 2-dimensional culture (DC)
and 3DC conditions. To assess the</P>
<P STYLE="margin-bottom: 0cm">anti-tumor effect of cross-reacting
material 197 (CRM197), which is a specific</P>
<P STYLE="margin-bottom: 0cm">inhibitor of HB-EGF, on NB cells, we
also performed terminal deoxynucleotidyl</P>
<P STYLE="margin-bottom: 0cm">transferase dUTP nick-end labeling
(TUNEL) assay to detect apoptotic cells.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: HB-EGF was predominantly
expressed in two out of four NB cell lines</P>
<P STYLE="margin-bottom: 0cm">under 2DC and 3DC conditions. CRM197
significantly induced apoptosis of NB cells 
</P>
<P STYLE="margin-bottom: 0cm">with high HB-EGF expression.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: HB-EGF plays an important
role in neuroblastoma tumorigenesis and</P>
<P STYLE="margin-bottom: 0cm">CRM197 showed an effective antitumor
effect in neuroblastoma cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright© 2015 International
Institute of Anticancer Research (Dr. John G.</P>
<P STYLE="margin-bottom: 0cm">Delinassios), All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26168483 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">16. Mol Biol Cell. 2015 Jul 8. pii:
mbc.E14-11-1547. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Interferon-gamma-inducible Rab20
regulates endosomal morphology and EGFR</P>
<P STYLE="margin-bottom: 0cm">degradation in macrophages.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Pei G(1), Schnettger L(2), Bronietzki
M(1), Repnik U(3), Griffiths G(3),</P>
<P STYLE="margin-bottom: 0cm">Gutierrez MG(4).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)*Research Group Phagosome Biology,
Helmholtz Centre for Infection Research,</P>
<P STYLE="margin-bottom: 0cm">Inhoffenstrasse 7, 38124 Braunschweig,
Germany. (2)The Francis Crick Institute,</P>
<P STYLE="margin-bottom: 0cm">Mill Hill Laboratory, The Ridgeway,
London, NW7 1AA, United Kingdom.</P>
<P STYLE="margin-bottom: 0cm">(3)Department of Biosciences,
University of Oslo, 0316 Oslo, Norway. (4)The</P>
<P STYLE="margin-bottom: 0cm">Francis Crick Institute, Mill Hill
Laboratory, The Ridgeway, London, NW7 1AA,</P>
<P STYLE="margin-bottom: 0cm">United Kingdom
Maximiliano.Gutierrrez@crick.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Little is known about the molecular
players that regulate changes in the</P>
<P STYLE="margin-bottom: 0cm">endocytic pathway during immune
activation. Here, we investigated the role of</P>
<P STYLE="margin-bottom: 0cm">Rab20 in the endocytic pathway during
activation of macrophages. Rab20 is</P>
<P STYLE="margin-bottom: 0cm">associated with endocytic structures
but the function of this Rab GTPase in the</P>
<P STYLE="margin-bottom: 0cm">endocytic pathway remains poorly
characterized. We found that in macrophages,</P>
<P STYLE="margin-bottom: 0cm">Rab20 expression and endosomal
association significantly increased after</P>
<P STYLE="margin-bottom: 0cm">interferon-gamma (IFN-γ) treatment.
Moreover, IFN-γ as well as Rab20 expression</P>
<P STYLE="margin-bottom: 0cm">induced a dramatic enlargement of
endosomes. These enlarged endosomes are the</P>
<P STYLE="margin-bottom: 0cm">result of homotypic fusion promoted by
Rab20 expression. The expression of Rab20 
</P>
<P STYLE="margin-bottom: 0cm">or the dominant-negative mutant
Rab20T19N did not affect transferrin or Dextran</P>
<P STYLE="margin-bottom: 0cm">70 kDa uptake. However, knockdown of
Rab20 accelerated epidermal growth factor</P>
<P STYLE="margin-bottom: 0cm">(EGF) trafficking to LAMP-2-positive
compartments and EGF receptor (EGFR)</P>
<P STYLE="margin-bottom: 0cm">degradation. Thus, this work defines a
function for Rab20 in the endocytic</P>
<P STYLE="margin-bottom: 0cm">pathway during immune activation of
macrophages.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2015 by The American Society for
Cell Biology.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26157167 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">17. Cell Biol Int. 2015 Jul 4. doi:
10.1002/cbin.10511. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gab1 amplifies signalling in response
to low-intensity stimulation by HGF.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Aasrum M(1), Ødegård J(1), Thoresen
GH(1,)(2), Brusevold IJ(1,)(3), Sandnes</P>
<P STYLE="margin-bottom: 0cm">DL(1), Christoffersen T(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Pharmacology,
Institute of Clinical Medicine, University of Oslo</P>
<P STYLE="margin-bottom: 0cm">and Oslo University Hospital, P.O. Box
1057, Blindern, 0316 Oslo, Norway.</P>
<P STYLE="margin-bottom: 0cm">(2)Department of Pharmaceutical
Biosciences, School of Pharmacy, University of</P>
<P STYLE="margin-bottom: 0cm">Oslo, P.O. Box 1068, Blindern, 0316
Oslo, Norway. (3)Department of Oral Biology</P>
<P STYLE="margin-bottom: 0cm">and Department of Paediatric Dentistry
and Behavioural Science, Faculty of</P>
<P STYLE="margin-bottom: 0cm">Dentistry, University of Oslo, P.O. Box
1052, Blindern, 0316 Oslo, Norway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The receptor tyrosine kinases EGFR and
Met induce phosphorylation of the docking 
</P>
<P STYLE="margin-bottom: 0cm">protein Gab1, and there is evidence
that Gab1 may have a role in the signalling</P>
<P STYLE="margin-bottom: 0cm">from these receptors. Studying
hepatocytes, we previously found that although</P>
<P STYLE="margin-bottom: 0cm">Gab1 mechanistically interacted in
different ways with EGFR and Met, it was</P>
<P STYLE="margin-bottom: 0cm">involved in mitogenic signalling
induced by both EGF and HGF. It has been</P>
<P STYLE="margin-bottom: 0cm">reported that in EGFR signalling Gab1
is required particularly at a low dose of</P>
<P STYLE="margin-bottom: 0cm">EGF. Whether this also applies to
HGF/Met signalling has not been investigated.</P>
<P STYLE="margin-bottom: 0cm">We have studied the role of Gab1 in
activation of the Akt and ERK pathways at</P>
<P STYLE="margin-bottom: 0cm">low- and high-intensity stimulation
with EGF and HGF in cultured hepatocytes. In 
</P>
<P STYLE="margin-bottom: 0cm">cells where Gab1 was depleted by a
specific Gab1-directed siRNA, the EGF-induced 
</P>
<P STYLE="margin-bottom: 0cm">phosphorylation of ERK was lowered and
HGF-induced phosphorylation of both ERK</P>
<P STYLE="margin-bottom: 0cm">and Akt was substantially reduced.
These effects were more marked at low-dose HGF</P>
<P STYLE="margin-bottom: 0cm">stimulation. The inhibitory consequence
of Gab1 depletion was particularly</P>
<P STYLE="margin-bottom: 0cm">pronounced for HGF-induced Akt
phosphorylation. The results suggest that Gab1 is 
</P>
<P STYLE="margin-bottom: 0cm">an important signal amplifier for
low-intensity stimulation by HGF.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">This article is protected by copyright.
All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26146811 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">18. Oncol Lett. 2015
Jun;9(6):2781-2786. Epub 2015 Mar 23.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Type II cyclic guanosine
monophosphate-dependent protein kinase inhibits</P>
<P STYLE="margin-bottom: 0cm">epidermal growth factor receptor
activation in different cancer cell lines.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Jiang LU(1), Wu M(1), Wu Y(1), Lan
T(1), Wang Y(1), Qian H(1), Chen Y(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Physiology, School of
Medicine, Jiangsu University, Zhenjiang,</P>
<P STYLE="margin-bottom: 0cm">Jiangsu 212013, P.R. China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Previous data has revealed that type II
cyclic guanosine monophosphate-dependent 
</P>
<P STYLE="margin-bottom: 0cm">protein kinase (PKG II) inhibits
epidermal growth factor (EGF)-induced</P>
<P STYLE="margin-bottom: 0cm">phosphorylation/activation of the
epidermal growth factor receptor (EGFR) and</P>
<P STYLE="margin-bottom: 0cm">mitogen-activated protein
kinase/extracellular-signal-regulated kinase (MAPK/ERK)</P>
<P STYLE="margin-bottom: 0cm">in gastric cancer cells. The aim of the
present study was to determine whether</P>
<P STYLE="margin-bottom: 0cm">PKG II inhibited EGF-induced
phosphorylation/activation of EGFR and MAPK/ERK in</P>
<P STYLE="margin-bottom: 0cm">cell lines derived from different
cancer tissues. SW480, HepG2, OS-RC-2, A549,</P>
<P STYLE="margin-bottom: 0cm">MCF-7 and U251 cells were transfected
with adenoviral constructs encoding PKG II 
</P>
<P STYLE="margin-bottom: 0cm">cDNA (Ad-PKG II) to upregulate the
expression of PKG II, and then treated with</P>
<P STYLE="margin-bottom: 0cm">8-(4-chlorophenylthio)guanosine
3',5'-cyclic monophosphate (8-pCPT-cGMP) in order</P>
<P STYLE="margin-bottom: 0cm">to activate the kinase. Western blot
analysis was performed to investigate the</P>
<P STYLE="margin-bottom: 0cm">phosphorylation of EGFR and MAPK/ERK.
The results demonstrated that treatment</P>
<P STYLE="margin-bottom: 0cm">with 100 ng/ml EGF for 5 min increased
the tyrosine (Tyr)1068 phosphorylation of 
</P>
<P STYLE="margin-bottom: 0cm">EGFR and the threonine 202/Tyr204
phosphorylation of MAPK/ERK. Transfecting the</P>
<P STYLE="margin-bottom: 0cm">cells with Ad-PKG II, and stimulating
the kinases with 8-pCPT-cGMP efficiently</P>
<P STYLE="margin-bottom: 0cm">inhibited the EGF-induced
phosphorylation of EGFR and MAPK/ERK. The results</P>
<P STYLE="margin-bottom: 0cm">revealed that PKG II had an inhibitory
effect upon EGFR activation and the</P>
<P STYLE="margin-bottom: 0cm">consequent MAPK/ERK-mediated signaling
of cell lines derived from the various</P>
<P STYLE="margin-bottom: 0cm">cancer tissues.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4473676</P>
<P STYLE="margin-bottom: 0cm">PMID: 26137146 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">19. Mol Cell Biol. 2015 Jun 29. pii:
MCB.00286-15. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Phosphatidic acid (PA) increases EGF
receptor (EGFR) expression by stabilizing</P>
<P STYLE="margin-bottom: 0cm">mRNA, inhibiting RNAse-A, and by
inhibiting lysosomal and proteasomal degradation</P>
<P STYLE="margin-bottom: 0cm">of the internalized EGFR.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hatton N(1), Lintz E(1), Mahankali
M(1), Henkels K(1), Gomez-Cambronero J(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Wright State University School of
Medicine, Department of Biochemistry and</P>
<P STYLE="margin-bottom: 0cm">Molecular Biology, Dayton, Ohio 45435.
(2)Wright State University School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, Department of Biochemistry
and Molecular Biology, Dayton, Ohio 45435.</P>
<P STYLE="margin-bottom: 0cm">julian.cambronero@wright.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Overexpression of epidermal growth
factor (EGFR) is one of the frequent</P>
<P STYLE="margin-bottom: 0cm">mechanisms implicated in cancer
progression and so is the overexpression of the</P>
<P STYLE="margin-bottom: 0cm">enzyme Phospholipase D (PLD) and its
product of reaction, phosphatidic acid (PA).</P>
<P STYLE="margin-bottom: 0cm">However, understanding how these
signaling molecules interact at the level of</P>
<P STYLE="margin-bottom: 0cm">gene expression is lacking.
Catalytically active PLD enhanced expression of EGFR 
</P>
<P STYLE="margin-bottom: 0cm">human breast cancer cells.
Overexpression of the PLD2 isoform increased EGFR mRNA</P>
<P STYLE="margin-bottom: 0cm">and protein expression and prevented
siEGFR-mediated reduction in EGFR</P>
<P STYLE="margin-bottom: 0cm">expression. Several mechanisms
contributed to the alteration in EGFR expression. 
</P>
<P STYLE="margin-bottom: 0cm">First was the stabilization of EGFR
mRNA prolonging its half-life in PLD2 cells. 
</P>
<P STYLE="margin-bottom: 0cm">Second, RNaseA enzymatic activity was
inhibited by phosphatidic acid (PA). Third,</P>
<P STYLE="margin-bottom: 0cm">protein stabilization also occurred, as
indicated by PLD-resistance to</P>
<P STYLE="margin-bottom: 0cm">cycloheximide-induced EGFR protein
degradation. Fourth, PA inhibited lysosomal</P>
<P STYLE="margin-bottom: 0cm">and proteasomal degradation of
internalized EGFR. A co-localization of PLD2, EGFR</P>
<P STYLE="margin-bottom: 0cm">and JAK3 phophorylation at Tyr980/981
followed receptor endocytosis, and the</P>
<P STYLE="margin-bottom: 0cm">presence of PLD2 increased
stabilization of intracellular EGFR in large recycling</P>
<P STYLE="margin-bottom: 0cm">vesicles at ∼15 min of EGF
stimulation. Thus, PLD2-mediated production of PA</P>
<P STYLE="margin-bottom: 0cm">contributed to the control of EGFR
exposure to ligand through a multi-prolonged</P>
<P STYLE="margin-bottom: 0cm">transcriptional and
post-transcriptional program during the out-of-control</P>
<P STYLE="margin-bottom: 0cm">accumulation of EGFR signaling in
cancer cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Society for
Microbiology. All Rights Reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26124282 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">20. Cancer Sci. 2015 Jun 29. doi:
10.1111/cas.12730. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Inhibition of microRNA-214 ameliorates
hepatic fibrosis and tumor incidence in</P>
<P STYLE="margin-bottom: 0cm">platelet-derived growth factor C
transgenic mice.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Okada H(1), Honda M(1,)(2), Campbell
JS(3), Takegoshi K(1), Sakai Y(1), Yamashita</P>
<P STYLE="margin-bottom: 0cm">T(1), Shirasaki T(1), Takabatake R(1),
Nakamura M(1), Tanaka T(4), Kaneko S(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Gastroenterology,
Kanazawa University Graduate School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, Kanazawa, Japan.
(2)Department of Advanced Medical Technology, Kanazawa</P>
<P STYLE="margin-bottom: 0cm">University Graduate School of Health
Medicine, Kanazawa, Japan. (3)Department of 
</P>
<P STYLE="margin-bottom: 0cm">Pathology, University of Washington
School of Medicine, Seattle, WA, USA. (4)The 
</P>
<P STYLE="margin-bottom: 0cm">Tohkai Cytopathology Institute: Cancer
Research and Prevention, Gifu, Japan.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Differentially regulated microRNAs
(miRNAs) are associated with hepatic fibrosis;</P>
<P STYLE="margin-bottom: 0cm">however, their potential usefulness for
blocking hepatic fibrosis has not been</P>
<P STYLE="margin-bottom: 0cm">exploited fully. We examined the
expression of miRNAs in the liver of a</P>
<P STYLE="margin-bottom: 0cm">transgenic mouse model in which
platelet-derived growth factor C (PDGF-C) is</P>
<P STYLE="margin-bottom: 0cm">overexpressed (Pdgf-c Tg), resulting in
hepatic fibrosis and steatosis and the</P>
<P STYLE="margin-bottom: 0cm">eventual development of hepatocellular
carcinoma (HCC). Robust induction of</P>
<P STYLE="margin-bottom: 0cm">miR-214 correlated with fibrogenesis in
the liver of Pdgf-c Tg mice, atherogenic 
</P>
<P STYLE="margin-bottom: 0cm">high-fat diet-induced NASH mice, and
patients with chronic hepatitis B or C.</P>
<P STYLE="margin-bottom: 0cm">Pdgf-c Tg mice were injected with
locked nucleic acid (LNA)-antimiR-214 via the</P>
<P STYLE="margin-bottom: 0cm">tail vein using Invivofectamine(®) 2.0
and the degree of hepatic fibrosis and</P>
<P STYLE="margin-bottom: 0cm">tumor incidence were evaluated. Pdgf-c
Tg mice treated with LNA-antimiR-214</P>
<P STYLE="margin-bottom: 0cm">showed a marked reduction in fibrosis
and tumor incidence compared with saline-</P>
<P STYLE="margin-bottom: 0cm">or LNA-miR-control-injected control
mice. In vitro, LNA-antimiR-214 significantly</P>
<P STYLE="margin-bottom: 0cm">ameliorated TGF-β1-induced
pro-fibrotic gene expression in Lx-2 cells. MiR-214</P>
<P STYLE="margin-bottom: 0cm">targets a negative regulator of EGFR
signaling, Mig-6. Mimic-miR-214 decreased</P>
<P STYLE="margin-bottom: 0cm">the expression of Mig-6 and increased
the levels of EGF-mediated p-EGFR (Y1173</P>
<P STYLE="margin-bottom: 0cm">and Y845) and p-Met (Tyr1234/1235) in
Huh-7 cells. Conversely, LNA-antimiR-214</P>
<P STYLE="margin-bottom: 0cm">repressed the expression of these
genes. In conclusion, miR-214 appears to</P>
<P STYLE="margin-bottom: 0cm">participate in the development of
hepatic fibrosis by modulating the EGFR and</P>
<P STYLE="margin-bottom: 0cm">TGF-β signaling pathways.
LNA-antimiR-214 may be a potentially therapy in the</P>
<P STYLE="margin-bottom: 0cm">prevention of hepatic fibrosis. This
article is protected by copyright. All</P>
<P STYLE="margin-bottom: 0cm">rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">This article is protected by copyright.
All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26122702 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
</BODY>
</HTML>